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ABSTRACT 
The extracellular-regulated kinase (ERK) signalling pathway is involved in the control 
of different biological processes such as survival, proliferation and differentiation. In 
PC12 cells, the ERK signalling pathway integrates different external stimuli: epidermal 
growth factor (EGF) stimulates the ERK pathway transiently and induces cell 
proliferation, whereas nerve growth factor (NGF) induces sustained activation of ERK 
and promotes cell differentiation into sympathetic-like neurons. The second messenger 
3’,5’-cyclic adenosine monophosphate (cAMP) controls a plethora of cellular events 
from metabolic to cellular signalling pathways. Over the years, lines of evidence have 
shown that cAMP is also involved in the regulation of cell growth and cell 
differentiation, suggesting a possible crosstalk between these two pathways. 
Selective phosphodiesterase (PDE) inhibitors were used to block the degradation of 
cAMP. These inhibitors increased the level of cAMP, but had different effects on the 
activation of ERK. Upon both NGF and EGF stimulations, cilostamide had the strongest 
effect and doubled the intensity of the phosphorylation of ERK, identifying PDE3 to 
control the level of cAMP relevant for the regulation of the ERK pathway. The 
treatment with cilostamide enhanced the differentiation of PC12 cells and the 
combination of both cilostamide and rolipram (a PDE4 inhibitor) turned the 
proliferative effect of EGF into a differentiation effect. 
The route for cAMP in the regulation of the ERK pathway was decomposed by using 
the cAMP analogues 8-pCPT-2’-O-Me-cAMP and 6-Bnz-cAMP. They specifically 
activate the Exchange protein activated by cyclic AMP (Epac) and the cAMP regulated 
protein kinase (PKA) respectively, which were hypothesised to be the effectors of 
cAMP in the regulation of ERK. The Epac agonist mimicked the effects of cilostamide 
on the activation of ERK, but failed to enhance cell differentiation. The PKA agonist 
reduced the phosphorylation ERK upon EGF. It was suggested that the activation of 
ERK in response to cAMP was mainly mediated through Epac rather than PKA, and 
that the activation of both PKA and Epac are required to induce cellular differentiation. 
To elucidate the differential regulation of the activation of ERK upon NGF and EGF 
stimulation and in response to cAMP, the activity of Ras and Rap1 were measured by 
affinity pulldown assays. Upon EGF the signal was transduced through Ras only, 
whereas upon NGF the signal was mediated through both Ras and Rap1. cAMP 
sensitised Rap1 that became activated upon EGF stimulation indicating that cAMP can 
switch on the Rap1/B-Raf pathway. This correlated with the increase in the   4 
phosphorylation of ERK in response to high levels of cAMP upon EGF stimulation. 
Then, the role of Raf-1 and C3G, a guanine exchange factor for Rap1, were investigated 
using small interfering RNA. The depletion of Raf-1 showed that Raf-1 is not essential 
for transducing the mitogen signal upon NGF stimulation and suggested that Ras 
mediates the signal through B-Raf upon EGF stimulation to compensate for the loss of 
Raf-1. The depletion of C3G also confirmed that the activation of ERK in response to 
cAMP is mediated through the Rap1/B-Raf pathway. 
Finally, the interaction between Raf-1 and AKAP79 was demonstrated for the first time 
suggesting the existence of a complex between Raf-1, AKAP and PKA and therefore a 
possible molecular mechanism for the inhibition of Raf-1 by cAMP through PKA.  
The data presented in this thesis demonstrates that cAMP participates to finely tune the 
regulation of the ERK signalling pathway and can be use as a tool to elucidate the 
network comprising the ERK cascade.   5 
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1.1  MAPK SIGNALLING PATHWAY 
1.1.1  Mitogen-activated protein kinase (MAPK) signalling pathways 
Mitogen-activated protein kinase signalling pathways are responsible for the 
transduction of a wide range of extracellular signals from the plasma membrane to the 
nucleus to allow the appropriate cellular response to occur. They are involved in the 
regulation of gene expression as well as cytoplasmic activities. The MAPK signalling 
pathways are evolutionary conserved in all eukaryotes and the best characterised 
pathways can be classified into at least three distinguished MAPK subfamilies (Fig. 
1.1): the extracellular signal-regulated kinases (ERKs), the c-Jun N-terminal kinases 
(JNKs) and the p38-MAPKs (Davis, 2000; Schaeffer and Weber, 1999; Tibbles and 
Woodgett, 1999; Wada and Penninger, 2004). Each pathway responds to different 
external stimuli and exerts distinct biological functions such as cell proliferation, cell 
differentiation, cell cycle regulation or apoptosis. However, there are also overlapping 
activators and effectors, such as the transcription factor Elk, which is a substrate for 
both ERK and JNK, or Mnk2 and MAPKAP2/3 which are phosphorylated by both ERK 
and p38 (Pearson et al., 2001). The ERK signalling pathway is activated in response to 
growth factor stimuli and is known to be involved in cell proliferation, differentiation 
and apoptosis (Houslay and Kolch, 2000). JNKs and p38-MAPKs signalling pathways 
are stress responsive and seem to be involved in the control of cell cycle checkpoints, 
differentiation and apoptosis (Davis, 2000; Schaeffer and Weber, 1999; Tibbles and 
Woodgett, 1999). 
The MAPK signalling pathways share common mechanisms and a conserved structure 
consisting of a module of three kinases. Basically, the three kinases activate each other 
in a cascade of phosphorylations that relays extracellular signals. The first kinase or 
MAPKK kinase (MAPKKK) is activated by a small G-protein that itself is activated by 
cell surface receptors in response to an extracellular stimulus. The MAPKKK 
phosphorylates and activates the MAPK kinase (MAPKK), which in turn 
phosphorylates and activates the MAP kinase (MAPK). The role of the small G-protein 
is to connect the MAPK module to the cell surface receptor. It does so by, when 
activated, physically binding the MAPKKK and recruiting it to the cell membrane 
where the activation of the MAPKKK takes place. The MAPKKKs integrate the input Chapter 1                                                                                                         Introduction 
  17 
signals and exhibit complex regulation. The MAPKKs, however, are very specific for 
their substrates and phosphorylate only a restricted subset of MAPKs. The MAPKs have 
multiple substrates located both in the nucleus and in the cytosol. MAPKs constitute the 
effector ends of the kinase cascade. 
 
Figure 1. 1: Classification of the MAPK signalling pathways. The MAPK signalling 
pathways can be classified into three distinguished subfamilies: the extracellular signal-
regulated kinases (ERKs), the c-Jun N-terminal kinases (JNKs) and the p38-MAPKs. 
 
1.1.2  Extra-cellular-signal-regulated kinase pathway 
The Extra-cellular-signal-regulated kinase  (ERK) pathway was the first signalling 
pathway to be entirely mapped from the cell membrane to the nucleus. The MAP kinase 
module consists of Raf protein kinase as MAPKKK, MEK protein kinase as MAPKK 
and ERK protein kinase as MAPK (Fig.1.2). The ERK cascade is initiated by the small 
G-protein Ras that is activated in response to mitogen stimulations of receptor tyrosine 
kinases (RTKs) at the cell membrane. Upon activation Ras recruits Raf from the cytosol 
to the cell membrane where the activation of Raf takes place. At the plasma membrane, 
Raf is activated by phosphorylation. In its activated state, Raf phosphorylates and 
activates the dual specificity kinase MEK, which in turn phosphorylates and activates Chapter 1                                                                                                         Introduction 
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ERK (Chong and Guan, 2003; Kolch, 2000). Phosphorylated ERK can enter the nucleus 
and can affect directly gene expression by phosphorylating transcription factors such as 
Elk1, Ets-2 or c-myc. ERK can also phosphorylate a wide range of cytoplasmic 
substrates. Ras and Raf are oncogenes, and the ERK pathway is hyperactivated in 30% 
of all cancers. 
 
Figure 1. 2: The ERK Signalling pathway. Upon mitogen stimulation of the receptor 
tyrosine kinase (RTK), Raf is recruited by Ras to the plasma membrane where it is 
phosphorylated. Raf can phosphorylate and activate MEK, which in turn phosphorylates 
and activates ERK. Phosphorylated ERK can enter into the nucleus and activate 
transcription factors or activates cytoplasmic substrates. 
1.1.3  Receptor Tyrosine Kinases  
Receptor tyrosine kinases (RTKs) are members of the large family of protein tyrosine 
kinases. The tyrosine kinases are enzymes that catalyze the transfer of phosphoryl group 
from ATP to tyrosine residues of protein substrates (Hubbard and Miller, 2007). 90 
protein tyrosine kinases have been identified and 58 of them are RTKs (Robinson et al., 
2000). The RTKs have in common a single transmembrane domain, a single 
cytoplasmic tyrosine kinase domain and are differentiated by their extracellular domain 
(Huang and Reichardt, 2003). Basically, the RTKs are activated by dimerisation 
initiated by ligand binding, which induces conformational changes of the receptor 
resulting in the auto-phosphorylation of tyrosine residues in the kinase activation loop Chapter 1                                                                                                         Introduction 
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and other areas of the kinase domain. These phosphotyrosine residues serve as docking 
sites for adaptor and scaffolding proteins such as Grb2 and Crk through their Src 
homology-2 (SH2) or phosphotyrosine-binding (PTB) domains (Hubbard and Miller, 
2007). These adaptor proteins recruit downstream signalling proteins such as the 
guanine nucleotide exchange factors SOS and C3G that activate respectively the small 
G-proteins Ras and Rap1 leading to the activation of downstream signalling pathways. 
1.1.3.1  EGF Receptor 
The epidermal growth factor receptor (EGFR or ErbB1) and its three homologues 
ErbB2, ErbB3 and ErbB4 constitute one of the 20 subfamilies of RTKs (Robinson et al., 
2000). These receptors are involved in cell division, adhesion and proliferation. 
Overexpression or mutations of these receptors contribute to several cancers including 
breast, lung, colorectal and pancreatic cancers (Yarden and Sliwkowski, 2001). The 
overall structure of the EGFR consists of an extracellular domain, a single 
transmembrane domain, a juxtamembrane domain (JM) and a carboxy-terminal domain 
(Fig.1.3.a). The extracellular domain consists of two ligand binding domain (L1 and 
L2), and two cysteine rich domains (CR1 and CR2). The carboxy-terminal domain 
contains the kinase domain flanked by tyrosine autophosphorylation sites (Burgess et 
al., 2003; Jorissen et al., 2003). When EGF binds to the ligand binding domains of 
EGFR, receptor dimerisation is induced, which is required for the activation of the 
kinase domain (Burgess et al., 2003; Moriki et al., 2001). After dimerisation, the 
carboxy-terminus becomes rapidly phosphorylated through autophosphorylation by the 
tyrosine kinase domain. The phosphorylations of the tyrosine residues induce the 
recruitment of the Grb2 adaptor protein through its SH2 domain leading to the 
activation of the MAPK pathway (Nioche et al., 2002). 
1.1.3.2  NGF Receptor: TrkA 
Another RTK subfamily contains the Trk (tropomyosin-related kinase) receptor tyrosine 
kinases TrkA, TrkB and TrkC, also termed tropomyosin receptor kinases. These 
receptors were first identified as a colon-derived oncogenes in which tropomyocin was 
fused to a tyrosine kinase domain (Jing et al., 1992). These receptors can be activated by 
one or more of four neurotrophins, which are nerve growth factor (NGF), brain-derived 
neurotrophic factor (BDNF), and neurotrophins 3 and 4 (NT3 and NT4) (Bibel and 
Barde, 2000; Huang and Reichardt, 2003). These receptors are involved in cell survival, Chapter 1                                                                                                         Introduction 
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proliferation and neuronal differentiation. These three receptors share a highly 
conserved tyrosine kinase domain, a less conserved extracellular domain and a single 
transmembrane domain (Fig.1.3.b). The extracellular domain consists of two cysteine 
clusters (C1, C2) separated by the ligand binding domain that contains multiple repeats 
of leucine-rich motifs (LRR1-3) and two immunoglobulin-like domains (Ig1, Ig2) 
(Schneider and Schweiger, 1991). The binding of NGF induces the dimerisation of the 
receptors (Jing et al., 1992) that results in the phosphorylation of tyrosine residues in the 
activation loop of the kinase domain. This induces autophosphorylation of tyrosines 
located outside of the loop. There are two specific phosphorylated tyrosine residues 
identified to be docking sites for adaptor molecules: Y490 and Y785 in TrkA (Friedman 
and Greene, 1999). Y785 resides in the C-terminus of the receptor and was identified to 
bind and phosphorylate phospholipase C- (PLC-) via its SH2 domain. Y785 is also a 
site for association of TrkA with Csk homologous kinase (CHK) that was identified to 
be involved in NGF-promoted out growth in PC12 cells, which was suppressed by 
injection of anti CHK antibodies (Yamashita et al., 1999). Y490 promotes the binding 
and phosphorylation of Shc via its phosphotyrosine binding domain (PTB). This 
induces the binding of Grb2-SOS complex to TrkA that participates in the activation of 
Ras (Basu et al., 1994). This site was identified to mediate the activation of the ERK 
pathway and to be involved in neurite outgrowth. Furthermore, it seems that 
phosphorylated Y490 recruits and phosphorylates the adaptor fibroblast growth factor 
receptor substrate-2 (FRS2) via its PTB domain, providing binding sites for additional 
signalling proteins such as Grb2 and Crk (Yan et al., 2002). The association of Crk to 
FRS2 induces the activation of the guanine exchange factor C3G leading to the 
activation of Rap1 (Nosaka et al., 1999). 
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Figure 1. 3: Receptor Tyrosine Kinases. RTKs have in common a single 
transmembrane domain, a single cytoplamic tyrosine kinase domain and are 
differentiated by their extracellular domains. a) The extracellular domain of the EGF 
receptor consists of two ligand binding domain (L1 and L2), and two cysteine rich 
domains (CR1 and CR2). The carboxy-terminal domain contains the kinase domain 
flanked by tyrosine autophosphorylation sites. b) The extracellular domain of the NGF 
receptor (TrkA) consists of two cysteine clusters (C1, C2) separated by the ligand 
binding domain that contains multiple repeats of leucine-rich motifs (LRR1-3) and two 
immunoglobulin-like domains (Ig1, Ig2). There are two specific phosphorylated 
tyrosine residues identified to be docking sites for adaptor molecules: Y490 and Y785 
in TrkA. 
1.1.4  Small G-proteins Ras and Rap-1 
The Ras proteins are a superfamily of small GTP-binding proteins that can hydrolyse 
GTP. These small GTPase proteins cycle between an inactive GDP-bound form and an 
active GTP-bound form. This family comprises Ras and its isoforms H-Ras, N-Ras and 
K-Ras, as well as the Ras-like small GTPases Rap1, Rap2, Ral, TC21, Rheb, R-Ras and 
M-Ras (Bos, 1998; Hancock, 2003). Ras proteins are localised at cellular membranes, 
although they are not intrinsic membrane proteins. Therefore, they are targeted to 
cellular membranes after undergoing a series of posttranslational modifications 
including prenylation, proteolysis to cleave their C-terminal CAAX motif, exposing the 
cysteine that is finally carboxymethylated. This creates a hydrophobic C-terminus 
allowing membrane association (Mor and Philips, 2006). The conversion of the inactive 
to the active form is mediated by guanine-nucleotide exchange factors (GEFs), such as 
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proteins (section 1.1.3). GEFs catalyse the release of GDP from the guanine nucleotide 
binding pocket of Ras, allowing the binding of GTP that is tenfold more abundant in the 
cytosol than GDP (Hernandez-Alcoceba et al., 2000). Active Ras can interact and 
activate several effector proteins such as Raf kinases (Raf-1, B-Raf and A-Raf), 
phosphatidylinositol 3-kinase (PI3K), RalGEFs (RalGDS, Rlf and Rgl) (Bos, 1998; 
Hancock, 2003). The signalling is terminated by hydrolysis of GTP to GDP by the 
intrinsic GTPase activity of Ras in combination with the help of GTPase-activating 
proteins (GAPs), which accelerate the intrinsic GTPase activity of Ras proteins. 
Ras is an oncogene that is implicated in up to 30% of all cancers (Bos, 1989; 
Hernandez-Alcoceba et al., 2000) and various types of cancers are due to mutations of 
the different isoforms. In particular, K-Ras is mutated in about 50% of adenocarcinomas 
of the colon and in 90% of pancreatic carcinomas (Bos, 1989), mutations in N-Ras are 
found in 30% of myelogenous leukaemias and in 13% of melanomas. In general, Ras 
becomes oncogenic due to mutations that make Ras insensitive to the action of GAPs, 
therefore preventing Ras inactivation. 
Rap1 is the closest relative of Ras and they share 100% similarity in their effector 
domains (Bos et al., 2001; Mor and Philips, 2006). However, Rap1 has a tenfold lower 
intrinsic GTPase activity than Ras, suggesting that the nucleotide exchange reaction 
might be different. Rap1 has two isoforms Rap1a and Rap1b. Rap1 is activated through 
stimulation of various transmembrane receptors including RTKs, heterotrimeric G-
Protein-coupled receptors, cytokine receptors and cell-adhesion molecules. The first 
GEF for Rap1 to be identified was the Crk SH3-domain-binding guanine-nucleotide 
releasing factor (C3G). C3G mediates the activation of Rap1 induced by RTKs (Wu et 
al., 2001). In addition to its catalytic region, C3G contains several proline-rich 
sequences that associate to the SH3 domain of Crk (Nosaka et al., 1999). Rap1 can also 
be activated by the exchange protein directly activated by cAMP (Epac) in response to 
elevated levels of cAMP (Bos, 2003; Enserink et al., 2002). Rap1 has been shown to 
bind to both Raf-1 and B-Raf, but Rap1 specifically activates B-Raf while it inhibits 
Raf-1 activation (Okada et al., 1999; Vossler et al., 1997). Chapter 1                                                                                                         Introduction 
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1.1.5  Raf Kinases 
The Raf family of serine/threonine-specific kinases regroups kinases highly conserved 
in structure. Raf kinases contains three conserved regions CR1, CR2 and CR3 (Chong 
and Guan, 2003). CR1 contains the Ras binding domain (RBD) and the cysteine-rich 
domains (CRD). These two domains are required for the binding to Ras and are 
involved in Raf activation. CR2 is serine/threonine rich and contains inhibiting 
phosphorylation sites. CR3 contains the catalytic domain where activating 
phosphorylation sites are located. 
There are thee active raf genes in humans, A-raf, B-raf and c-raf-1 encoding for three 
Raf kinase isoforms, A-Raf, B-Raf and c-Raf (or Raf-1). Raf-1 is a 74 kDa protein and 
consists of 648 amino acids, while A-Raf is slightly smaller and is a 68 kDa protein 
(606 amino acids). B-Raf is subjected to alternative splicing which gives rise to proteins 
varying in length from 75-100 kDa. They are distinguished by their tissue-specific 
expression pattern (Storm et al., 1990). Raf-1 is ubiquitously expressed with highest 
expression in striated muscle, cerebellum and foetal brain. A-Raf is mainly expressed in 
urogenital tissues, and B-Raf is more highly expressed in neuronal tissues, testis and 
haematopoetic cells (Erhardt et al., 1995; O'Neill and Kolch, 2004). Raf kinases are the 
entry point to the ERK pathway and hence play a central role to control the signal flow 
through the ERK pathway (Dhillon and Kolch, 2002). They have distinct biological 
functions, which were studied using Raf knockout animal models (Hagemann and Rapp, 
1999; O'Neill and Kolch, 2004). A-Raf knockout mice survied up to 21 days. They 
showed neurological and intestinal abnormalities and died from extensive bowel 
distension (Pritchard et al., 1996). B-Raf knockout mice died in utero from massive 
haemorrhage caused by apoptosis of endothelial cells (Wojnowski et al., 1997). 
However, more recent studies with conditional B-Raf knockout mice showed no 
endothelial phenotype, but a role for B-Raf in placenta development and neuronal 
development (Galabova-Kovacs et al., 2008; Galabova-Kovacs et al., 2006; Zhong et 
al., 2007). Raf-1 knockout mice are growth retarded and die in utero from widespread 
apoptosis with anomalies in the placenta and in the foetal liver (Mikula et al., 2001). 
The Raf kinases have a crucial role during embryonic development and organogenesis. 
A-Raf is involved in intestinal and neurological development, B-Raf suppresses 
apoptosis and Raf-1 is responsible for cell growth and the development of skin, lung 
and placenta. Interestingly, all three Raf isoforms serve distinct functions (Galabova-Chapter 1                                                                                                         Introduction 
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Kovacs et al., 2006; Hagemann and Rapp, 1999) but they share Ras as a common 
upstream small G-protein activator and MEK as the only downstream substrate 
(Schaeffer and Weber, 1999). The regulation of Raf kinases is complex and still not 
completely understood. 
1.1.5.1  Activation of Raf kinases 
1.1.5.1.1  Initiation of Raf activation by Ras 
The activation of Raf is a complex event that takes place at the plasma membrane where 
the small G-protein Ras is localised. It involves membrane relocalisation, 
phosphorylation and dephosphorylation of active residues and the presence of adaptor 
and scaffolding proteins. 
In resting cells, Raf-1 is phosphorylated on S259 and S621 (corresponding to S365 and 
S729 in B-Raf), which are binding sites for the dimeric protein 14-3-3. It was proposed 
that 14-3-3 stabilises Raf kinases in a closed and inactive conformation by holding 
together the CR2 and CR3 regions masking the catalytic domain of Raf (Dhillon and 
Kolch, 2002). The first step in the activation of Raf is its binding to activated Ras (Ras-
GTP) at the cell membrane (Traverse et al., 1993). The RBD of Raf has a higher affinity 
for Ras-GTP than for Ras-GDP. Therefore, in presence of active Ras, Raf translocates 
from the cytosol to the plasma membrane. The binding to Ras displaces 14-3-3 from 
phosphorylated S259 (Tzivion et al., 1998), which is dephosphorylated by protein 
phosphatase 2 A (PP2A) (Kubicek et al., 2002). Raf-1 can be activated only if S259 is 
dephosphorylated (Dhillon et al., 2002a; Morrison et al., 1993). Ras-GTP binds to the 
RBD with high affinity and to the CRD of Raf. Single mutations of specific amino acids 
(Gln66, Lys84 and Arg89) in the RBD can disrupt the interaction between Raf-1 and 
Ras (Fabian et al., 1993). The RBD alone is sufficient for the translocation of Raf-1 to 
the cell membrane, but it is not sufficient for Raf-1 to be fully activated (Kolch, 2000). 
The binding of Ras to the CRD is required for the activation of Raf and is thought to 
enhance the interaction between Raf-1 and Ras (Dhillon and Kolch, 2002). The 
interaction between Ras and Raf unmasks the catalytic site by dissociating the 
regulatory domain from the kinase domain of Raf. Now, Raf is in an open conformation 
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  25 
1.1.5.1.2  Full activation of Raf by phosphorylation 
To be fully activated, Raf kinases require the phosphorylation of specific tyrosine and 
serine residues within the CR3 domain. 
In Raf-1 (Fig. 1.4), mitogen stimulation results in the phosphorylation of S338 and 
Y341 that lie upstream the kinase domain in the N-region (negative charge in this 
region is essential for kinase activity), and the phosphorylation of T491 and S494 within 
the activation loop in the kinase domain (Chong et al., 2001; Fabian et al., 1993; King et 
al., 1998). The phosphorylation of S338 is induced by mitogens, integrin and Ras and is 
absolutely required for the activation of Raf-1. The mutation of serine to alanine blocks 
the activation of Raf-1 (Barnard et al., 1998; Diaz et al., 1997; King et al., 1998), 
whereas mutation of serine to phosphomimetic acid aspartic results in a slight activation 
of Raf-1 (Diaz et al., 1997). The substitution of Y341 to phenylalanine also blocks the 
activation of Raf-1 by mitogens, oncogenic Ras and activated Src (Diaz et al., 1997; 
Marais et al., 1995) and the replacement by an acid aspartic residue results in strong 
activation of Raf-1 (Fabian et al., 1993) indicating the crucial role of Y341 in the 
activation of Raf-1. PAK1 and PAK3 have been identified to be responsible for the 
phosphorylation of S338 in a PI3K dependent manner (King et al., 1998). However the 
phosphorylation of S338 by PAKs occurs in the cytosol and not at the plasma 
membrane. Therefore, PAKs phosphorylate S338 in a Ras- or growth factor-
independent manner. More data suggest that PAKs are not the only kinases responsible 
for the phosphorylation of S338. For example, dominant-negative PAKs do not block 
the phosphorylation of S338 upon growth factor stimulation (Chiloeches et al., 2001; 
Wellbrock et al., 2004). It is more likely that other kinases are involved but they remain 
to be identified (Mason et al., 1999). It was demonstrated that a tyrosine kinase of the 
Src family is responsible for the phosphorylation of Y341 (Marais et al., 1995). 
Within the activation loop, T491 and S494 have been identified to be phosphorylated 
upon mitogen stimulation and to participate to the activation of Raf-1. Substitutions of 
both sites with acidic residues enhance the kinase activity of Raf-1 (Chong et al., 2001). 
The kinases responsible for their phosphorylation have not been identified yet and Raf 
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Figure 1. 4: Model for Raf-1 activation. In quiescent cells, Raf-1 is held in a stable 
and inactive conformation by 14-3-3 that binds to the phosphorylated S259 and S621. 
Mitogenic stimulation induces the activation of Ras and recruitment of Raf-1 to the 
plasma membrane. Active Ras displaces 14-3-3 from S259, which becomes available 
for dephosphorylation by PP2A. Raf-1 is in an open conformation exposing both 
catalytic domain and the MEK docking site. Raf-1 is now ready for activation. 
Activating kinases including Src and PAK phosphorylate other sites such as Ser338 and 
Tyr341. Activated Raf-1 can then phosphorylate MEK. Raf-1 is then released from Ras 
and the membrane, and begins to return to an inactive state by rephosphorylation of 
Ser259 allowing 14-3-3 to bind and stabilise the inactive conformation. 
These phosphorylation sites required for the activation of Raf-1 are conserved in A-Raf 
(Fig. 1.5) and it seems that A-Raf is activated by similar mechanisms to Raf-1 (Marais 
et al., 1997). 
However, the activation of B-Raf is different although Ras is essential for its activation. 
The main difference in the activation of B-Raf relies in the N-region (Fig. 1.5). The 
equivalent Y341 of Raf-1 is replaced by and aspartic acid (D449) and therefore is 
negatively charged (Mason et al., 1999). The substitution of D449 with phenylalanine 
reduces its basal activity but B-Raf can still be activated by Ras (Marais et al., 1997). In 
addition, S446 (equivalent to S338 of Raf-1) is constitutively phosphorylated (Mason et 
al., 1999). The consequence is that B-Raf has elevated basal kinase activity compare to 
Raf-1. It is highly responsive to Ras and does not required tyrosine phosphorylation by 
Src (Marais et al., 1997). B-Raf is fully activated by Ras and does not require secondary 
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  27 
 
Figure 1. 5: Structure and phosphorylation sites of Raf kinases. The Raf isoforms 
have in common three conserved regions CR1, CR2 and CR3. The CR1 contains the 
Ras binding domain (RBD) and cysteine rich domain (CRD) involved in the interaction 
between Raf and active Ras at the plasma membrane. The activating phosphorylation 
sites are highlighted in red. The phosphorylation sites involved in the regulation of Raf 
are highlighted in blue. The asterix indicates the PKA phosphorylation sites (see section 
1.3.1). The inhibitory ERK feedback phosphorylation sites are indicated in green (see 
section 1.1.5.2.4). 
1.1.5.2  Regulation of Raf 
1.1.5.2.1  14-3-3 Protein 
It has been demonstrated that 14-3-3 and Raf-1 form a complex in resting cells (Li et 
al., 1995). It is thought that 14-3-3 stabilizes Raf-1 in an inactive conformation holding 
together CR2 and CR3 regions masking the catalytic domain of Raf-1 (Dhillon and 
Kolch, 2002; Muslin et al., 1996). The 14-3-3 proteins are members of a family of 
highly conserved and ubiquitously expressed 28-33 kDa acidic polypeptides. Their 
name is based on their fraction number on DEAE-cellulose chromatography and 
migration position on starch gel electrophoresis. There are at least seven genes that have 
been identified, which code for nine isotypes of 14-3-3 proteins (Yaffe et al., 1997). 
They spontaneously form homo or heterodimers. The 14-3-3 proteins bind to a large 
variety of proteins including protein kinases such as PKCs (Meller et al., 1996), or 
proteins involved in apoptosis such as BAD (Zha et al., 1996), but also proteins Chapter 1                                                                                                         Introduction 
  28 
involved in cell cycle control such as Cdc25 phosphatases (Peng et al., 1997). 14-3-3 
binds to phosphoserine and phosphothreonine proteins containing the consensus motifs 
RSXpSXP or RXXXpSXP (Yaffe, 2002), where pS stand for phosphoserine and X 
stand for any amino acid. All Raf isoforms contain two consensus motifs located in the 
regulatory and the catalytic domains, but the role of 14-3-3 in the regulation of Raf 
remains unclear and 14-3-3 has been suggested to be involved in both positive and 
negative regulation of Raf. For Raf-1, one 14-3-3 dimer binds to phosphorylated S259 
in the regulatory region and to phosphorylated S621 in the C-terminus (Tzivion et al., 
1998). The phosphorylation on S259 has an inhibitory effect on the activation of Raf-1, 
which was demonstrated by mutation of S259 resulting in constitutively active kinase 
(Morrison et al., 1993). In contrast the phosphorylation of S621 is required for the 
kinase activity of Raf-1. This was demonstrated by mutation of S621 that resulted in an 
inactive Raf kinase activity (Morrison et al., 1993; Yip-Schneider et al., 2000). Three 
different models have been proposed to explain the role of 14-3-3 in the regulation of 
Raf-1. In the first model, Tzivion et al propose that the free arm of 14-3-3 that was 
displaced from phosphorylated S259 bind to a third, yet unidentified phosphoserine on 
Raf-1 (Tzivion et al., 1998). They hypothesised that this new bridge between the third 
binding site and S621 hold Raf-1 in an active conformation. The second model 
proposed by Thorson et al suggests that 14-3-3 stabilises the active conformation of 
Raf-1 and protect phosphoserine 621 from dephosphorylation by phosphatases (Thorson 
et al., 1998). The third model suggests that the interaction between 14-3-3 and Raf-1 is 
required for the recruitment to the plasma membrane of Raf-1 by Ras (Roy et al., 1998). 
At the plasma membrane, 14-3-3 is completely released from the active Raf-1 and will 
reassociate during inactivation of Raf-1. 
It has been demonstrated that 14-3-3 interacts with B-Raf in vivo (Yamamori et al., 
1995). The interaction sites seem to be located in the N- and C-terminus domains of B-
Raf (Papin et al., 1996). One 14-3-3 binding consensus motif in the C-terminal catalytic 
domain of B-Raf is centred on S728 corresponding to S621 in Raf-1. The substitution of 
serine 728 to alanine disrupts the interaction between B-Raf and 14-3-3. The kinase 
activity of B-Raf was reduced by 50-60% in vitro and severely impaired in vivo. 
Furthermore, this mutation compromised dramatically the ability of B-Raf to induce 
PC12 cell differentiation (MacNicol et al., 2000). From their results, MacNicol et al 
suggested that the role of 14-3-3 binding to B-Raf is to scaffold the binding of B-Raf to 
its downstream effectors (MacNicol et al., 2000). Chapter 1                                                                                                         Introduction 
  29 
1.1.5.2.2  RKIP 
Originally, the Raf kinase inhibitor protein (RKIP) was identified in a two-hybrid screen 
as a Raf-1 associated protein (Yeung et al., 1999). RKIP was shown to bind to Raf-1, 
MEK and ERK both in vitro and in vivo. In addition, confocal microscopy revealed that 
RKIP and Raf-1 co-localise in both quiescent and Ras-transformed cells (Yeung et al., 
1999). But RKIP inhibits the activation and phosphorylation of MEK by Raf-1, without 
inhibiting the phosphorylation of ERK by MEK. The inhibition of RKIP by antibody 
microinjection or the downregulation of the expression of RKIP using antisense RNA, 
cause the activation of the ERK pathway. However overexpression of RKIP inhibits the 
ERK pathway and cellular transformation, which confirms that RKIP suppresses this 
pathway (Yeung et al., 1999). MEK and RKIP have been shown to bind to different 
binding sites on Raf-1, Raf-1 and RKIP bind to different binding sites on MEK, while 
MEK and Raf-1 bind to overlapping binding sites on RKIP, making their binding 
mutually exclusive. Thus, RKIP is a scaffold for MEK and ERK, but an inhibitor of the 
Raf-1/MEK interaction. RKIP dissociates the interaction between the two kinases in a 
competitive manner (Yeung et al., 2000). The binding of RKIP to Raf-1 is controlled by 
growth factor and upon stimulation the association between Raf-1 and RKIP is lost, 
allowing Raf-1 to activate MEK. When the activity of ERK declines, then RKIP 
reassociates with Raf-1 (Yeung et al., 2000). However the mechanism through which 
RKIP dissociates from Raf-1 is not fully known and remains to be established. 
Trakul et al. demonstrated that mutation of S338 and Y341 to phosphomimetic residues 
in Raf-1 prevented its association with RKIP and therefore inhibition (Trakul et al., 
2005). They demonstrated that also B-Raf co-precipitated with RKIP. However the 
depletion in RKIP did not enhance the kinase activity of B-Raf, while the activity of 
Raf-1 was increased. Since the S445 corresponding to S338 on Raf-1 is constitutively 
phosphorylated and that Y341 is replaced by an aspartic acid in B-Raf, it was then not 
surprising that the activity of B-Raf was not inhibited by RKIP. 
In contrast to these findings, Park et al demonstrated that RKIP inhibits the activity of 
B-Raf in melanoma cancer cells (Park et al., 2005). They demonstrated that RKIP 
associates with B-Raf using yeast two hybrid and co-immunoprecipitation experiments. 
They also demonstrated that in Raf-1 knockout MEF cells, the phosphorylation of MEK 
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inhibits the kinase activity of B-Raf. In contrast, the downregulation of RKIP by siRNA 
in Raf-1 knockout MEF cells increased the phosphorylation of MEK. Then, they 
demonstrated that when RKIP was transfected in Cos-1 cells, the basal activity of B-Raf 
was inhibited and the activity of B-Raf activated by Ras was reduced. Furthermore, the 
activity of B-Raf was inhibited by bacterial recombinant RKIP in vitro. And finally they 
showed that overexpression of RKIP in PC12 cells inhibits the differentiation of the 
cells that is mediated by B-Raf. 
1.1.5.2.3  Chaperones 
Heat shock proteins are members of a group of highly conserved proteins. As molecular 
chaperones, they have diverse role such as assisting in the folding of newly synthesised 
proteins or helping to stabilise the tertiary structure of certain proteins (Helmbrecht et 
al., 2000). It has been shown that both Raf-1 and B-Raf exist in multiprotein complexes 
including Hsp90, Hsp70 and cdc37 (Jaiswal et al., 1996; Stancato et al., 1997). 
Geldanamycin is a drug that binds to Hsp90 and prevents Hsp90 from binding to its 
substrates. Treatment with geldanamycin reduces the levels of Raf-1 in the cell causing 
its aggregation, ubiquitination and further degradation (Stancato et al., 1997). It seems 
as well that chaperones are involved in signal regulation. Jaiswal et al demonstrated that 
in PC12 cells, the activation of the ERK pathway upon NGF stimulation is principally 
due to B-Raf activity over Raf-1 activity, which correlates with the association of B-Raf 
with Hsp90 (Jaiswal et al., 1996).  
Bag-1 is another chaperone for Raf-1. Bag-1 has been shown to bind to Raf-1 and to 
redirect Raf-1 to mitochondrial membrane where Raf-1 binds to Bcl-2 (Wang et al., 
1996a). It was also demonstrated that Bag-1 increases the kinase activity of Raf-1 in 
vitro, but this is likely to be due to its chaperone function to keep Raf-1 in an active 
conformation rather than direct activation (Wang et al., 1996b). 
1.1.5.2.4  ERK-induced Feedback regulation of Raf-1 
Previous observations have suggested that Raf-1 might be subject to feedback 
inhibition. For example, Alessi et al showed that Raf-1 activation is prolonged when 
MEK is pharmacologically inhibited (Alessi et al., 1995). It was also demonstrated that 
Raf-1 activity is elevated in cells overexpressing IMP (Impedes mitogenic signal 
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scaffold/adaptor protein KSR that scaffolds the interaction between Raf, MEK and 
ERK) (Matheny et al., 2004). In cells overexpressing IMP, MEK and ERK can not be 
activated. However Raf-1 remains active. Therefore it was hypothesized that MEK 
and/or ERK might be involved in the downregulation of Raf-1. Dougherty et al 
identified six residues (S29, S43, S289, S296, S301 and S642) that become 
hyperphosphorylated after mitogen stimulation (Fig. 1.5) correlating with the 
inactivation of Raf-1 (Dougherty et al., 2005). The mutation of these six sites to alanine 
abolishes the hyperphosphorylation of Raf-1, results in the prolonged mitogen-induced 
kinase activity and accumulation of Raf-1 at the plasma membrane (Dougherty et al., 
2005). The treatment with U0126, a MEK inhibitor, revealed that the 
hyperphosphorylation and the downregulation of Raf-1 are dependent on the MEK/ERK 
pathway. They found that activated ERK2 is capable to phosphorylate these sites except 
S43 in vitro, suggesting that ERK is the most likely to be responsible for this feedback 
regulation of Raf-1. Furthermore they also found that the hyperphosphorylated Raf-1 is 
not degraded but recycled to an inactive form by dephosphorylation of S29, S289, S296, 
S301 and S642 by PP2A. This is consistent with the work of Hekman and colleagues 
who reported that the phosphorylation of S296 and S301 contribute to Raf-1 inhibition 
(Hekman et al., 2005). However, the direct feedback regulation of Raf-1 by ERK is 
subject to debate. It was also demonstrated that Raf-1 is phosphorylated by ERK on 
S289, S296 and S301, but this phosphorylation resulted in increasing the kinase activity 
of Raf-1 (Balan et al., 2006). 
1.1.6  MEK and ERK 
The Raf isoforms share MEK as a common substrate in vivo (Schaeffer and Weber, 
1999). Two MEK isoforms are known: MEK1 (43 kDa) and MEK2 (46 kDa). They are 
encoded by two different genes located at different chromosomes (Brott et al., 1993). 
MEK is activated by phosphorylation of two serine residues within its activation loop, 
S217/218 and S221/222 (Dhanasekaran and Premkumar Reddy, 1998). The mutation of 
one of these sites to alanine can inhibit the activity of MEK, suggesting that both sites 
are necessary and sufficient for the activation of MEK (Zheng and Guan, 1994). The 
interaction of MEK with Raf is dependent on a proline-rich sequence unique to MEK 
kinases and deletion of this sequence impaired the ability of MEK to bind to Raf and 
reduces the ability of Raf to activate MEK (Catling et al., 1995). Although all Raf Chapter 1                                                                                                         Introduction 
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isoforms can activate MEK in vitro, they interact differentially with MEK1 and MEK2. 
A-Raf activates preferentially MEK1, whereas Raf-1 seems to activate both MEK1 and 
MEK2 equally well. B-Raf has a higher MEK kinase activity and binds to MEK1 and 
MEK2 with a higher affinity than Raf-1 and A-Raf (Marais et al., 1997; Papin et al., 
1996). Oncogenic B-Raf phosphorylates MEK1 10 times more efficiently than Raf-1 
and 500 times more efficiently than A-Raf (Pritchard et al., 1995). MEKs are dual 
specificity kinases that can phosphorylate both threonine and tyrosine residues. MEK1 
and MEK2 phosphorylate ERK1/2 on threonine 183 and tyrosine 185 in their activation 
loop (Dhanasekaran and Premkumar Reddy, 1998; Schaeffer and Weber, 1999). 
ERK1 and ERK2 are serine/threonine kinases which have more than 160 known 
substrates including transcription factors, cytosolic proteins such as Rsk and 
cytoskeletal proteins (Yoon and Seger, 2006). Phosphorylated ERK can also translocate 
to the nucleus where it phosphorylates and activates transcription factors including Elk-
1, Ets and c-Myc. Activated ERK can also phosphorylate SOS and Raf-1, inhibiting 
respectively Ras and Raf-1 activation and serving as a negative feedback mechanism of 
the ERK signalling pathway (Dhillon et al., 2007; Dougherty et al., 2005; Langlois et 
al., 1995). 
1.1.7  PC12 cells: proliferation versus differentiation 
The rat PC12 cell line is derived from a rat pheochromocytoma tumour found in the 
adrenal medullary glands (Greene and Tischler, 1976). PC12 cells are a commonly used 
model cell system to study cell proliferation and differentiation, which are regulated by 
the ERK signalling pathway (Marshall, 1995). These cells have the property to either 
proliferate or differentiate depending on the type of mitogen stimulation. Upon 
epidermal growth factor (EGF) stimulation cells proliferate. However, upon nerve 
growth factor (NGF) stimulation the cells differentiate into sympathetic-like neurons 
(Dichter et al., 1977; Greene and Tischler, 1976). The fate of the cell has been shown to 
depend on the longevity of the ERK signal (Kao et al., 2001; Marshall, 1995; Traverse 
et al., 1992). It is commonly accepted that EGF causes a transient activation of the ERK 
pathway allowing the cells to continue to divide (Kao et al., 2001). However, NGF 
causes a sustained activation of the pathway, allowing the translocation and the 
accumulation of phosphorylated ERK in the nucleus. In the nucleus phosphorylated 
ERK can activate specific transcription factors and can induce the expression of specific Chapter 1                                                                                                         Introduction 
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genes causing the cells to withdraw from the cell cycle and therefore to differentiate 
(Traverse et al., 1992; Yao et al., 1998). This is supported by the observations that EGF 
can induce sustained activation of ERK and PC12 cell differentiation when EGFRs are 
overexpressed (Marshall, 1995). Indeed, overexpression of the EGF receptors slows 
down or prevents the inactivation of the receptors resulting in the prolonged activation 
of ERK and translocation in the nucleus.  
1.1.8  Regulation of the differential activation of the ERK pathway in 
PC12 cells 
As described above the fate of PC12 cells depends on the duration of the ERK signal. 
The question is how the signal is integrated through the same pathway to induce 
different biological responses? It seems that the differential activation of ERK is 
encoded at the receptor level and is dependent on the activation of the Ras family 
proteins as well as the Raf kinases involved. It is commonly accepted that both NGF 
and EGF can activate Ras, which can activate both Raf-1 and B-Raf. One hypothesis is 
that Ras is responsible for both transient and sustained activations of ERK (Lu et al., 
2000; Zwartkruis et al., 1998). Another hypothesis is that only NGF, but not EGF can 
activate Rap1 and therefore B-Raf, causing the sustained activation of the ERK pathway 
(Marshall, 1995; York et al., 1998). This suggests that two distinct pathways are 
involved in the activation of ERK and that Rap1/B-Raf is responsible for the sustained 
activation of ERK upon NGF stimulation. In contrast to this hypothesis, Kao et al 
demonstrated that both NGF and EGF stimulations activate Rap1 and therefore B-Raf, 
suggesting that both growth factors mediate the signal through both Ras/Raf-1 and 
Rap1/B-Raf pathways. They were the first to work on endogenous proteins in PC12 
cells involved in the activation of ERK (Kao et al., 2001). They showed that in PC12 
cells upon both EGF and NGF stimulation, Raf-1 and B-Raf were stimulated (Fig. 1.6). 
They demonstrated that the activation of B-Raf contributed to about 90% of the 
activation of ERK showing that B-Raf is the principal MEK kinase. They demonstrated 
that upon both EGF and NGF stimulation, Ras was transiently activated leading to the 
transient activation of Raf-1. However Rap1 was transiently activated upon EGF 
stimulation, whereas the activation of Rap1 was prolonged upon NGF stimulation. 
Therefore, the sustained activation of ERK upon NGF stimulation was the result of a 
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demonstrated that the longevity of the activation of ERK correlated with the stability of 
the complex formation at the receptor between Crk-C3G and Rap1, and therefore could 
cause prolonged B-Raf activation. Both EGF receptor (EGFR) and NGF receptor 
(TrkA) recruit a variety of signalling molecules to their receptor complexes consisting 
of adaptor proteins and GEFs upon stimulation. Ras activation is mediated through the 
association of the adaptor protein Grb2 and the GEF SOS, while the activation of Rap1 
is mediated through the formation of a complex between Crk and the GEF C3G. Some 
of the proteins forming the receptor complexes are shared between both receptors such 
as phosphatidylinositol 3-kinase or adaptor proteins such as Shc and Grb2. Other 
proteins are specific for each receptor (Segal and Greenberg, 1996). The main 
difference between EGFR and TrkA is that TrkA can recruit the adaptor protein FRS2 
(for fibroblast growth factor receptor substrate 2), which is a lipid-anchored docking 
protein. FRS2 can bind directly to TrkA through its phosphotyrosine binding domain 
(PTB) and is phosphorylated upon NGF stimulation. FRS2 can then recruit Grb2 and 
SHP-2. Kao et al demonstrated that the complex formed between Crk-C3G, Rap1 and 
B-Raf is scaffolded and stabilised at the NGF receptor by FRS2, thus leading to the 
sustained activation of ERK (Kao et al., 2001).  
The differential regulation of the activation of the ERK pathway is a complex event that 
is still not completely understood and that might results from positive and negative 
feedback regulation as well as crosstalk with other pathways such as the cAMP 
pathway. Chapter 1                                                                                                         Introduction 
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Figure 1. 6: Differential regulation of the ERK signalling pathway. In PC12 cells, 
EGF stimulation result in the transient activation of the ERK pathway causing the cells 
to proliferate, whereas NGF stimulation results in the sustained activation of the ERK 
pathway inducing the differentiation of the cells. According to Kao et al, the stability of 
the complex formation at the receptor determines the longevity of the signal and the 
outcome of the stimulation (Kao et al., 2001). 
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1.2  THE cAMP SIGNALLING PATHWAY 
The activation of the cAMP signalling pathway involves the binding of an extracellular 
ligand to a G protein-coupled receptor (GPCR), which through G proteins regulates one 
of several isoforms of adenylyl cyclase (ACs) leading to the generation of cAMP. 
Cyclic AMP mediates the signal through its three main effectors that are protein kinase 
A (PKA), nucleotide exchange factors Epac (exchange protein directly activated by 
cAMP) and cyclic nucleotide-gated (CNG) ion channels. The level of cAMP is also 
regulated by the family of phosphodiesterase (PDEs) enzymes that degrade cAMP and 
through their different subcellular compartmentalisation shape pools of cAMP within 
subcellular microdomains (Houslay, 1998; Zaccolo, 2006). 
1.2.1  cAMP generation and degradation 
3’,5’-cyclic adenosine monophosphate (cAMP) is a second messenger involved in 
regulation of a plethora of diverse cellular processes such as neurotransmission, muscle 
contraction, intracellular transport mechanisms and ion fluxes, and the regulation of 
metabolic processes such as glycogenolysis and lipolysis. In other contexts, cAMP can 
have long term effects on, for example, the regulation of the cell cycle, embryonic 
development, cell growth, proliferation and differentiation. 
The generation of cAMP is catalysed by adenylyl cyclases (ACs) that convert ATP to 
cAMP and pyrophosphate (Tang and Hurley, 1998). The reaction proceeds by the 
inversion of configuration at the -phosphate due to the direct displacement of 
pyrophosphate by attack of the 3’-OH on the -phosphate (Eckstein et al., 1981; Tang 
and Hurley, 1998). Then cAMP is degraded by phosphodiesterases (PDEs) that 
hydrolyse cAMP into AMP (Fig. 1.7). 
 
Figure 1. 7: The metabolism of cAMP. The second messenger cAMP is generated 
from ATP by adenylyl cyclases and hydrolysed into AMP by phosphodiesterases. Chapter 1                                                                                                         Introduction 
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1.2.2  Adenylyl Cyclases 
Nine membrane-bound isoforms (AC1 to AC9) and one soluble isoform (AC10) of 
mammalian ACs have been identified (Sunahara and Taussig, 2002). All membrane-
bound AC isoforms are found in excitable tissues such as neurons and muscles, 
however AC1 and AC3 are only found in the brain. The soluble AC10 is predominantly 
found in the testis. The membrane-bound AC isoforms exhibit a basal activity that is 
enhanced upon binding of stimulatory G protein -subunit (Gs) and reduced upon 
binding to the inhibitory G protein -subunit (Gi). Their activities are differentially 
regulated by binding calcium/calmodulin, through phosphorylation by PKC or PKA and 
by the association of various G-protein subunits (Hurley, 1999). The proposed structure 
(Fig. 1.8) based on the amino acid sequence includes a short variable amino terminus 
(N), six hydrophobic transmembrane spans (M1), a large cytoplasmic domain (C1), a 
second set of six transmembrane spans (M2) and another large cytoplasmic domain 
(C2). The C1 and C2 domains are subdivided into C1a and C1b; C2a and C2b. The C1a 
and C2a are homologous and contain the catalytic domains. The membrane-bound ACs 
share about 60% of sequence similarity and the most conserved sequences are located in 
the cytoplasmic domains C1 and C2 (between 50-90%). Mutations of amino acids in the 
C1 and C2 domains have demonstrated that these domains contribute to ATP binding 
and catalysis (Dessauer et al., 1997).  
The activation of adenylyl cyclase is initiated by the binding of hormones (Tang and 
Hurley, 1998), cytokines (Tachibana et al., 1998) or neurotransmitters (Spada et al., 
1997) to G protein-coupled receptors at the cell surface (Robinson et al., 1968). All 
membrane-bound ACs can also be directly activated by forskolin (Hurley, 1999). 
GPCRs communicate with intracellular membrane-associated G proteins consisting of a 
guanosine diphosphate-bound -subunit and a  heterodimer. The binding of the ligand 
to the GPCR induces a conformational change in the intracellular domain of the 
receptor that leads to the exchange of guanosine diphosphate (GDP) for guanosine 
triphosphate (GTP). The binding to GTP induces conformational changes resulting in 
the dissociation of the heterotrimeric G protein into  and  subunits. The dissociated 
-subunit binds to AC, which induces a conformational change in AC that brings 
together the C1 and C2 domains, resulting in the activation of AC (Hurley, 1999). Chapter 1                                                                                                         Introduction 
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Figure 1. 8: Schematic representation of membrane-bound adenylyl cyclases. The 
overall structure of the membrane-bound ACs consists of a variable cytosolic N-
terminus, six hydrophobic transmembrane spans (M1), a large cytoplasmic domain 
(C1), a second set of six transmembrane spans (M2) and another large cytoplasmic 
domain (C2). The C1 and C2 domains are subdivided into C1a and C1b; C2a and C2b. 
The C1a and C2a are homologous and contain the catalytic domains. 
1.2.3  Phosphodiesterases 
The termination of the cAMP signalling is controlled by phosphodiesterases (PDEs), 
which were first discovered shortly after the identification of cAMP (Butcher and 
Sutherland, 1962). PDEs hydrolyse the 3'-phosphoester bond of the 3', 5’-purine ribose 
cyclic monophosphate nucleotides leaving the residual 5'-monophosphate, thus 
terminating the cyclic nucleotide stimulated pathways in cells. This is important not 
only in the ablation of cellular signalling, but also in the maintenance of tight regulation 
of downstream effectors activity. In mammalian, there are currently 35 characterized 
PDEs encoded by more than 21 different genes and classified into 11 families of PDEs 
(see table 1.1) based on their amino acid sequences, substrate specificities, endogenous 
and exogenous regulators and pharmacological properties (Mehats et al., 2002). The 
mammalian PDEs share a common architecture consisting of a conserved catalytic 
domain located at the C-terminus and regulatory domains mostly at the N-terminus of 
the protein. The catalytic core contains common structural elements that are important 
for the hydrolysis of cyclic nucleotides, which consists of a PDE-specific motif (H-D-
[L/I/V/M/F/Y]-X-H-X-[A/G]-X-X-N-X-[L/I/V/M/F/Y]) and two consensus divalent 
cation (Zn
2+ or Mg
2+)-binding domains (Francis et al., 2001). 
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PDE 
Family 
Pharmacological 
classification 
Cyclic 
nucleotide 
substrates 
Inhibitors  No. of 
genes  Regulation 
PDE1  Ca
2+/CaM stimulated 
PDE 
cAMP and 
cGMP 
Vinpocetine 
(14M), W-7 
(300M) 
3 (+)Ca
2+/CaM 
(-) PKA, CamKII 
PDE2  cGMP-stimulated PDE  cAMP and 
cGMP 
EHNA (1M)  1  (+) cGMP, PKC 
(+/-) N-terminal 
targeting domain 
PDE3  cGMP-inhibited PDE  cAMP > cGMP  Cilostamide 
(20nM), 
milrinone 
(150nM), 
zardaverine 
(IC50 0.5-2M) 
2  (+) PKA, PKB 
(-) cGMP 
(+/-) N-terminal 
targeting domain 
PDE4  High affinity, rolipram-
sensitive cAMP-
specific PDE 
cAMP Rolipram  (1M)  4  (+) PKA, ERK, 
phosphatidic acid 
(-) ERK, 
caspases 
(+/-) N-terminal 
targeting domain 
PDE5  cGMP-specific PDE  cGMP  Zaprinast 
(130nM), 
sildenafil (10nM) 
1  (+) cGMP, PKG, 
PKA 
(-) caspases 
PDE6  Phosphoreceptor 
cGMP-specific PDE 
cGMP Zaprinast 
(400nM) 
3 (+)  Transducin 
(-) cGMP 
PDE7  High affinity, rolipram-
insensitive cAMP-
specific PDE 
cAMP IBMX  (4M) 2  (+/-)  PKA 
PDE8  High affinity and IBMX-
insensitive cAMP-
specific PDE 
cAMP Dipyridamole 
(9M) 
2 PAS  domain 
PDE9  High affinity cGMP-
specific PDE 
cGMP Zaprinast 
(35M) 
1  
PDE10  cAMP-inhibited cGMP 
PDE 
cAMP<cGMP Dipyridamole 
(1M) 
1 (-)  cAMP 
PDE11  Dual specificity cGMP-
binding PDE 
cAMP and 
cGMP 
Zaprinast 
(12M) 
1  
Table 1. 1: Properties of cyclic nucleotides PDE families 
1.2.3.1  The PDE1 family of phosphodiesterases 
There are three distinct isoforms of PDE1 called PDE1A, B and C. These isoforms are 
encoded by different genes and show differential tissue expression. The PDE1 isoforms 
are activated upon binding of Ca
2+ /CaM and have different affinities for Ca
2+ /CaM 
complex. The Ca
2+ /CaM complex binds within two regions of their N-terminal 
regulatory domains and determines subtle changes in the regulation of activity of PDE1 
isoforms (Kakkar et al., 1999). PDE1C hydrolyses both cAMP and cGMP with high 
affinity, while PDE1A and PDE1B selectively hydrolyse cGMP. Antagonists of CaM 
inhibit PDE1 activity but are not only selective for PDE1. Catalytic site inhibitors such 
as vinpocetine inhibit all PDE1, but PDE1C with less potency, and are not specific for 
any individual isoform (Kakkar et al., 1999).  Chapter 1                                                                                                         Introduction 
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1.2.3.2  The PDE2 family of phosphodiesterases 
The splice variants of PDE2 (PDE2A1, PDE2A2 and PDE2A3) are encoded by a single 
gene. These enzymes can hydrolyse both cAMP and cGMP (Rosman et al., 1997; Yang 
et al., 1994). The activation of PDE2 enzyme occurs following the binding of cGMP to 
the GAF domains located at the N-treminus of the protein (Martinez et al., 2002), 
increasing the affinity of the catalytic site for cAMP. PDE2 is localised to the adrenal 
cortex and several areas of the brain, as well as in goblet cells, olfactory neurones and in 
capillary and endothelial cells (Sadhu et al., 1999). PDE2 activity has been implicated 
in cardiac Ca
2+ channel control, catecholamine secretion in the central nervous system 
(Beavo, 1995) and in olfactory neurone signalling (Juilfs et al., 1997). 
1.2.3.3  The PDE3 family of phosphodiesterases 
There are two characterized PDE3 genes, PDE3A and PDE3B (Movsesian, 2002). 
PDE3A encodes for three different PDE3A isoforms PDE3A1, PDE3A2 and PDE3A3, 
whereas PDE3B encodes for a unique PDE3B enzyme (Movsesian, 2002). All PDE3 
isoforms show high affinity for cAMP and cGMP. However they poorly hydrolyse 
cGMP. PDE3A has been reported to be expressed in blood vessels, cardiovascular 
system and oocytes (Movsesian, 2002; Reinhardt et al., 1995). The highest level of 
PDE3B has been reported in brain, renal collecting duct epithelium, hepatocytes, 
adipocytes and developing spermatocytes (Movsesian, 2002; Reinhardt et al., 1995). 
The overall structure of PDE3 enzymes consists of a C-terminal catalytic domain and 
two N-terminal hydrophobic membrane association regions, named NHR1 and NHR2 
(Degerman et al., 1997). The catalytic domain consists of a 44 amino acid sequence that 
is specific for this PDE family and contributes for the catalytic activity and the inhibitor 
selectivity of PDE3 isoforms (Manganiello and Degerman, 1999). The two N-terminal 
hydrophobic domains are responsible for the membrane association of PDE3 isoforms, 
allowing them to have different subcellular locations (Shakur et al., 2000). They are 
predominantly membrane-associated but they can be either cytosolic. For example, 
PDE3A1 that possesses both NH1 and NH2 regions is found mainly in the particulate 
fraction; PDE3A2 that possesses only NH2 is found both in the cytosol and the 
particulate fraction; PDE3A3 which lacks both domains is cytosolic (Maurice et al., 
2003). Following the N-terminal hydrophobic domains are consensus sites for 
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PKB increases their PDE activity (Manganiello and Degerman, 1999; Smith et al., 
1991). Taken together, it is suggested that the hydrophobic domain may be involved in 
the association between PDE3 with either chaperones, which assist in targeting and 
membrane insertion or with anchoring proteins analogous to the PKA anchoring 
proteins (AKAPs), which target PKA to cellular membranes such as the plasma 
membrane, the endoplasmic reticulum, Golgi or mitochondria, in order to target PDE3 
isoforms in proximity to membrane-associated signalling molecules (Shakur et al., 
2001; Shakur et al., 2000). PDE3 isoforms are also directly regulated by cGMP that 
competes for the cAMP binding site of the catalytic domain (Manganiello and 
Degerman, 1999; Tilley and Maurice, 2002). A number of PDE3 inhibitors exist, such 
as cilostamide, milirone and amrinone.  
1.2.3.4  The PDE4 family of phosphodiesterases 
PDE4 enzymes currently provide the largest known PDE family. Four genes PDE4A-D 
encode for the PDE4 isoforms, giving rise to at least 18 different splice variants. These 
isoforms can be grouped into long, short and super-short categories (Houslay and 
Adams, 2003). All PDE4 isoforms have a conserved catalytic region, located within a 
360 amino acid domain. The ‘long’ isoforms have two of the conserved N-terminal 
regulatory domains, termed UCR1 (for upstream conserved region 1) and UCR2 of 59 
and 79 amino acids, respectively. A linker region (LR1) of 24 amino acids separates 
UCR1 and UCR2, which is the site spliced to produce truncated proteins lacking UCR1 
in the ‘short’ isoforms. The ‘super-short’ PDE4 species have an N-terminal truncation 
within the UCR2 region of the protein and unique N-terminal sequences (Houslay, 
2001). The various PDE4 isoforms are expressed in almost all cell types, except blood 
platelets. PDE4 enzymes are specific for the hydrolysis of cAMP. Modulation of PDE4 
activity is carried out by post-translational modifications such as phosphorylation, and 
through interaction with adapter proteins and phospholipids (Houslay, 2001). Indeed, 
selected PDE4 variants are localised to subcellular regions through interactions with 
various scaffolding or anchoring proteins including AKAPs (A kinase anchoring 
proteins), RACK (receptor for activated c kinase), -arrestin (Houslay, 2001; Houslay 
and Adams, 2003). For example, long forms of PDE4 isoforms are activated by PKA 
phosphorylation, whereas long and short forms of PDE4 are differentially regulated by 
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  42 
1.2.4  cAMP effectors: PKA, Epac, ion gated channels 
Cyclic AMP activates several downstream signalling mechanisms through direct 
interaction with proteins. The best characterised cAMP effector is the protein kinase A 
(PKA). It was thought to be the only direct effector of cAMP (Brostrom et al., 1970; 
Walsh et al., 1968), with the exception of the cyclic nucleotide-gated ion channels 
found in specialised cells like olfactory neurons (Zufall et al., 1997), until the discovery 
of nucleotide exchange protein directly activated by cAMP termed Epac (de Rooij et al., 
1998). 
1.2.4.1  Protein Kinase A: PKA 
Protein kinase A (PKA) was first characterised in 1968 (Walsh et al., 1968). It is 
activated through the cooperative binding of cAMP. The inactive PKA is a 
heterotetrameric holoenzyme consisting of two regulatory subunits (R) and two 
catalytic subunits (C). The cooperative binding of two cAMP molecules to each of the R 
subunits induces a conformational change which results in the release of the C subunits 
that can phosphorylate their target proteins (Johnson et al., 2001). More and more 
proteins that can be phosphorylated and activated by PKA are still being identified 
(Shabb, 2001). The consensus sites for PKA phosphorylation have been identified as R-
R-X-S/T, R/K-X-X-S/T and R/K-X-S/T, where X stands for any hydrophobic amino 
acid (Kennelly and Krebs, 1991; Shabb, 2001). Three different genes encode for the C 
subunits C, C and C. Four genes express the R subunits RI, RI, RII and RII 
(Chrivia et al., 1988; Jahnsen et al., 1986; Scott et al., 1987). Two types of 
heterotetramers have been reported to exist in vivo: PKA holoenzymes type I (RI2C2 
and RI2C2) and type II (RII2C2 and RII2C2). The PKAII holoenzymes are assembled 
preferentially over PKAI under physiological conditions (Francis and Corbin, 1994). 
The assembly of different catalytic and regulatory subunits gives rise to a number of 
PKA holoenzymes which possess different biological characteristics (Skalhegg and 
Tasken, 2000). The PKA type I complex is generally cytoplasmic and is activated 
transiently by weak cAMP signalling (Houslay and Milligan, 1997). The type II 
complex, however, is associated with cellular structures and organelles and responds 
only to high and persistent cAMP stimulation (Rubin et al., 1979; Stein et al., 1987). 
PKA, along with other signalling proteins, can be targeted to distinct subcellular regions 
through the interaction with A-kinase anchoring protein (AKAPs).  Chapter 1                                                                                                         Introduction 
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1.2.4.2  Exchange Protein Directly Activated by cAMP: Epac 
More recently a new effector for cAMP, the exchange protein directly activated by 
cAMP or Epac, was discovered. This discovery came out when Bos’ group noticed that 
the activation of Rap1 was insensitive to the inhibition of PKA (de Rooij et al., 1998). 
Epac is a cAMP-responsive guanine nucleotide exchange factor (GEF) for the small 
GTP-binding proteins Rap1 and Rap2 (de Rooij et al., 1998). Two isoforms have been 
identified, Epac1 and Epac2 (Fig. 1.9). Both isoforms have a N-terminal DEP 
(dishevelled, Egl-10, pleckstrin) domain involved in membrane localisation (de Rooij et 
al., 1998), a cAMP binding domain (CBD), a Ras exchange motif (REM) and a guanine 
nucleotide exchange factor homology domain (GEF) (Christensen et al., 2003). Epac 2 
has another CBD and a Ras-association domain (RA) that can interact with active Ras. 
It is likely that the CBD folds upon the GEF domain to prevent interaction with 
effectors. The conformation of Epac changes when binding to cAMP, exposing the GEF 
domain that activates downstream targets (Qiao et al., 2002). The main effectors of 
Epac1 and 2 are the Ras-like small G-proteins Rap1 and Rap2 (de Rooij et al., 1998; 
Enserink et al., 2002; Rehmann et al., 2003).  
 
Figure 1. 9: The structure of Epac1 and Epac2. The Epac isoforms consist of a N-
terminal DEP (dishevelled, Egl-10, pleckstrin) domain involved in membrane 
localisation, a cAMP binding domain (CBD), a Ras exchange motif (REM) and a 
guanine nucleotide exchange factor homology domain (GEF). Epac 2 has another CBD 
and a Ras-association domain (RA) that can interact with active Ras. 
1.2.4.3  Cyclic Nucleotide-gated ion channels 
Cyclic nucleotide-gated (CNG) ion channels on the cell membrane are biological 
effectors of cyclic nucleotide action. To date, over 20 genes encoding different subtypes 
of CNGs have been cloned from invertebrates and vertebrates (Wei et al., 1997). The 
CNG channels belong to the class of ligand-gated cation channels and are opened by the 
direct binding of cAMP or cGMP. They contribute to cellular control of the membrane 
potential and intracellular Ca
2+ levels. The CNG ion channels are multi-subunit pore-
forming channels. The best-studied cAMP gated channel is the olfactory cyclic Chapter 1                                                                                                         Introduction 
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nucleotide channel, which is activated equally by both cAMP and cGMP (Shabb, 2001). 
This nonselective ion channel is activated in response to odorant binding to G protein-
coupled olfactory receptors which, in turn, results in the activation of adenylyl cyclase 
(Shabb, 2001).  
1.2.5  Compartmentalization of the cAMP-depedent PKA activity: AKAP 
The intracellular targeting and compartmentalization of the cAMP-dependent PKA 
signalling is controlled through the association with A-kinase anchoring proteins or 
AKAPs. The AKAP family comprises about 50 anchoring proteins that have diverse 
structures. They bind to PKA and to co-precipitate with PKA catalytic activity (Tasken 
and Aandahl, 2004; Wong et al., 2004). All AKAPs contain a PKA-binding domain 
located at the C-terminus and a unique targeting domain in the N-terminus that 
participates in the association of AKAPs with membranes or organelles targeting the 
PKA-AKAP complex to specific subcellular compartments. In general, AKAPs bind the 
PKA type II (RII2C2) with high affinity and poorly bind to PKA type I (RI2C2) (Carr et 
al., 1992; Herberg et al., 2000). The PKA-binding domain consists of 14-18 
hydrophobic amino acids forming an amphipathic -helix that binds to the N-terminal 
dimerisation domain of the R subunits of PKA (Dell'Acqua and Scott, 1997; Newlon et 
al., 1997; Wong et al., 2004). More recently it was reported that some AKAPs bind 
specifically to the RI subunits of PKA (McConnachie et al., 2006; Wang et al., 2006a) 
and others have dual affinity for both RI and RII PKA subunits (Huang et al., 1999). 
AKAP79, AKAP82 and AKAP220 were characterised as dual specific AKAPs and can 
bind to both RI and RII PKA subunits (JarnÃss and TaskÃ©n, 2007). In addition to 
these domains certain AKAPs are able to form multivalent complexes by interaction 
with phosphatases, kinases and other proteins involved in signal transduction (Wong et 
al., 2004). AKAPs participate in the spatial and temporal regulation of the PKA 
signalling by exposing PKA to isolated cAMP gradients and allowing efficient catalytic 
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1.3  EVIDENCE OF CROSSTALK BETWEEN THE cAMP & THE ERK 
SIGNALLING PATHWAYS 
1.3.1  Inhibition of Raf-1 by cAMP through PKA 
In the early 1990s, it was discovered that elevation of cAMP induced a profound 
inhibition in the activation of ERK by growth factors in Rat1 and NIH3T3 fibroblasts 
and in vascular smooth muscle cells (Cook and McCormick, 1993; Hafner et al., 1994; 
Sevetson et al., 1993; Wu et al., 1993). Raf-1 was identified to be the target of cAMP 
and that PKA was required for the inhibition of Raf-1 by cAMP (Cook and McCormick, 
1993; Hafner et al., 1994; Sevetson et al., 1993; Wu et al., 1993). However there are 
still debates about the exact mechanisms.  
One possible mechanism that has been suggested involves the small G-protein Rap1 
(Schmitt and Stork, 2001). Indeed Rap1 was first identified as an inhibitor of ERK in 
Rat-1 fibroblasts (Cook and McCormick, 1993). This model suggests that Rap1, 
activated in a PKA dependent manner, antagonises Ras activation of Raf-1 by binding 
and sequestering Raf-1 away from Ras (Okada et al., 1999; Schmitt and Stork, 2001). 
However, studies using Epac selective activator have demonstrated that the activation of 
Rap1 did not inhibit ERK activation (Enserink et al., 2002). It is unlikely that Rap1 is 
responsible for blocking Raf-1 activation upon elevated levels of cAMP. 
Another possible mechanism involves direct phosphorylation of Raf-1 by PKA resulting 
in the inhibition of Raf-1. It was demonstrated that PKA can phosphorylate Raf-1 on 
serines 43, 233, 259 and 621 both in vitro and in vivo (Dhillon et al., 2002b; Dumaz et 
al., 2002; Hafner et al., 1994; Sidovar et al., 2000). These sites appear to be 
phosphorylated in resting cells but are hyperinduced by PKA (Dhillon et al., 2002a). 
Moreover, these sites work independently to inhibit Raf-1 and they have to be all 
mutated to render Raf-1 completely resistant to PKA inhibition (Dumaz et al., 2002; 
Sidovar et al., 2000). Wu et al demonstrated that the phosphorylation on S43, which is 
located just upstream to the RBD, lowers the affinity of Raf-1 to Ras-GTP that is the 
active form of Ras (Wu et al., 1993). Therefore the phosphorylation of S43 by PKA 
prevents Raf-1 to bind and to be activated by Ras. However, the phosphorylation of S43 
is not exclusive for the inhibition of Raf-1 by PKA as it was demonstrated that mutation 
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susceptible to inhibition by PKA (Dhillon et al., 2002b; Dumaz et al., 2002). 
Phosphorylated serines 233, 259 and 621 are docking sites for 14-3-3 proteins, which 
are adapter proteins that bind to short phosphorylated peptide motifs (Yaffe, 2002). It 
was demonstrated that S259 is the major phosphorylation site for the inhibition by PKA 
(Dhillon and Kolch, 2002). When 14-3-3 binds to these sites, it antagonises Ras 
binding. The mechanisms through which this occurs remained unclear but it is thought 
that 14-3-3 binding to Raf-1 might directly compete with Ras for the CRD of Raf-1 or 
might modify Raf-1 conformation and mask the RBD. Dumaz and Marais from their 
research have suggested a model for the regulation of Raf-1 by cAMP (Dumaz and 
Marais, 2005). They proposed that in resting cells, S259 and S621 are phosphorylated 
allowing 14-3-3 to bind and trap Raf-1 in an inactive form. In normal conditions, Ras 
activation recruits Raf-1 to the plasma membrane removing 14-3-3 from the 
phosphorylated S259, which can be dephosphorylated by PP2A. Once S259 is 
dephosphorylated then Raf-1 can be activated through a series of further 
phosphorylations. Upon elevated cAMP levels, activated PKA can also phosphorylate 
Raf-1 on S43 and S233. The phosphorylation on S233 creates a new binding site for 14-
3-3. It seems that 14-3-3 has a higher affinity for phosphorylated S233 than S621, and 
therefore 14-3-3 would bind to phosphorylated S233 rather than to phosphorylated 
S621. Their hypothesis is that in this particular conformation due to high levels of 
cAMP, Ras cannot displace 14-3-3 from phosphorylated S259 and Raf-1 cannot be 
activated. 
1.3.2  Activation of B-Raf by cAMP via Rap1 
While it has been well documented that cAMP induces the inhibition of cell 
proliferation, cAMP can also stimulate cell proliferation and differentiation by 
promoting ERK activity in certain cell types such as ovarian granulosa cells, melanoma 
or neuronal cells (Houslay and Kolch, 2000; Vossler et al., 1997; Young et al., 1994). It 
was demonstrated that the activation of ERK by cAMP requires the activation of Rap1 
and B-Raf (Dugan et al., 1999; Schmitt and Stork, 2000; Zanassi et al., 2001). As 
described previously in the section 1.1.4, Rap1 can bind to and activate B-Raf (Vossler 
et al., 1997; York et al., 1998). Furthermore, agonist screening assays showed that 
cAMP elevating agents such as forskolin increased the level of phosphorylation of Rap1 
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still subject to debate regarding the involvement of PKA. Both PKA-dependent and 
independent activation of Rap1 by cAMP have been proposed. In the PKA-dependent 
mechanism, it was suggested that PKA activates Rap1 through the phosphorylation of 
Src (Obara et al., 2004). In the PKA independent mechanism, the activation of Rap1 
seems to be mediated by a Rap1 specific GEF, also called exchange protein directly 
activated by cAMP (Epac) described in the section 1.2.4.2. (de Rooij et al., 1998; 
Enserink et al., 2002).  
The activation of B-Raf by cAMP remains controversial and the models described 
above have been challenged by several studies. For example, the activation of Rap1 by 
cAMP or Epac agonist (8-CPT(MeO)cAMP) did not always result in the activation of 
B-Raf (Zwartkruis et al., 1998) or the activation of ERK (Enserink et al., 2002).  
1.3.3  The Crosstalk between the cAMP and the ERK signalling pathways 
in PC12 cells 
In PC12 cells, cAMP induces neuronal differentiation (Greene and Tischler, 1976; 
Gunning et al., 1981; Vossler et al., 1997). As described in the sections 1.1.7 and 1.1.8, 
the neuronal differentiation of PC12 cells is a result of the longevity of the activation of 
ERK. York et al demonstrated that sustained activation of ERK upon NGF stimulation 
is the result of the activation of two distinct pathways where the small G-protein Ras 
initiates the activation of ERK, which is sustained by the activation of Rap1 (York et 
al., 1998). They identified the formation of a stable complex at the receptor between the 
adaptor protein Crk and the GEF C3G that selectively activates Rap1. This is supported 
by the work of Kao et al that show that the complex formation between Crk, C3G and 
Rap1 is scaffolded and stabilised by FRS2 that binds to TrkA (NGF receptor) but not to 
EGF receptor (Kao et al., 2001). They showed that the longevity of this complex 
correlates with the sustained activation of ERK upon NGF stimulation. They also 
demonstrated that in PC12 cells, endogenous B-Raf contributes to 90% of the activation 
of ERK, showing that PC12 cell differentiation is mainly mediated through B-Raf 
compare to Raf-1. Previous work from Erhardt and colleagues in PC12 cells showed 
that Raf-1 is inhibited by cAMP, whereas B-Raf is resistant to the inhibition by cAMP 
in serum-containing medium (Erhardt et al., 1995). While the mechanisms are still not 
totally understood, there is much evidence of the inhibition of Raf-1 by cAMP through 
PKA as described in the section 1.3.1. Finally, Vossler et al demonstrated that the Chapter 1                                                                                                         Introduction 
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activation of ERK by cAMP requires both Rap1 and B-Raf (Vossler et al., 1997). As 
described in the previous section 1.3.2, the mechanisms of the activation of Rap1 by 
cAMP might involve PKA or Epac (the exchange factor protein directly activated by 
cAMP).  
From these observations we hypothesised that the signal initiated by growth factors 
would utilise distinct pathways: Ras/Raf-1/MEK/ERK and Rap1/B-Raf/MEK/ERK. The 
transient activation of ERK upon EGF would be mainly mediated through Ras/Raf-
1/MEK, whereas the sustained activation of ERK would be mediated through both 
Ras/Raf-1/MEK and Rap1/B-Raf/MEK. The cAMP pathway would interact with the 
ERK pathway by inhibiting Raf-1 through PKA and by activating B-Raf though the 
activation of Rap1 by either PKA or Epac to strengthen the mitogen signal (Fig. 1.10).  
 
Figure 1. 10: Schematic representation of the crosstalk between the ERK and the 
cAMP signalling pathways. We hypothesised that the signal initiated by growth 
factors would utilise distinct pathways: Ras/Raf-1/MEK/ERK and Rap1/B-
Raf/MEK/ERK. The transient activation of ERK upon EGF would be mainly mediated 
through Ras/Raf-1/MEK and transiently through Rap1/B-Raf/MEK, whereas the 
sustained activation of ERK would be mediated through both Ras/Raf-1/MEK and 
Rap1/B-Raf/MEK. The cAMP would serve to finely tune the regulation of the ERK 
pathway by inhibiting Raf-1 through PKA and activating B-Raf though the activation of 
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The aim of this research is to determine the mechanisms through which cAMP crosstalk 
with the ERK signalling pathway occurs and to verify if PKA and Epac are involved in 
these mechanisms. This research also aimed to elucidate the mechanisms through which 
NGF mediates sustained activation of ERK and PC12 cell differentiation, while EGF 
mediates transient ERK activation of ERK and cell proliferation. 
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2.1  MATERIALS 
2.1.1  Antiserum 
Primary Abs  Type  Host  WB Dilution  Supplier 
Phospho-p44/42 
MAPK 
(Thr202/Tyr204) 
Monoclonal Mouse 1:2000  Cell Signaling 
Technology® 
Phospho-p44/42 
MAPK 
(Thr202/Tyr204) 
Polyclonal Rabbit  1:1000  Cell Signaling 
Technology® 
ERK Polyclonal  Rabbit  1:1000  Cell Signaling 
Technology® 
ERK 1 (C-16)  Polyclonal  Rabbit  1:1000  Santa Cruz 
Biotechnology 
ERK 2 (C-14)  Polyclonal  Rabbit  1:1000  Santa Cruz 
Biotechnology 
Anti-ERK1/2 pan Ab  Polyclonal  Rabbit  1:1000  Biosource 
Phospho-MEK1/2 
(Ser217/221)  Polyclonal Rabbit  1:1000  Cell Signaling 
Technology® 
MEK  1  Monoclonal Mouse 1:1000  BD  Biosciences 
MEK  2  Monoclonal Mouse 1:2500  BD  Biosciences 
MEK1/2 Polyclonal Rabbit  1:1000  Cell Signaling 
Technology® 
Raf-1 Polyclonal  Rabbit  1:1000  Cell Signaling 
Technology® 
c-Raf  Monoclonal Mouse 1:1000  BD  Biosciences 
Phospho-c-Raf 
(Ser259)  Polyclonal Rabbit  1:1000  Cell Signaling 
Technology® 
Phospho-c-Raf 
(Ser338)  Monoclonal Rabbit 1:1000  Cell Signaling 
Technology® 
B-Raf Polyclonal  Rabbit  1:1000  Upstate® 
Ras  Monoclonal Mouse 1:1000 Upstate® 
Rap1 Polyclonal  Rabbit  1:1000  Upstate® 
Ras-GRF2 (C3G)  Monoclonal  Mouse  1:250  BD Biosciences 
PDE3A (G-20)  Polyclonal  Goat  1:1000  Santa Cruz 
Biotechnology 
PDE3B (H-300)  Polyclonal  Rabbit  1:1000  Santa Cruz 
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Primary Abs  Type  Host  WB Dilution  Supplier 
Phospho-(Ser/Thr) 
PKA Substrate  Polyclonal Rabbit  1:1000  Cell Signaling 
Technology® 
AKAP 79  Polyclonal  Rabbit  1:1000  Santa Cruz 
Biotechnology 
AKAP  82 Monoclonal Mouse 1:5000  BD Transduction 
Laboratories 
AKAP 220  Monoclonal  Mouse  1:250  BD Transduction 
Laboratories 
AKAP 250  Polyclonal  Goat  1:1000  Santa Cruz 
Biotechnology 
FLAG Monoclonal  Mouse  1:10000  Sigma 
Phospho-SRC(Tyr418) Polyclonal  Rabbit  1:1000  Biosource 
Table 2. 1: List of primary antibodies 
 
Secondary Ab  Type  Host  Dilution  Supplier 
Anti-Rabbit IgG  Peroxidase conjugate  Goat  1/5000  Sigma 
Anti-Mouse IgG  Horseradish 
peroxidase conjugate  Sheep 1/5000  Amersham 
Biosciences 
Anti-Goat IgG  Peroxidase conjugate  Rabbit  1/5000  Sigma 
AlexaFluor® 680 Anti-
Rabbit IgG 
Fluorescent dye 
conjugate  Goat 1/2000  Molecular  Probes 
AlexaFluor® 680 Anti-
Mouse IgG 
Fluorescent dye 
conjugate  Goat 1/2000  Molecular  Probes 
IRDyeTM 800 Anti-
Mouse IgG 
Fluorochrome 
conjugate  Rabbit, Goat  1/5000  Rockland Inc. 
IRDyeTM 800 Anti-
Rabbit IgG 
Fluorochrome 
conjugate  Donkey 1/5000  Rockland  Inc. 
IRDyeTM 800 Anti-
Goat IgG 
Fluorochrome 
conjugate  Donkey 1/5000  Rockland  Inc. 
Table 2. 2: List of secondary antibodies 
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2.1.2  Pharmacological inhibitors 
Calbiochem 
Cilostamide, N-Cyclohexyl-N-methyl-4-(1,2-dihydro-2-oxo-6-quinolyloxy) butyramide 
Rolipram, 4-[3-(Cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone 
Sigma-Aldrich 
EHNA, erythro-9-(2-Hydroxy-3-nonyl) adenine hydrochloride 
IBMX, 3-Isobutyl-1-methylxanthine 
Vinpocetine, (3, 16)-Eburnamenine-14-carboxylic acid ethyl ester 
KT5720, (9S,10S,12R)-2,3,9,10,11,12-Hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-
epoxy-1H-diindolo[1,2,3-fg:3,2,1-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic 
acid hexyl ester 
2.1.3  cAMP analogues 
BioLog Life Science Institute 
PKA agonist, N
6- Benzoyladenosine- 3', 5'- cyclic monophosphate (6-Bnz-cAMP) 
EPAC agonist, 8- (4- Chlorophenylthio)- 2'- O- methyladenosine- 3', 5'- cyclic 
monophosphate ( 8-pCPT-2'-O-Me-cAMP / 8-CPT-2'-O-Me-cAMP) 
2.1.4  General Reagents 
All reagents were purchased from Sigma unless listed here. 
Amersham Biosciences: ECL
TM Western Blotting Detection Reagent 
BDH Biochemical: NaCl, Hepes 
Bio-Rad Laboratories: Precision Plus Protein Prestained Standard, Bio-Rad Protein 
Assay 
Costar: 6-well tissue culture plates 
Dharmacon: Smart pools of ON-TARGET plus siRNAs for rat B-Raf and Raf-1 
Fisher BioReagents: Tris/Base 
ICN Biomedicals: PBS (tablets) 
Invitrogen: LipofectAMINE 2000 transfection reagent, Novex™ mini-cell gel tank, 
Novex™ XCell II™ Blot module, NuPage
® 4-12% Bis-Tris gels, NuPAGE
® MES 
buffer, NuPAGE
® MOPS buffer, NuPAGE
® transfer buffer 
Life Technologies/Gibco: DMEM, L-glutamine, MBP, trypsin 
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Promega: Nerve Growth Factor, mNGF (2.5S, Murine), Pure Yield™ Plasmid 
Maxiprep System 
Qiagen: plasmid purification kits (maxi) 
Roche Diagnostics/Boehringer Mannheim: EDTA, EGTA, leupeptin, Complete 
EDTA-Free protease inhibitor cocktail tablets 
Sterilin: dishes for agar plates 
Upstate: cAMP HTS Immunoassay kit, Raf-1 and B-Raf Kinase Cascade Assay Kit 
Whatman: Protran BA85 nitrocellulose membrane, 3MM paper 
2.2  CELL CULTURE 
2.2.1  PC12 cells 
The PC12 cells, a cell line derived from a pheochromocytoma of the rat adrenal 
medulla, were maintained in complete, antibiotic-free media made of Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 10% (v/v) Horse Serum, 5% 
(v/v) foetal bovine serum (FBS) and 3.2 mM L-Glutamine. They were grown at 37˚C in 
5% CO2. When reaching about 80% of confluency, cells were split at a ratio of 1:4 into 
fresh media. 
2.2.2  HEK 293 cells 
The human embryonic kidney cell line, HEK 293 cells, was maintained in complete 
media made of DMEM complemented with 10% (v/v) FBS, 2 mM L-Glutamine, 1% 
(v/v) MEM and penicillin/streptomycin (100 units/ml). They were grown at 37˚C in 5% 
CO2. When the cells were about 80% confluent they were splited 1:10. This was done 
by rinsing once the cells with 5 ml of pre-warmed and steril phosphate buffered saline 
(PBS) solution then by applying 1ml of trypsin for 2 min at room temperature to detach 
the cells from the bottom of the culture flask. The cells were diluted into 9 ml of fresh 
medium of which 1ml was dispensed into a new culture flask. 
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2.2.3  HEK2 cells 
HEK2 cells were maintained in complete media made of DMEM complemented with 
10% (v/v) newborn calf serum (NCS), 2 mM L-Glutamine, 1% (v/v) MEM, 2% (v/v) G-
418 and penicillin/streptomycin (100 units/ml). They were grown at 37˚C in 5% CO2. 
When the cells were about 80% confluent, they were trypsinised and splited 1:5 in new 
culture flask as described above. 
2.2.4  Transfection 
2.2.4.1  PolyFect
® DNA transfection of HEK 293 cells 
DNA transfection of HEK 293 cells was performed using PolyFect
® reagent from 
Qiagen. The cells were plated onto 100 mm dishes and grown overnight to 50%-80% 
confluency. 8 μg of DNA was diluted with basal medium (DMEM) to a total volume of 
300 μl. 80 μl of PolyFect
® reagent was added to the DNA solution, mixed by pipetting 
and incubated at room temperature for 10-15 min. During that time, the medium from 
the culture dishes was removed and replaced with 7 ml of fresh growth medium. 1ml of 
normal growth medium was added to the DNA solution and mixed by gentle pipetting. 
The total DNA mixture was added to the cells and mixed by gentle swirling. The cells 
were treated and/or harvested 24-48 h after transfection. 
2.2.4.2  siRNA transfection of PC12 cells with Lipofectamine
TM 2000 
One day before transfection, PC12 cells were plated onto poly-L-lysine pre-coated 6-
well plates in normal growth medium and in an appropriate dilution that they will be 30-
50% confluent at the time of transfection. The day of the transfection, the siRNA 
oligomer was diluted in the appropriate volume of Opti-MEM
® I Reduced Serum 
Medium to have a final concentration of 100 nM (or 200 pmol) per well. 
Lipofectamine
TM 2000 (4 μl/well) was diluted in the appropriate amount of Opti-MEM
® 
I Reduced Serum Medium. Both mixtures were mixed gently and incubated for 10 min 
at room temperature. After the 10 min the diluted oligomer solution was combined with 
the diluted Lipofectamine
TM 2000 solution to allow complex formation to occur. The 
final mixtures were mixed gently and incubated for 20 min at room temperature. During 
that time, the medium was removed from the well and replaced by 800 μl of pre-
warmed Opti-MEM
® I Reduced Serum Medium. After the 20 min, the oligomer-
Lipofectamine
TM 2000 complexes were added to each well and mixed by swirling the Chapter 2                                                                                            Material & Methods 
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plates. After 6 hours of incubation, the Opti-MEM
® I Reduced Serum Medium was 
removed and replaced by fresh growth medium. The cells were incubated for 72-96 
hours at 37ºC in 5% CO2 before being treated and assessed for gene knockdown. 
2.2.5  Cell Treatment 
2.2.5.1  Time courses 
6 well plates were coated with 10% (v/v) poly-L-lysine in PBS for 1 hour at room 
temperature. The poly-L-lysine was then removed and the plates were let to dry at room 
temperature. PC12 cells were plated onto the pre-coated plates in normal growth 
medium and left to adhere over night at 37˚C in 5% CO2. 3 hours before starting an 
experiment, the medium was removed and replaced by a serum-free medium (DMEM 
supplemented with 3.2 mM L-Glutamine). The cells were then treated with indicated 
drugs and stimulated with either NGF or EGF for different periods of time. 
2.2.5.2  Differentiation of PC12 cells 
PC12 cells were plated onto poly-L-lysine pre-coated 6-well plates in normal growth 
medium and left to adhere over night at 37˚C in 5% CO2. The cells were treated with 
the appropriate drug then stimulated with NGF or EGF for 72 hours. The cells were 
observed under a microscope (AxioVert B5) and for each treatment 10 phase contrast 
images were taken randomly with a Carl Zeiss monochrome digital camera (AxioCam 
MRm) and analyzed with the Axiovision software. 
2.2.6  Preparation of cell lysates 
Time points were sampled by discarding the medium and washing cells once with ice-
cold PBS. Then, the cells were lysed by adding ice-cold 3T3 Lysis buffer or RIPA 
buffer supplemented with cocktails of protease and phosphatase inhibitors. Cells were 
removed from the bottom of the plates using a cell scraper and transferred into 1.5 ml 
eppendorf tubes. The tubes were rotated on a wheel for 20 min at 4˚C. To remove the 
unwanted cell debris, the lysates were centrifuged for 5 min at 13000 g and at 4˚C. The 
supernatants were transferred into fresh eppendorf tubes and used directly or stored at -
20˚C. The protein concentration was measured as described in the section 2.2.2 and was 
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2.3  BIOCHEMISTRY 
2.3.1  Buffers 
•  3T3 Lysis Buffer: 25 mM Hepes, pH 7.4, 50 mM NaCl, 10% (v/v) glycerol and 
1% (v/v) Triton X-100. Before use, this buffer was supplemented with Complete 
EDTA-Free protease inhibitor cocktail and with phosphatase inhibitors (1 mM sodium 
orthovanadate, 50 mM sodium fluoride and 5 mM sodium pyrophosphate). 
•  RIPA Buffer: 50 mM Tris/HCl, pH 8, 132 mM NaCl, 0.1% (v/v) SDS, 1% (v/v) 
triton X-100, 1.1 mM EDTA, and 5.5 mM EGTA. Before use, the RIPA buffer was 
supplemented with protease, phosphatase and proteasome inhibitors. 
•  TBS: 20 mM Tris/HCl, pH 7.6, 137 mM NaCl 
•  TBST: 20 mM Tris/HCl, pH 7.6, 137 mM NaCl and 1% (v/v) TWEEN 20 
•  Stripping Buffer: 0.75% (w/v) glycine, 0.87% (w/v) NaCl 
•  PDE Assay diluting buffer: 20 mM Tris/HCl, pH 7.4 and 10 mM MgCl2 
•  5 Sample Buffer: 10% (w/v) SDS, 300 mM Tris/HCl, pH 6.8, 0.05% (w/v) 
bromophenol blue, 50% (v/v) glycerol, 10% (v/v) mercaptoethanol 
•  Dialysis Buffer: 50 mM Tris/HCl, pH 8.0, 100 mM NaCl, 5% (v/v) glycerol 
2.3.2  Protein Assay 
Total protein concentration of each samples were measured using the BioRad’s protein 
assay based on the Bradford assay and carried out in 96 well microtitre plates. A 
spectrophotometric standard curve of protein concentration was produced using a serial 
dilution from 0 to 5 μg bovine serum albumin (BSA). 10 μl of diluted lysate sample was 
analysed in triplicate. The Bio-Rad Bradford Assay reagent was diluted 1:5 with 
distilled water and 200 μl was added to each well. The 96-well plate was then analysed 
using the Revelation package on a computer, connected to an MRX microtitre plate 
reader, which read absorbance at a wavelength of 590 nm. Protein concentrations were 
determined by plotting the standard curve and using a least squared regression analysis 
to obtain the line of best fit. The equation of the line was used to determine the protein 
concentration of each sample. 
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2.3.3  Western Blot 
2.3.3.1  Electrophoresis 
Proteins were separated according to their molecular weight by electrophoresis using 
the NuPAGE® Novex® system from Invitrogen. This system is based upon a Bis-Tris-
HCl buffered polyacrylamide gel that works in neutral pH (pH 7.0), which minimizes 
protein modifications. Polyacrylamide gradient gels (4-12% Bis-Tris polyacrylamide 
gels) were used to optimize the separation of small to medium-sized proteins. Proteins 
to be analysed were denaturated using sample buffer that contains reducing agents 
(mercaptoethanol and SDS). SDS also confers a net negative charge on the proteins, 
which allow them to migrate across the gel when the electic current is applied. Thus, the 
denaturated and negatively charged proteins migrate through the polyacrylamide gels 
toward the anode depending on their size, with the smaller proteins migrating further 
through the gel than the larger proteins. Proteins were separated along a protein 
standard marker (Precision Plus Protein Prestained Standard from BioRad) to estimate 
the size of the proteins of interest. NuPAGE
® MES buffer was used to separate small 
proteins (such as ERK), while NuPAGE
® MOPS was used to separate larger proteins 
(such as Raf). Electrophoresis were run for about 45 min at 160 V. 
2.3.3.2  Protein Transfer 
Proteins separated in the polyacrylamide gels (as described above) were transferred onto 
nitrocellulose membranes by electroblotting. Basically, a polyacrylamide gel was placed 
on a sheet of Whatman 3MM paper. Then a nitrocellulose membrane was placed on top 
of the gel and the membrane was covered with another sheet of Whatman paper. The 
assembly was covered on both side with sponges (provided by Invitrogen) and finally 
the “swandich” was placed in a XCell II™ Blot Module and immersed in NuPAGE
® 
Transfer Buffer from Invitrogen as followed: the gel facing the negative electrode and 
the membrane facing the positive electrode. Thus, when the electric current was applied 
the negatively charged proteins in the gel migrated to the nitrocellulose membrane 
toward to positive electrode. Transfers were carried out for 1.5 h at 30 V.  
2.3.3.3  Blocking 
The membranes were blocked for at least 1h with gentle shaking in 5% (w/v) milk in 1 
TBS (for ODYSSEY analysis) or in 5% (w/v) milk in 1 TBST (for ECL analysis). 
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2.3.3.4  Immunoblotting and Detection 
ODYSSEY Near-infrared Detection 
After blocking, the membranes were incubated with one or two specific 
primaryantibodies (see table 1) in 1 TBST for 1h at room temperature, or over night at 
4ºC with shaking. The membranes were then washed 3 times for 5 min each with 1 
TBST. The membranes were incubated with one or two appropriate fluorescently-
labelled secondary antibodies (see table 2) in 1 TBST for 1h at room temperature. 
Before scanning, the membranes were washed 3 times for 5 min each with 1 TBST. 
ECL Detection 
After blocking, the membranes were incubated with a specific primary antibody (see 
table 1) in 1% (w/v) milk or BSA in 1 TBST according to the manufacturer for 1h at 
room temperature, or over night at 4ºC with shaking. The membranes were then washed 
3 times for 5 min each with 1 TBST. The membranes were incubated with the 
appropriate peroxidase-conjugated secondary antibody (see table 2) in 1% (w/v) milk in 
1 TBST for 1h at room temperature. The membranes were washed 3 times for 5 min 
each in 1 TBST. Then, they were placed into ECL
TM Western Blotting Detection 
Reagent for 1min to be revealed on a photographic film.  
2.3.4  Immunoprecipitation 
Cell lysates were adjusted to the concentration of 1 μg/μl of protein in a total volume of 
500 μl in 3T3 lysis buffer. An aliquot of 25 μl of each cell lysates was kept to be 
resolved on a gel. Adequate volumes of protein G sepharose beads were washed 3 times 
in 3T3 lysis buffer to remove ethanol from the slurry. The beads were resuspended in 
3T3 lysis buffer. The cell lysates were pre-cleared with 50 μl of washed protein G 
sepharose beads for 30 min at 4ºC. The beads were removed by centrifugation and the 
supernatants were placed into new eppendorfs. 5 μl of appropriate antibody was added 
to the cell lysates and the tubes were set to rotate for an hour at 4ºC. Then, 50 μl of 
protein G sepharose beads was added to the tubes, which were set to rotate for 2 hours 
or overnight at 4ºC. The protein G sepharose beads were pelleted by centrifugation at 
13000 g for 1 min and at 4ºC. The supernatants were removed carefully by aspiration to 
avoid removing any beads. The beads were washed at least 3 times with lysis buffer. 
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resuspended in 50 μl of 5sample buffer and boiled for 5 min to be resolved by Western 
Blotting. 
2.3.5  Phosphodiesterase Activity Assay 
This assay measures the hydrolysis of cAMP by phosphodiesterases. 
2.3.5.1  Activation of Dowex 1X8-400 anion exchange resin 
Dowex resin was prepared in large batches. To activate the Dowex 1X8-400, 4L of 1M 
NaOH solution was added to 400 g of the resin and incubated at room temperature for 
15 min with gentle mixing. The resin was allowed to settle by gravity. The supernatant 
was removed and the resin was washed at least 30 with 4L of distilled water until the 
pH reached 7. Then, the resin was resuspended into 4L of 1M HCl and incubated at 
room temperature for 15 min with gentle mixing before being allowed to settle by 
gravity. The resin was finally washed at least 3 with 4L of distilled water until the pH 
reached 3. The activated resin was stored in distilled water in a 1:1 ratio and at 4°C. 
Before used, the appropriate amount of beads was centrifuged to remove the water, and 
resuspended in absolute ethanol in a 2:1 ratio (EtOH:beads). 
2.3.5.2  Protocol 
Samples were diluted to the concentration of 1.5 μg/μl of protein in a total volume of 40 
l in PDE Assay diluting buffer (20 mM Tris/HCl, 10 mM MgCl2, pH7.4). All tubes 
were set up on ice. 10 μl of PDE inhibitor at the indicated concentration was added to 
the protein solution. 50 μl of substrate solution (2 μM cAMP containing 3 μCi 
[
3H]cAMP in 20 mM Tris/HCL, 10 mM MgCl2, pH7.4) was added to the mixture. The 
tubes were quickly vortexed to collect all the components at the bottom of the tubes. 
The tubes were incubated for 10 min at 30˚C and then for 1 min at 100˚C to inactivate 
any PDE present in the samples. The tubes were placed on ice to cool down. 25 μl of 
Snake Venom (Crotalus atrox venom from Sigma) at 1 mg/ml was added to the samples 
and the samples were incubated for 10 min at 30˚C. The Snake venom, which has 5’-
nucleotidase activity, prevents hydrolysed cAMP from recircularising. The non-
hydrolysed cAMP nucleotides were separated by batch binding of the mixture of 
Dowex-1-chloride. The Dowex removes the charged nucleotides but not the uncharged 
nucleosides. Dowex mixture was centrifuged to discar the dH2O and the Dowex resin 
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tubes, mixed and incubated on ice for 20 min. The tubes were centrifuged at 13000 g for 
2 min to pellet the Dowex beads. 150 μl of the clear supernatant was added to new 
eppendorf tubes containing 1 ml of Opti-scint scintillation fluid. The hydrolysis of 
cAMP was measured by using a Wallac 1409 liquid scintillation counter. 
 
Tubes Buffer  Inhibitor  Substrate  Snake 
venom&Dowex 
Control  +  + + 
Samples  + + +  + 
Blank  +  + + 
Tot Counts     +  
2.3.5.3  PDE Activity calculation 
The PDE activity was calculated using the following equation: 
PDE Activity = 2.61  [(Control-A)/Average Tot Count]  10  (1000/μg protein) 
Where A represents the value obtained for each samples – blank. 
2.61 stands for the Dowex practical concentration. 
10 stands for the concentration of cAMP (in pM) hydrolysed in 100 l in 10 min. 
2.3.6  Raf Kinase Assays 
2.3.6.1  Endogenous Raf-1 or B-Raf in PC12 cells 
The activity of the Raf kinases (Raf-1 or B-Raf) was studied using the kinase cascade 
assay kit from Upstate. This assay kit is designed to measure the Raf dependent 
phosphotransferase activity in a kinase cascade reaction using inactive recombinant 
MEK1 as substrate for Raf kinases and inactive recombinant ERK2 as substrate for 
MEK1. To avoid interferences from active MEK and ERK in cell lysates, Raf-1 or B-
Raf were immunoprecipitated as described in section 2.5.5. 10 μl of immunoprecipitated 
Raf were assayed for each condition in conjunction with 0.4 μg of inactive MEK1 and 1 
μg of inactive ERK2 in Assay Dilution Buffer I (ADBI: 20 mM MOPS, pH 7.2, 25 mM 
-glycerol phosphate, 5 mM EGTA, 1 mM sodium orthovanadate, 1 mM dithiothreitol) 
to bring the total volume of the reaction to 45 μl. The reaction was initiated by adding 
10 μl of MgCl2 ATP cocktail (500 μM cold ATP and 75 mM MgCl2 in ADBI). The Chapter 2                                                                                            Material & Methods 
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tubes were centrifuged pulse to collect all the components at the bottom of the tubes and 
gently vortexed. The tubes were incubated for 30 min at 30°C. The reactions were 
stopped by adding 20 μl of 5 sample buffer and boiling for 5 min. The samples were 
analysed by Western Blot as described in section 2.5.3. The membranes were 
immunoblotted for phosphorylated ERK to measure Raf activity. Then the membranes 
were probed for total ERK and Raf-1 or B-Raf to ensure equal loading. 
2.3.6.2  Transfected B-Raf in HEK 293 cells 
A one-step kinase assay was used to assess the activity of transfected B-Raf in HEK 293 
cells. In this assay, only inactive recombinant MEK1 was used as B-Raf substrate. 
FLAG-tagged transfected B-Raf was immunoprecipitated using an anti-FLAG antibody 
as described in section 2.5.5. 10 μl of immunoprecipitated B-Raf was assayed in 
combination with 1 μg of inactive recombinant MEK1 and 20 μl of MgCl2 ATP cocktail 
(500 μM cold ATP and 75 mM MgCl2 in ADBI). The total volume of the assay was 
adjusted to 40 μl with ADBI (Assay Dilution Buffer I). The tubes were centrifuged 
pulse to collect all the components at the bottom of the tubes and gently vortexed. The 
tubes were incubated for 30 min at 30°C. The reactions were stopped by adding 20 μl of 
5 sample buffer and boiling for 5 min. The samples were analysed by Western Blot as 
described in section 2.5.3. The membranes were immunoblotted for phosphorylated 
MEK to measure Raf activity. Then the membranes were probed for total MEK and B-
Raf to ensure equal loading. 
2.3.7  cAMP Assay 
2.3.7.1  Principle 
The level of cAMP in PC12 cells was measured using the cAMP HTS Immunoassay kit 
from Upstate
. This assay is a competitive enzyme-linked immunosorbent assay 
(ELISA) for sensitive and rapid chemiluminescent quantitation of cAMP from cell 
extracts. The principle of a competitive ELISAs is based on the competition between 
labelled and unlabeled antigen for available antibody binding sites. The standard and the 
unknown samples are mixed with an alkaline phosphatase (AP)-labelled cAMP 
conjugate and a specific anti-cAMP antibody, and incubated on well of 96-well 
microtiter plates coated with a capture antibody. The AP-labelled cAMP conjugate will 
bind to the anti-cAMP antibody where its binding sites are not occupied by unlabeled 
cAMP. Thus, a sample containing a high concentration of cAMP will have a low Chapter 2                                                                                            Material & Methods 
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concentration of labelled cAMP. Therefore, the chemiluminescence intensity is 
inversely proportional to the amount of cAMP in a sample or standard. 
2.3.7.2  Protocol 
The cAMP standard provided was diluted in lysis buffer to generate a range of cAMP 
standard dilutions with the highest concentration starting at 100 pmol/μl. Then, a serial 
1:10 dilution was performed. The cell lysates were prepared as described in section 2.4. 
The protein concentration of each cell lysate was adjusted to 1 g/l in assay diluent 
buffer. 50 μl of cAMP standards and prepared samples were added in triplicate to each 
well of 96-well anti-rabbit coated plate provided by the kit. 25 μl of cAMP alkaline 
phosphatase conjugate tracer (diluted 1:3000 with 1 assay diluent) was added to all 
wells. Then, 50 μl of the rabbit anti-cAMP antibody (diluted 1:2000 with 1 assay 
diluent) was added to all wells. The plate was covered with cling film and incubated for 
30 min at room temperature with shaking. Following the incubation time, the reagents 
were removed by inverting the plate over the sink and blotting the plate on a clean paper 
towel to remove excess fluid. The wells were washed 5 times with 1 wash buffer. 100 
μl of the alkaline phosphatase substrate was added to each well. The plate was covered 
with cling film and incubated for 30 min at room temperature with shaking. Finally the 
plate was read for 1.0 second with a luminometer. 
2.3.7.3  Calculation 
The results obtained were analysed using curve fitting software called PRISM. The data 
was fitted to a one-site competitive binding curve. 
2.3.8  Ras and Rap1 Activation Assays 
The activity of Ras and Rap1 were measured by affinity pull-down assay. This assay is 
based on the differential affinity of Ras-GTP and Ras-GDP for the Ras Binding Domain 
(RBD) of Raf-1, and of Rap1-GTP and Rap1-GDP for the Rap Binding Domain (RBD) 
of RalGDS. Indeed, Raf-1 RBD binds specifically to GTP loaded Ras (the active form 
of Ras) and that RalGDS RBD binds specifically to GTP loaded Rap1 (the active form 
of Rap1). The GST-tagged RalGDS-RBD beads were obtained from Upstate
®. The 
GST-tagged RBD of Raf-1 was expressed in E. coli and the fusion protein was purified 
on glutathione-Sepharose beads as described in section 2.3.2.  Chapter 2                                                                                            Material & Methods 
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Cell lysates were adjusted to the concentration of 1 μg/μl of protein in a total volume of 
500 μl. An aliquot of 25 μl of each cell lysate was kept to be resolved on a gel. The cell 
lysates were pre-cleared with 50 μl of washed protein G sepharose beads for 30 min at 
4ºC. The beads were removed by centrifugation and the supernatants were placed into 
new eppendorfs. 5 μl of appropriate RBD was added to the cell lysates and the tubes 
were set to rotate for 2 h at 4ºC. The RBD beads were pelleted by centrifugation at 
13000 g for 1 min and at 4ºC. The supernatants were removed by aspiration carefully to 
avoid removing any beads. The beads were washed at least 3 times with lysis buffer. 
They were resuspended in 30 μl of 5sample buffer and boiled for 5 min before being 
resolved by Western Blotting. 
2.3.9  Statistical analysis 
Unless stated, each data was first analysed using the non-parametric Kruskal-Wallis 
one-way analysis of variance method to determine if significant differences existed 
within the data. If p < 0.05, then the test was followed by a Mann-Whitney analysis to 
assess whether two treatments were significantly different from each other. The p value 
was set to 0.05. 
2.4  MOLECULAR BIOLOGY 
2.4.1  Large scale production of Plasmid DNA 
Plasmid DNAs were prepared and purified with the PureYield
TM Plasmid Maxiprep 
System from Promega. 
2.4.1.1  Preparation and lysis of bacterial cell cultures 
Transformed competent E. Coli cells were grown overnight in 250 ml of L-broth (170 
mM NaCl, 0.5 % (w/v) Bacto-Yeast extract, 1 % (w/v) Bacto-Tryptone pH 7.5) 
supplemented with the appropriate antibiotic at 37ºC with shaking. The cells were 
pelleted by centrifugation at 5000 g for 10 min. The supernatants were discarded and 
the tubes were drained on a paper towel to remove excess media. The cells were 
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and 100 g/ml RNase A). 12 ml of cell lysis solution (0.2 M NaOH and 1% SDS) was 
added to each tube and mixed by inverting the tubes 3-5 times. The tubes were 
incubated for 3 min at room temperature. 12 ml of neutralisation solution (4.09 M 
guanidine hydrochloride, 759 mM potassium acetate and 2.12 M acetic acid) was added 
to the lysed cells. The mixtures were mixed by inverting the tubes 10-15 times to 
precipitate the cellular debris. The lysates were then centrifuged at 14000 g for 20 min 
at room temperature to pellet the cellular debris. The lysates were filtered through a 
cloth and transferred to fresh tubes. 
2.4.1.2  DNA purification 
The lysates were poured into the blue PureYield
TM clearing column assembled on top of 
a white PureYield
TM maxi binding column fixed onto a vacuum manifold port. 
Maximum vacuum was applied allowing the DNA to bind the binding membrane in the 
PureYield
TM maxi binding column. After the vacuum was completed, the blue 
PureYield
TM clearing columns were removed and discarded. 5 ml of endotoxin removal 
wash (complemented with the appropriate volume of isopropanol as described by the 
manufacturer) was added to the PureYield
TM maxi binding column and vacuumed. 20 
ml of column wash (60% ethanol, 60 mM potassium acetate, 8.3 mM Tris/HCl and 0.04 
mM EDTA) was loaded onto the binding column and then vacuumed to draw the wash 
through. The membranes were totally dried by applying a vacuum for 5-10 min. The 
binding columns were placed into 50 ml centrifuge tubes. The DNA was eluted by 
adding 1.5 ml of nuclease-free water into the binding membranes. The tubes were 
centrifuged at 2000 g for 5 min to collect the DNA in the 50 ml tubes. The eluates were 
then transferred into bijou bottles. 
2.4.1.3  Quantification of DNA 
DNA was quantified by spectrophotometry. 1 l of DNA was diluted in 1 ml of 
deionised water and absorbance measurement was taken at 260 nm. 
2.4.2  GST fusion protein synthesis 
2.4.2.1  Transformation of competent E. Coli 
Competent E. Coli cells were transformed with 1μl of recombinant protein-containing 
construct plasmid DNA of interest and incubated on ice for at least 20 min. The cells 
were heat shocked at 42°C for 1 min and then placed on ice. They were transferred to Chapter 2                                                                                            Material & Methods 
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1ml of L-Broth and incubated for 1 h at 37°C with shaking. 100 μl of the culture was 
plated onto LB agar plate supplemented with 100 μg/ml of ampicillin. The plate was 
incubated at 37°C overnight. Colonies were picked from the plates, transferred into 50 
ml of L-broth supplemented with 100 μg/ml of ampicillin and incubated overnight at 
37°C with shaking. 
2.4.2.2  Protein expression 
The cells from the overnight culture were used to inoculate 450 ml of L-broth 
supplemented with 100 μg/ml of ampicillin and incubated at 37°C with shaking for 1 to 
2 hours until the absorbance at 600 nm (OD600) of the culture reached 0.6 to1.0. Then, 
the expression of fusion protein was induced by adding 0.2 mM isopropyl--D-
thiogalactopyranoside (IPTG). The cells were grown for a further 2 to 5 hours at 30°C 
with shaking. Samples of cells before and after induction of protein expression were 
taken, separated by gel electrophoresis and visualised by Coomassie blue stain to ensure 
protein expression. The induced cells were pelleted by centrifugation at 8000 g for 10 
min at 4°C and frozen at –80°C until required. 
2.4.2.3  GST fusion protein elution and purification 
Frozen cells were thawed on ice and resuspended in 10 ml of ice-cold PBS (1 tablet of 
PBS diluted in 100 ml of dionised H2O) supplemented with 1mg/ml of lysozyme and 
transferred to “oak ridge” centrifuge tubes. The cells were sonicated on ice at 40 V for 
3 30 seconds periods with 30 seconds intervals. 1/500 volume of 10% Triton X-100 
was added to the mixture to lyse the cells. The cell lysate was centrifuged at 11000 g for 
15 min at 4°C. The supernatant containing the protein was transferred to 15 ml 
centrifuge tubes. 1 ml of glutathione beads was added to the supernatant and incubated 
for 1 hour at 4°C with rotation to enable binding to the protein. The beads were then 
collected by centrifugation at 3000 g for 2 min and the supernatant discarded. The beads 
were washed in 5 ml of PBS. After removing the supernatant, the beads were 
resuspended in 1 ml PBS and transferred to eppendorf tube. The beads were washed a 
further 3 in 1 ml of PBS. The fusion proteins were eluted from the beads with 600 l 
of elution buffer (10 mM glutathione in 50 mM Tris/HCl, pH 8) as follows: the beads 
were resuspended in 600 l of elution buffer, incubated for 20 min at 4°C with rotation, 
and pelleted by brief centrifugation. The supernatant was carefully removed to a fresh 
tube. The elution step was repeated 3 times and the eluates were pooled together. Chapter 2                                                                                            Material & Methods 
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Finally, the fusion protein sample was dialysed to remove glutathione in 650 ml of 
dialyse buffer (50 mM Tris/HCl, pH 8.0, 100 mM NaCl, 5% (v/v) glycerol) with 3 
buffer changes. 
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3.1  INTRODUCTION 
The second messenger cAMP regulates a large variety of biological processes from 
metabolic to cellular signalling pathways. It is now commonly accepted that cAMP 
induces cell growth inhibition (Cook and McCormick, 1993; Sevetson et al., 1993; 
Stork and Schmitt, 2002; Wu et al., 1993). However, in certain cell types, cAMP is 
associated with cell proliferation and cell differentiation (Stork and Schmitt, 2002). In 
PC12 cells, it has been demonstrated that cAMP induces cell differentiation into 
sympathetic-like neurones (Dumaz et al., 2002; Houslay and Kolch, 2000; Piiper et al., 
2002; Stork and Schmitt, 2002). The mechanisms through which this occurs are not 
totally understood and are highly controversial.  
3.1.1  Cyclic AMP induces PC12 differentiation 
As described in the general introduction of this thesis (see sections 1.1.7 and 1.1.8), the 
differentiation and the proliferation of PC12 cells are mediated through the activation of 
the ERK signalling pathway (Marshall, 1995). The fate of the cells has been 
demonstrated to be dependent on the longevity of the signal initiated by stimuli induced 
by different growth factors (Kao et al., 2001; Marais et al., 1995; Traverse et al., 1992). 
Upon EGF stimulation, the activation of ERK is transient and the cells proliferate, 
whereas upon NGF stimulation, the activation of ERK is sustained and the cells 
differentiate (Dichter et al., 1977; Greene and Tischler, 1976). It is well known that 
cAMP is associated with the differentiation of the PC12 cells into sympathetic-like 
neurones (Houslay and Kolch, 2000; Piiper et al., 2002). As described in the section 1.3 
growing lines of evidence show that the second messenger cAMP interacts with the 
ERK signalling pathway, identifying PKA and Epac, the main effectors of cAMP, as the 
link molecules between these two pathways. It is widely accepted that PKA can inhibit 
Raf-1, whereas Epac has been shown to activate Rap1, which according to Stork and 
colleagues activates B-Raf (Stork and Schmitt, 2002). Raf-1 and B-Raf are the main 
protein kinases transducing the signal through the ERK pathway. Therefore, cAMP 
might play an important role in the mechanisms of the regulation of the ERK signalling 
pathway. 
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3.1.2  Selective Phosphodiesterase Inhibitors 
The level of cAMP has to be elevated in the cells in order to study the crosstalk between 
the cAMP and the ERK signalling pathways. In theory, this can be done by either 
activating the production of cAMP using adenylyl cyclase activators such as forskolin 
(Hansen et al., 2003; Vossler et al., 1997) or pituitary adenylate cyclase-activating 
polypeptide PACAP (Deutsch and Sun, 1992), or by blocking the hydrolysis of cAMP 
by inhibiting the phosphodiesterases. Selective phosphodiesterase inhibitors have been 
synthesised to specifically inhibit the different PDE isoforms. The research and 
development on PDE inhibitors is growing rapidly and there are already three drugs 
targeting PDE5 (sildenafil, tadalafil and vardenafil) and three drugs targeting PDE3 
(anagrelide, pimobendan, milirone) available on the market. There are two drug 
candidates of PDE4 inhibitors that are waiting for approval and about twenty PDE4 
inhibitors are undergoing clinical studies. Vinpocetine, cilostamide and rolipram are 
specific inhibitors for PDE1, PDE3 and PDE4 respectively (Fig. 3.1). These compounds 
are competitive inhibitors for the cAMP binding site within the catalytic domain of their 
respective PDE. All PDEs contain a conserved catalytic domain of about 270 amino 
acids at the carboxyl terminus that consists of three helical subdomains: an N-terminal 
cyclin-fold region, a linker region and a C-terminal helical bundle. These three 
subdomains form a deep hydrophobic pocket. This pocket is composed of four sites 
(Fig. 3.2): a metal-binding site (M site), a core poket (Q pocket), a hydrophobic pocket 
(H pocket) and a lid region (L region) (Houslay and Adams, 2003; Jeon et al., 2005). 
The M site contains metal atoms likely to be zinc and magnesium, which are though to 
be involved in the stabilization of the structure and in the activation of hydroxide to 
mediate the catalysis. The Q pocket provides the specific hydrogen bonding between a 
conserved glutamine residue to all PDEs with the substrate or with the inhibitor. 
Vinpocetine is a potent vasodilatator and has been designed by different 
pharmacological companies as a drug for the potential treatment of vascular diseases 
including cerebrovascular and ophtalmological diseases, but due to poor efficacy and 
side effects (dizziness) the drugs were withdrawn. PDE1 inhibitors are also been 
investigated in the treatment of neurodegenerative diseases such as Parkinson’s disease 
(Kakkar et al., 1996). Rolipram is the most studied PDE4 inhibitor and has been 
investigated for its anti-inflammatory effect in asthma (Giembycz, 2000; Houslay and 
Adams, 2003). However rolipram induces central nervous system and cardiovascular 
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developed as therapeutic drugs for the treatment of ischemic and idiopathic dilated 
cardiomyopathy, which is a syndrome characterised by impaired myocardial 
contractibility and inappropriate systemic and pulmonary vasoconstriction. PDE3 
inhibitors have also been investigated in the treatment of type 2 diabetes mellitus 
(Reinhardt et al., 1995). It has also been suggesting that phoshpodiesterase inhibitors 
might serve as anti-cancer drugs (Hirsh et al., 2004). PDE inhibitors, by elevating the 
intracellular levels of cAMP, could suppress the activity of the oncogene Ras and 
therefore blocking the constitutive activation of ERK and induce apoptosis in certain 
type of cancer cells. PDE inhibitors might improve the chemotherapeutic of cancer 
treatments by reducing side effects. 
 
Figure 3. 1: Chemical structures of Vinpocetine, cilostamide and rolipram that are 
selective inhibitors for PDE1, PDE3 and PDE4 respectively. Chapter 3                                                                                     Effects of PDE inhibitors 
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Figure 3. 2: Representation of the surface of the active site of PDE5A occupied by 
sildenafil (a PDE5 inhibitor). The active site is composed of four subsites: a metal-
binding site (M site), a core pocket (Q pocket), an hydrophobic pocket (H pocket) and a 
lid region (L region). This picture was taken from (Jeon et al., 2005). 
 
 
 
In this chapter, the effects of cAMP on the activation of the ERK signalling pathway 
and the differentiation of PC12 cells were investigated by elevating the levels of cAMP 
using phosphodiesterase inhibitors to block the degradation of cAMP. This chapter also 
aims to investigate if the signal initiated by NGF or EGF is mediated through distinct 
pathways or not. Chapter 3                                                                                     Effects of PDE inhibitors 
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3.2  RESULTS 
3.2.1  ODYSSEY Near-Infrared Imaging System 
3.2.1.1  Near-infrared fluorescence vs. chemiluminescence: stable signal and 
accuracy 
Most of the Western blots performed throughout this work were analyzed and 
quantified using the ODYSSEY Near-infrared imaging system. This method was used 
preferably to conventional chemiluminescent detection methods that are less accurate 
for quantification. Chemiluminescent detection methods rely on enzymatic reactions 
producing light, which is detected on photographic films. However enzymatic reactions 
are not linear, and the horseradish peroxidase used is inhibited by substrate. Therefore, 
the light emission is not constant and is changing over time. Moreover, the dynamic 
range of X-ray film is limited, and especially when highly diverse signals are to be 
compared the detection by film also becomes non-linear. Consequently the exposure 
time to generate the data has to be optimized. This time-dependence and non-linearity 
of signal detection compromises quantification and accuracy of these methods. 
In comparison, fluorescent detection is static. The amount of light produced from the 
excitation of a fluorescent dye is constant when the fluorescent dye is excited. This 
property makes fluorescent detection a more precise and accurate measurement of the 
differences in signal produced by fluorescent-labelled antibodies bound to proteins on a 
Western blot.  
Fluorescent detection enables accurate quantification of proteins because the signal 
generated by the different amounts of proteins on a blot is linear and the dynamic range 
of fluorescence detection spans several orders of magnitude.  
3.2.1.2  Sensitivity and low background 
The ODYSSEY Near-infrared system is highly sensitive as near-infrared fluorophores 
available to label secondary antibodies provide excellent sensitivity. Moreover, in the 
near-infrared nitrocellulose membranes and biomolecules exhibit reduced 
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3.2.1.3  Multiplexed detection and quantification 
Multiplexed detection is another advantage of the ODYSSEY system. This scanner uses 
two separate near infrared (NIR) lasers and detectors to image labelled antibodies at 700 
and 800nm simultaneously. Therefore, using appropriate primary and secondary 
antibodies that avoid cross-reactivity and using spectrally distinct fluorophores, two 
proteins or two different activity states of a protein (e.g. phosphorylation state) can be 
analysed at the same time. For example, one detection channel can be used to detect a 
phosphorylated protein and the second channel to detect the total amount of the protein 
of interest to accurately normalize the signal intensities and to correct for loading and 
sampling errors. 
The ODYSSEY software provides tools to visualise, find and quantify the bands 
detected on the nitrocellulose membranes. The fluorescence detected in the 700nm 
channel image is displayed in red, while the fluorescence detected in the 800nm channel 
is displayed in green. Where the fluorescence from the two channels overlap, the image 
displayed is yellow (Fig. 3.3). Each band is automatically or manually found and a 
feature is drawn around the bands of interest. The image data within the feature are 
quantified immediately. When a feature is quantified, integrated intensity is calculated. 
The integrated intensity has also been referred to as pixel volume in other software. The 
integrated intensity is the sum of the intensity values for all pixels enclosed by a feature, 
multiplied by the area of the feature (countsmm
2). Since background pixels should not 
be part of this calculation, the background is calculated and subtracted. 
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Figure 3. 3: Analysis of Western Blot using the ODYSSEY Near-Infrared imaging 
system. This technique allows accurate and reproducible quantification of Western 
Blots. Serum starved PC12 cells were stimulated with NGF (100ng/ml) for 0, 2, 5, 10, 
20 and 40 min. The phosphorylation of ERK was evaluated by probing Western blots of 
cell lysates with mouse anti-phospho-ERK1/2 antibody detected with an Alexa fluor
TM 
680nm anti-mouse IgG secondary antibody. The total amount of ERK was evaluated by 
probing Western blots with rabbit anti ERK1/2 antibody detected with an IRDye
TM 
800nm anti-rabbit IgG secondary antibody. M stands for protein marker. 
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3.2.2  Kinetics of the phosphorylation of ERK upon NGF and EGF 
stimulation in PC12 cells 
PC12 cells are a commonly used model cell system to study the ERK signalling 
pathway. These cells have the property to either proliferate or differentiate depending 
on the type of mitogen stimulation. Upon epidermal growth factor (EGF) stimulation 
cells proliferate. However, upon nerve growth factor (NGF) stimulation the cells 
differentiate into sympathetic-like neurons (Dichter et al., 1977; Greene and Tischler, 
1976). These two easily distinguishable and mutually exclusive biological responses 
make the PC12 cell line an ideal model to study the diverse biological functions of ERK 
signalling pathway. The fate of the cell has been shown to depend on the longevity of 
the ERK signal (Kao et al., 2001; Marshall, 1995; Traverse et al., 1992). It is commonly 
accepted that EGF causes a transient activation of the ERK pathway (Kao et al., 2001) 
allowing the cells to continue to divide. However, NGF causes a sustained activation of 
the pathway causing the cells to withdraw from the cell cycle and differentiate (Traverse 
et al., 1992; Yao et al., 1998). 
To verify that the PC12 cells used for this research behaved as described above, the 
cells were serum starved for 3 to 4 hours and then stimulated with either NGF or EGF 
for the indicated periods of time. Cell lysates were probed using antibodies against 
phosphorylated ERK to measure the activation of ERK, and against ERK to measure the 
total amount of protein loaded in the gel. The anti phospho-ERK antibody used was a 
monoclonal antibody raised in mouse, whereas the total ERK antibody was a polyclonal 
antibody raised in rabbit thereby avoiding cross-reactivity between both primary 
antibodies. The anti phospho-ERK antibody was detected using a secondary antibody 
directed against mouse IgG and labelled with a fluorophore that fluoresces at 700nm. 
The total ERK antibody was detected using a secondary antibody directed against rabbit 
IgG and labelled with a fluorophore that fluoresces at 800nm. Again, the two secondary 
antibodies were raised in different species (donkey and goat) to avoid any cross-
reactivity. After scanning the nitrocellulose membranes with the ODYSSEY imager 
(Fig. 3.4.a), the bands detected were quantified using the ODYSSEY software. A 
ratiometric analysis was used to normalise the amount of phosphorylated ERK protein 
over the total amount of protein to correct any loading errors (Fig. 3.4.b). The results 
obtained were expressed as percentage of the highest ratio.  Chapter 3                                                                                     Effects of PDE inhibitors 
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Upon NGF stimulation the peak of activation of the ERK pathway was around 10 
minutes and ERK remained phosphorylated after 40 minutes. Whereas, upon EGF 
stimulation, the activation of ERK was quicker, reached the maximum activation around 
5 minutes and was back to basal levels at 40 minutes. As expected, the activation of the 
ERK pathway in PC12 cells was sustained upon NGF stimulation, whereas the signal 
was transient upon EGF stimulation. Chapter 3                                                                                     Effects of PDE inhibitors 
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Figure 3. 4:  Phosphorylation of ERK under NGF or EGF stimulation. Serum 
starved PC12 cells were stimulated with NGF (100ng/ml) or EGF (100ng/ml) for 0, 2, 
5, 10, 20 and 40 min. a) The activation of ERK was evaluated by probing Western blots 
of cell lysates with mouse anti-phospho-ERK1/2 antibody detected with an Alexa 
fluor
TM 680nm anti-mouse IgG secondary antibody. The total amount of ERK was 
evaluated by probing Western blots with rabbit anti ERK1/2 antibody detected with an 
IRDye
TM 800nm anti-rabbit IgG secondary antibody. B) The values are expressed as the 
percentage of the highest ratio of the integrated intensities of pERK over totalERK. The 
values shown are the means ± S.D. of 7 independent experiments. A repeated measures 
ANOVA test was performed: p<0.001, which confirmed that these curves are 
significantly different. M stands for protein marker. 
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3.2.3  Effect of PDE inhibitors on the phosphorylation of ERK 
To assess the existence of a possible crosstalk between the ERK and the cAMP 
signalling pathways, the first step was to increase the level of cAMP in PC12 cells. 
Instead of stimulating the production of cAMP using adenylyl cyclase activators, such 
as forskolin (Hansen et al., 2003; Vossler et al., 1997) or pituitary adenylate cyclase-
activating polypeptide PACAP (Deutsch and Sun, 1992), a different approach was 
taken. Phosphodiesterase (PDE) inhibitors were used to inhibit specific isoforms of 
PDEs in order to block the degradation of cAMP (Manallack et al., 2005). It is generally 
accepted that PDEs control discrete pools of cAMP in specific localisations within the 
cells (Fischmeister et al., 2006; Houslay and Adams, 2003; Mongillo et al., 2004; 
Shakur et al., 2000). Therefore, by using specific PDE inhibitors to block the 
degradation of cAMP, the pool of cAMP that might regulate the ERK pathway can be 
identified. Different PDE inhibitors available were screened and the phosphorylation of 
ERK was measured by quantifying Western blots using the ODYSSEY imager. It was 
also expected from this experiment to obtain some clues about which of York’s or 
Kao’s models (described in section 1.1.8) to support. 
The PC12 cells were serum starved for 3 to 4 hours in a serum-free medium. The cells 
were treated for 10 minutes with the different PDE inhibitors before being stimulated 
with either NGF or EGF for the indicated periods of time. The cell lysates were 
analysed by Western blot using the ODYSSEY imager. The nitrocellulose membranes 
were probed with antibodies against phosphorylated ERK to measure the activation of 
ERK, and against ERK to measure the total amount of protein loaded in the gel. These 
primary antibodies were detected with different fluorescent secondary antibodies as 
described in the section 3.1.2. Then, the ratio between pERK and total ERK (integrated 
intensity values) were calculated and normalised as percentage of the highest ratio, 
which was the peak of activation upon NGF or EGF stimulations without the PDE 
inhibitor treatment. The results obtained were plotted onto a graph (Fig. 3.5). 
First of all, upon any PDE inhibition and without mitogen stimulation, ERK was not 
phosphorylated (results not shown). This meant that the accumulation of cAMP in the 
basal state was not enough to activate the ERK pathway. 
However, upon NGF stimulation, the phosphorylation of ERK was increased when the 
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inhibited by cilostamide, where the phosphorylation of ERK was significantly increased 
2.6 fold after 10 min of stimulation. Unexpectedly, the inhibition of PDE4 (a cytosolic 
PDE) by rolipram did not significantly increase the phosphorylation of ERK. 
Upon EGF stimulation, every PDE inhibitor increased the phosphorylation of ERK. 
More remarkably the maximum of phosphorylation was located between 5 to 10 
minutes instead of 5 minutes in normal conditions. Again the activation of ERK was the 
strongest when PDE3 was inhibited by cilostamide, which was significantly different 
from the control after 10 of stimulation. But ERK phosphorylation was only increased 
by 1.6 fold. 
The results obtained upon EGF stimulation were quite surprising because it was 
expected that upon high levels of cAMP the ERK signalling pathway would be switched 
off resulting in no ERK phosphorylation. According to the York et al’s models (York et 
al., 1998), it was expected that the signal initiated by EGF would utilise only the 
Ras/Raf-1/MEK/ERK pathway. Research had shown that cAMP activates PKA that 
inhibits Raf-1 (Dumaz and Marais, 2003; Sidovar et al., 2000). Therefore, the pathway 
should be switched off at Raf-1 level and the signal should no longer be transduced 
toward ERK. The results obtained suggested that high level of cAMP upon mitogen 
stimulation activate or switch to other pathways such as Rap1/B-Raf/MEK/ERK 
(Dumaz and Marais, 2005; Houslay and Kolch, 2000; Stork and Schmitt, 2002), which 
support the Kao et al’s model (Kao et al., 2001). Another explanation is that Ras 
activates B-Raf and therefore would overcome the inhibition of Raf-1. This will be 
investigated further in the next chapters. Chapter 3                                                                                     Effects of PDE inhibitors 
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Figure 3. 5: Effect of PDE inhibitors on the phosphorylation of ERK. Serum starved 
PC12 cells were treated with Vinpocetine (100μM), EHNA (10μM), Rolipram (10μM), 
Cilostamide (10μM) and IBMX (100μM) for 10 min before being stimulated with either 
a) NGF (100ng/ml) or b) EGF (100ng/ml) and incubated at 37ºC for 0, 2, 5, 10, 20 and 
40 min. The activation of ERK was evaluated by probing Western blots of cell lysates 
with anti-phospho-ERK1/2 antibody. The total amount of ERK was evaluated by 
probing Western blots with anti ERK1/2 antibody. The values shown are the mean of 3 
independent experiments ± S.D. Effects of each PDE inhibitors were compared to 
respective basal stimulation values at time 10 min, *p < 0.05. Only the error bars for 
NGF and EGF stimulations without treatment and upon cilostamide treatments are 
shown for graph clarity. 
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3.2.4  Assaying changes in cAMP levels caused by PDE inhibitors  
In order to study the effects of cAMP on the ERK signalling pathway, the approach 
chosen was to raise the concentration of cAMP by blocking its degradation using PDE 
inhibitors. From the results described above (section 3.1.3), it has been demonstrated 
that the treatment with specific PDE inhibitors modulated the phosphorylation of ERK 
by enhancing or decreasing it. It was then crucial to assess if the level of cAMP actually 
rose within the cells.  
PC12 cells were plated onto 10 cm dishes pre-coated with poly-L-Lysine and left to set 
overnight. They were treated (or not in the control) for 30 min, the time necessary to 
achieve total inhibition, with the different PDE inhibitors at the concentrations indicated 
below. Then the cells were stimulated for 10 min with forskolin to activate the 
production of cAMP by the adenylyl cyclases. The concentration of cAMP was 
analysed from cell lysates using a cAMP HTS Immunoassay kit from Upstate
, which is 
a competitive ELISA. The samples were added in triplicates along with cAMP alkaline 
phosphatase conjugate tracer onto a 96 well-plate pre-coated with anti-rabbit antibody. 
Then, a rabbit anti-cAMP antibody was added to all wells. Therefore, the cAMP 
contained in each sample and the cAMP alkaline phosphatase conjugate tracer 
competed to bind to the anti-cAMP antibody, which bind to the anti rabbit antibody 
coated to the bottom of the wells. After incubation time followed by vigorous washings, 
alkaline phosphatase substrate was added to all samples. The samples were read using a 
luminometer. Because this assay is a non-competitive ELISA, high concentration of 
cAMP gives low intensity. The results obtained were analysed using curve fitting 
software called PRISM. The data was fitted to a one-site competitive binding curve 
(Fig. 3.6.b) and the results were plotted on the graph below (Fig. 3.6.c). 
As expected, upon forskolin stimulation, cAMP accumulated when the cells were 
treated with specific cAMP-phosphodiesterase inhibitors compare to the control where 
the cells were only stimulated with forskolin. However, it was expected that the increase 
in the level of cAMP would be much greater upon the treatment with cilostamide 
following the results described in section 3.1.3. Surprisingly, the increase in cAMP 
level was approximately the same in response to the different PDE inhibitor treatments. 
Then, how was it possible that each PDE inhibitor treatment had such different effects 
on the phosphorylation of ERK? This result might be evidence of the 
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regulated by PDE3 can affect the phosphorylation of ERK. This question will also be 
discussed further in the discussion part of this chapter. 
It has to be notified that the basal concentration of cAMP was not actually measured in 
this experiment. It was the changes in the accumulation of cAMP induced by forskolin 
and the inhibition of specific PDEs that was measured in this assay. Indeed, this assay 
was not sensitive enough to detect any cAMP concentration when the production of 
cAMP was not stimulated. Therefore the production of cAMP had to be induced by an 
elevating cAMP agent such as forskolin, which is the most commonly used adenylyl 
cyclase activator. However this experiment reflected the changes in the concentration of 
cAMP and was suitable to demonstrate that in the presence of PDE inhibitors, then 
cAMP accumulated within the cells. To consolidate these results, it would have been 
interesting to the same experiment in a different cell line, such as HEK293 cells that are 
an ideal model to study the cAMP signalling. It would have been also judicious to use 
other techniques to measure the level of cAMP in the cells. There are other tools 
available such as fluorescence resonance energy transfer (FRET) for example. This 
technique is based on the energy transfer mechanism that occurs between two 
chromophores that are in molecular proximity to each other. This technique allows 
monitoring the changes in the distance of chromophores attached to either two 
interacting proteins or to a single protein with a changing conformation. PKA can be 
used as cAMP sensors. This technique is based on the dissociation of the PKA subunits. 
In the absence of cAMP, PKA is a tretrameric holoenzyme consisting of two regulatory 
(R) subunits and two catalytic (C) subunits. In the presence of cAMP, the two C 
subunits dissociate from the R subunits. The R and the C subunits can be genetically 
labelled with cyan (CFP) and with yellow (YFP) fluorescent proteins respectively. 
Therefore, in the presence of cAMP, PKA is in a tetrameric configuration in which the 
C and R subunits are bound, which result in a high FRET signal. In the presence of 
cAMP, the R and the C subunits dissociate resulting in the loss of the FRET signal. This 
technique is used to monitor the changes in cAMP concentration and compartmentation 
in living cells using confocal microscopy. However this technique is difficult to carry 
out and has some disadvantages, such as transfection or the fact that active PKA 
phosphorylates and activates PDE4 to hydrolyse cAMP, which interferes with the 
accuracy of the measurement of cAMP (Nikolaev and Lohse, 2006).  Chapter 3                                                                                     Effects of PDE inhibitors 
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Figure 3. 6: Measurements of the level of cAMP when PDEs are inhibited with 
specific inhibitors. PC12 cells were treated with Vinpocetine (100μM), EHNA (10μM), 
Rolipram (10μM), Cilostamide (10μM) and IBMX (100μM) for 10 min before being 
stimulated with Forskolin (100μM) to generate the production of cAMP. The amount of 
cAMP was measured using the cAMP HTS Immunoassay kit from Upstate
, which is a 
competitive enzyme-linked immunosorbent assay (ELISA). The results were analyzed 
using PRISM software. The values shown are the mean of 3 different experiments ± 
SEM. *p < 0.05 compared to the control. 
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3.2.5  Analysis of PDE3 and PDE4 activities in PC12 cells 
Since it was demonstrated that the inhibition of PDEs enabled a raise in the level of 
cAMP within the cell and that resulted in enhancing the phosphorylation of ERK upon 
cilostamide and rolipram treatments, the activity of both PDE3 and PDE4 had to be 
measured in order to understand why cilostamide had a greater effect on ERK 
phosphorylation than rolipram upon mitogen stimulation.  
PC12 cells were seeded onto 6-well plates pre-coated with poly-L-Lysine and left to set 
overnight. They were harvested and lysed as described in the section 2.1.6 of the 
previous chapter. The principle of the assay is to measure the hydrolysis of cAMP by 
phosphodiesterases. To measure the activity of one specific PDE, this PDE is 
specifically inhibited and the activity of this PDE is then defined as the fraction of the 
total PDE activity that has been inhibited: 
Specific PDE activity = Total PDE activity – PDE activity treated with inhibitor 
Each lysate was assayed for the total PDE activity (control and IBMX, which is a non-
specific PDE inhibitior), PDE1, PDE2, PDE3 and PDE4 activities. The activity of 
PDE1, PDE3 and PDE4 were measured in the presence of vinpocetine, EHNA, 
cilostamide and rolipram, respectively, at the indicated concentrations. 
The results show that the contribution of PDE3 to the total PDE activity is almost 4 
times higher than PDE4 (Fig. 3.7). This would explain why the inhibition of PDE3 by 
cilostamide has a greater effect on the phosphorylation of ERK compared to the 
inhibition of PDE4 by rolipram. However, this does not eliminate the hypothesis 
stipulating that PDEs are localised within discrete subcellular microdomains delimiting 
specific pools of cAMP, hence PDE3 would control a pool of cAMP surrounding the 
ERK signalling pathway in PC12 cells. 
From these results it seems that the contribution of PDE2 to the total PDE activity is 
also high. However, this might not reflect the reality due to the fact that EHNA is not a 
very potent and selective PDE2 inhibitor (Chambers et al., 2006). Therefore, EHNA 
might also inhibit other phosphodiesterases compromising the real contribution of 
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Figure 3. 7: Activity of PDE3 and PDE4 in PC12 cells. This graph shows the total 
cAMP PDE activity in PC12 cells assayed with 1M cAMP as substrate. PDE3 activity 
is defined as the fraction inhibited by 10 M of Cilostamide, PDE4 activity is defined as 
the fraction inhibited by 10 M of Rolipram, PDE1 is defined as the fraction inhibited 
by 100 M of Vinpocetine and PDE2 is defined as the fraction inhibited by 10 M of 
EHNA. The values shown are means ± S.D. of 6 different experiments. The activity of 
PDE1, PDE2 and PDE4 were compared to the activity of PDE3, * p < 0.05  
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3.2.6  Analysis of the total PDE activity upon mitogen stimulation 
So far, it has been demonstrated that a high level of cAMP regulated by PDE3 enhances 
the phosphorylation of ERK upon mitogen stimulation. Little is known about the 
mechanisms through which this occurred. This is likely due to the activation of PKA 
and Epac by cAMP (Stork and Schmitt, 2002), which will be discussed in the next 
chapter. It was then important to investigate how the level of cAMP might change 
within the cells. Two different hypotheses had to be investigated in order to understand 
the cross-talk between the ERK and the cAMP signalling pathways. The first hypothesis 
is that mitogens activate adenylyl cyclase that would increase the production of cAMP. 
Unfortunately, the results obtained, using the Upstate kit to measure cAMP (results not 
shown), were not significant enough to allow a definitive conclusion. However, it has 
been demonstrated by different research groups that NGF increases the level of cAMP 
by activating soluble adenylyl cyclase (Golubeva et al., 1989; Knipper et al., 1993; 
Stessin et al., 2006) in PC12 cells. The second hypothesis is that mitogens inhibit PDEs 
to block the degradation of cAMP. In non-neuronal cells, it has been demonstrated that 
activated ERK upon mitogen stimulation, can phosphorylate and inhibit PDE4 (Baillie 
et al., 2000; Hoffmann et al., 1999). 
To test this hypothesis, PC12 cells were seeded onto 6-well plates pre-coated with poly-
L-lysine and left over night to set. After they had been serum starved for 3 to 4 hours, 
the cells were stimulated with either NGF or EGF at the concentrations indicated below 
for 0, 2, 5, 10, 20 and 40 minutes. The lysates were assayed with 1M of cAMP as 
described in the section 2.2.6 to measure the total PDE activity.  
The results (Fig. 3.8) demonstrated that there was no significant effect on the total PDE 
activity upon mitogen stimulation over time. Thus, within the sensitivity of the assay 
mitogens do not seem to regulate the activity of PDEs in PC12 cells. Therefore, it was 
assumed that the production of cAMP in response to mitogen stimulation was due to 
stimulation of adenylate cyclases rather than inhibition of PDEs. Chapter 3                                                                                     Effects of PDE inhibitors 
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Figure 3. 8: Mitogens have no effect on the total activity of phosphodiesterases in 
PC12 cells. PC12 cells were stimulated with either NGF (100ng/ml) or with EGF 
(100ng/ml) for 0, 2, 5, 10, 20 and 40 minutes. The lysates were assayed with 1M of 
cAMP as substrate to measure the total activity of PDEs. The results shown are 
expressed in pmoles/mg/min and are the mean ± S.D. of 3 independent experiments. 
The PDE activity for each time was compared to time 0 of the respective mitogen 
stimulation, * p < 0.05. Chapter 3                                                                                     Effects of PDE inhibitors 
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3.2.7  Effect of PDE inhibitors on PC12 cell differentiation 
It is well established that NGF mediates PC12 cells differentiation (Deutsch and Sun, 
1992; Greene and Tischler, 1976; Severin and Kondratyev, 1988; Sun et al., 2006; 
Traverse et al., 1992) by activating and sustaining the ERK signalling pathway. The 
exact mechanisms through which this occurs remain unclear at present and are at the 
centre of this research. The second messenger cAMP might be a key component in cell 
differentiation. Several research demonstrated that cAMP analogues (Schubert et al., 
1977; Vossler et al., 1997), pituitary adenylate cyclase-activating polypeptide PACAP 
(Deutsch and Sun, 1992) or forskolin (Hansen et al., 2003; Vossler et al., 1997), which 
all increase the level of cAMP, promote the differentiation of PC12 cells. 
Since the inhibition of PDEs has been demonstrated to increase the level of cAMP and 
to enhance the phosphorylation of ERK, it was crucial to examine whether it can also 
affect the differentiation of PC12 cells. To assess the possible involvement of cAMP in 
cell differentiation, PC12 cells were seeded onto 6-well plates pre-coated with poly-L-
lysine and incubated in normal medium at 37ºC and allowed to set over-night. At day 0, 
the cells were studied under the microscope to ensure that no cells were differentiated. 
The cells were then treated with cilostamide, rolipram or both PDE inhibitors at the 
indicated concentrations for 10 minutes before being stimulated with either NGF or 
EGF. The cells were then incubated for 72 hours at 37ºC. About 10 phase-contrast 
images of the cells were taken randomly for each treatment to have a significant number 
of cells. A cell was only considered fully differentiated if the neurite extension was 
twice the length of the cell body. The percentage of differentiated cells was expressed as 
the number of neurite-extending cells compared to the total number of cells for each 
treatment (Fig. 3.9).  
As expected, without stimulation or upon EGF stimulation and after 72h of incubation, 
PC12 cells remained round in morphology, meaning they did not differentiate. Upon 
NGF stimulation PC12 cells presented long neurites and 42% of the cells had 
differentiated. 
When the cells were treated with either cilostamide or rolipram and without mitogen 
stimulation, cells remained undifferentiated. Upon NGF stimulation, the treatment with 
cilostamide dramatically increased the differentiation of PC12 cells and 69% of the cells Chapter 3                                                                                     Effects of PDE inhibitors 
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differentiated. The treatment with rolipram did not increase the differentiation of the 
cells upon NGF stimulation and the cells differentiated normally. PDE4 being an 
ubiquitously expressed phosphodiesterase, it was expected that rolipram would have 
the same effect than cilostamide on the cell differentiation. However, these results are in 
line with the previous results (see section 3.2.3) showing that rolipram did not increase 
the phosphorylation of ERK upon NGF stimulation. Interestingly, when both PDE 
inhibitors were combined 75% of the cells differentiated, which was not significantly 
different from the treatment with cilostamide only, but these cells presented longer and 
more robust neurites. The neurites were twice longer than the neurites seen on the cells 
that had differentiated upon NGF stimulation alone or with cilostamide treatment. The 
most interesting effect was the combination of both PDE inhibitors upon EGF 
stimulation. Under these conditions, 34% of the cells differentiated significantly 
compared to the treatment with EGF, which was not expected as EGF promotes only 
proliferation but not differentiation of the cells. Thus, the “proliferative” effect of EGF 
was turned into a “differentiative” effect. Moreover, 17% of the cells had differentiated 
without mitogen stimulation when both PDE inhibitors were combined, suggesting that 
the accumulation of cAMP resulting from the combination of different PDE inhibitions 
can activate pathways involved in cell differentiation. Chapter 3                                                                                     Effects of PDE inhibitors 
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Figure 3. 9: Effect of Cilostamide and Rolipram on PC12 cell differentiation. A) 
PC12 cells were treated with Cilostamide (10μM) or Rolipram (10μM) for 10 min 
before being stimulated with either NGF (100ng/ml) or EGF (100ng/ml) and incubated 
at 37ºC. After 72h of incubation, phase-contrast images of representative cells were 
taken. B) The percentage of differentiated cells was determined by comparing the 
number of neurons over the total number of cells for each treatment. The values shown 
are means ± S.D. of the mean of 3 independent experiments. * p < 0.05. Chapter 3                                                                                     Effects of PDE inhibitors 
  92 
3.3  DISCUSSION 
Within the past decade, several lines of evidence for a crosstalk between the ERK and 
the cAMP pathways have been demonstrated (Houslay and Kolch, 2000; Qiu et al., 
2000; Stork and Schmitt, 2002). It seems that the second messenger cAMP might be 
involved in the regulation of the ERK signalling pathway and might play an important 
role in the duration and the strength of the signal transduced. The choice of the cell line 
to study this crosstalk was really important. The PC12 cell line is an ideal model and is 
widely used to study the ERK signalling pathway. Upon different mitogen stimuli these 
cells have the property to either proliferate or differentiate, which are two biological 
processes easily distinguishable under a microscope. Therefore, PC12 cells were a 
perfect cell line to study cell differentiation. Both proliferation and differentiation are 
the results of the activation of the ERK pathway (Greene and Tischler, 1976; Houslay 
and Kolch, 2000; Kao et al., 2001). It was demonstrated that the fate of the cell depends 
on the longevity of the activation of the pathway (Traverse et al., 1992). Upon EGF 
stimulation, the signal transduced through the ERK pathway is transient and PC12 cells 
proliferate, whereas upon NGF the signal is sustained and the cells differentiate into 
sympathetic-like neurones. 
Western blotting was the technique used to measure the phosphorylation of ERK 
throughout this research. This choice can be contested and some would argue that 
protein kinase assay was a more suitable technique to use because it is a more sensitive 
and it is a better quantitative assay than Western Blot. However, due to the number of 
samples to be analysed at once, protein kinase assays were too inconvenient for 
different reasons. First of all, a protein kinase assay is based on the phosphorylation of a 
substrate using the transfer of the -phosphate of adenosine-5'-[
32P] triphosphate ([-
32P] 
ATP) by the protein of interest. Therefore, this assay is highly radioactive and is very 
difficult to handle with a large number of samples. The second disadvantage is that 
kinase assays require to immunoprecipitate the total amount of the active kinase from 
the whole cell extract, which contains detergents and biochemicals in the lysis buffer 
that may affect the kinase activity. Moreover, immunoprecipitation is time consuming 
and part of the protein of interest can be lost during manipulation, which may alter the 
accuracy of this technique. Therefore Western blotting with antibodies indicative of 
activation was preferred to protein kinase assay to measure the activity of ERK. It had Chapter 3                                                                                     Effects of PDE inhibitors 
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been demonstrated and it is generally accepted that for ERK in particular, the results 
obtained by protein kinase assays correlate with the results obtained by Western blotting 
with activation specific (i.e. phosphorylation specific) antibodies. Western Blot is an 
easier and less time consuming technique. However, for the reasons described above it 
is not a good technique for quantification when the commonly used ECL technique is 
employed. Fortunately, we had an ODYSSEY scanner available. As described in the 
section 3.1.1 of this chapter, the ODYSSEY scanner allows rapid and accurate 
quantifications of blots probed with fluorescent-labelled secondary antibodies. It 
enables the comparison of different blots because pERK and the total amount of ERK 
were measured at the same time and on 2 different channels, which allows the 
normalisation of the results as a ratio pERK/ERK for each samples and therefore to 
correct any loading sample errors. Western blots analysed with the ODYSSEY scanner 
are well suited for quantification and for handling a large number of samples. 
To investigate the crosstalk between the ERK and the cAMP pathways, the level of 
cAMP had to be increased. Two different approaches were considered. The first 
approach was to activate the production of cAMP by activating adenylyl cyclases using 
activators such as forskolin or PACAP. Several studies already had demonstrated that 
forskolin and PACAP increased the level of cAMP and enhanced the differentiation of 
PC12 cells (Deutsch and Sun, 1992; Hansen et al., 2003; Vossler et al., 1997). The 
second approach was to inhibit the degradation of cAMP using PDE inhibitors. It is 
generally accepted that PDEs control discrete pools of cAMP in specific localisations 
within the cells (Fischmeister et al., 2006; Houslay and Adams, 2003; Mongillo et al., 
2004; Shakur et al., 2000). This approach was chosen not only because it has never been 
investigated previously, but also because it was a more subtle way to study the crosstalk 
between the ERK and cAMP pathways. The second messenger cAMP is involved in a 
plethora of other pathways than the MAPK pathway (Tasken and Aandahl, 2004). 
Therefore, increasing the general content of cAMP in the cell by activating adenylyl 
cyclases might affect these other pathways. However, inhibiting specific isoforms of 
PDEs using specific inhibitors can affect the level of cAMP within discrete cellular 
compartments, which might avoid crosstalk with other pathways. The results obtained 
show that not only the inhibition of specific PDEs increased the level of cAMP when 
the cells were stimulated with forskolin (Fig. 3.6) but the inhibition of PDE3 greatly 
increased the phosphorylation of ERK (Fig. 3.5) and the differentiation of PC12 cells 
(Fig. 3.9). These observations suggest the existence of the compartmentalisation of Chapter 3                                                                                     Effects of PDE inhibitors 
  94 
cAMP, where PDE3 is likely to control a pool of cAMP controlling the ERK signalling 
pathway in PC12 cells. This is also supported by the experiment where both PDE3 and 
PDE4 inhibitors were combined. The results show that cilostamide treatment (PDE3 
inhibitor) increased the differentiation of PC12 cells, whereas rolipram treatment had a 
minor effect on PC12 cell differentiation (Fig. 3.9). However, when both inhibitors 
were combined, the differentiation of PC12 cells was dramatically enhanced upon NGF 
stimulation and the proliferative effect of EGF was turned into a differentiation effect. 
The neurites produced were much longer and more “robust” upon NGF stimulation, and 
40% of cells had differentiated upon EGF, mimicking the normal effect of NGF 
stimulation. 
To consolidate these findings, I attempted to characterise PDE3 in PC12 cells by either 
probing Western Blots of cell lysates or PDE3 immunoprecipitations with different anti-
PDE3 antibodies. Unfortunately, the antibodies used (anti-PDE3A and anti-PDE3B 
from Santa Cruz) could not detect any PDE3 isoforms probably due to poor affinity. 
Several studies on cardiac myocytes demonstrated that PDEs are organised functionally 
and spatially to control the flux of cAMP (Fischmeister et al., 2006; Mongillo and 
Zaccolo, 2006). The second messenger cAMP is produced from adenylyl cyclases at the 
membrane that are activated by distinct transmembrane G protein-coupled receptors 
(GsPCRs). Different isoforms of PDEs regulate subcellular compartments of cAMP to 
control distinct downstream effects such as coordination and cell contractility. For 
example, PDE3 and PDE4 were shown to modulate the cAMP response to 1 adrenergic 
receptors (1-AR) stimulation, whereas PDE4 exclusively regulates the cAMP response 
generated by stimulation of the glucagon receptors (Glu-R) (Fischmeister et al., 2006; 
Rochais et al., 2006; Vandecasteele et al., 2006). Moreover Vandecasteele et al 
(Vandecasteele et al., 2006) suggested that the different PDE isoforms are organised in 
different subsets to delimitate compartments of cAMP within subcellular microdomains 
and to control the flux of cAMP from the membrane to the cytoplasm (Fig. 3.10). We 
can therefore imagine a similar organisation of PDE isoforms to regulate the level of 
cAMP surrounding the ERK signalling pathway in PC12 cells. This might explain why 
upon cilostamide (PDE3 inhibitor), but not upon other PDE inhibitor treatments, the 
phosphorylation of ERK is stronger and that the combination of cilostamide and 
rolipram dramatically enhanced the differentiation of PC12 cells. It would be interesting 
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phosphorylation of ERK upon cilostamide or rolipram alone over a time course to verify 
if there is any difference in the signal strength and then to confirm this theory. 
 
Figure 3. 10: Schematic representation of PDE-dependent cAMP 
compartmentalisation. This scheme represents the putative organisation of the 
different PDE isoforms in cardiac myocytes. Depending on the G-coupled receptor, 
PDEs are organised in different subsets to delimitate pools of cAMP and to control the 
flux of cAMP through the cytoplasm. This scheme was taken from a review by 
Fischmeister et al (Fischmeister et al., 2006). 
Another important finding is that the results gave some clues to resolve the 
“architecture” of the ERK pathway. It is not clear how the signal is coupled from the 
receptor to the ERK cascade and which small G-proteins and Raf kinases (Ras/Rap1 
and Raf-1/B-Raf) are involved. As described in the introduction, different models have 
been proposed to solve the sustained/transient activation of ERK. Even though it is 
commonly agreed that the signal triggered by both NGF and EGF utilises the Ras/Raf-
1/MEK/ERK pathway that results in the transient activation of ERK, it is not clear how 
the signal is sustained upon NGF stimulation. On one hand, York et al suggest that the 
sustained activation of ERK is due to the activation of Rap1/B-Raf upon NGF 
stimulation (York et al., 1998). Their model suggests that upon EGF stimulation, the 
signal is only transiently mediated through Ras/Raf-1/MEK/ERK and upon NGF the 
signal is mediated through two distinct pathways, Ras/Raf-1/MEK/ERK and Rap1/B-
Raf/MEK/ERK that is responsible for the activation of ERK. On the other hand, Kao et Chapter 3                                                                                     Effects of PDE inhibitors 
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al demonstrated that NGF and EGF stimulations can activate both Ras and Rap1 (Kao 
et al., 2001). They demonstrated that EGF can transiently stimulate Rap1 and that upon 
NGF the activation of Rap1 correlates with the sustained activation of ERK. They 
suggested that the difference in the longevity of the signal is due to Rap1, which is 
strongly coupled to the NGFR by the Crk-C3G complex scaffolding by FRS2. 
Therefore they proposed a model in which upon EGF stimulation the signal is 
transiently mediated through both Ras/Raf-1/MEK/ERK and through Rap1/B-
Raf/MEK/ERK, whereas upon NGF stimulation the signal is transiently mediated 
through Ras/Raf-1/MEK/ERK followed by the sustained activation of Rap1/B-
Raf/MEK/ERK. The study of a crosstalk with cAMP may help to clarify this point. 
Indeed, upon high level of cAMP, PKA is active and can phosphorylate and inhibit Raf-
1 (Dumaz and Marais, 2003; Sidovar et al., 2000). If the signal triggered by EGF was 
mediated only through Ras/Raf-1/MEK/ERK, therefore the pathway would be blocked 
at Raf-1 level upon high levels of cAMP. However, the results obtained during this 
research, show that upon high levels of cAMP, the signal is still switched on and is even 
longer upon EGF stimulation. This suggested that a second pathway other than Ras/Raf-
1/MEK/ERK had transduced the signal. This finding supports the Kao et al’s model and 
more experiments to confirm this hypothesis, particularly on Ras/Rap1 activity and on 
the knockdown of Raf-1 and C3G, have been investigated and will be discussed in the 
next chapters. 
Finally, the neuronal differentiation of PC12 cells is characterised by cell cycle arrest, 
activation of specific genes and neuritogenesis. Upon NGF stimulation, the 
phosphorylation of ERK is sustained allowing the translocation and the accumulation of 
phosphorylated ERK in the nucleus. Therefore, in the nucleus phosphorylated ERK can 
activate specific transcription factors and can induce the expression of specific genes 
involved in cell differentiation.  
I tried an experiment to investigate at which point in time the commitment to 
differentiation is made. To do so, I used the MEK inhibitor U0126 to block the ERK 
pathway. PC12 cells were plated onto poly-L-lysine pre-coated 6-well plates and left 
overnight to set. The cells were starved for at least 3h and then they were treated or 
untreated with U0126 (20M) and stimulated with NGF (100ng/ml) for 72h as 
followed. The positive control consisted of cells untreated with U0126 and stimulated 
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differentiation of the cell occurs, the cells were first stimulated with NGF before being 
treated with U0126 after 1h and 24h following the NGF stimulation. The negative 
control consisted of cells treated with U0126 for 10 min before NGF stimulation. As 
expected, PC12 cells differentiated when they were stimulated with NGF. They did not 
differentiate when they were pre-treated with U0126, which confirmed that U0126 can 
block the differentiation of PC12 cells. The results obtained showed that when the cells 
were first stimulated with NGF then treated with U0126 after 1h or 24h after 
stimulation, they had differentiated. The results confirmed that the determination of the 
fate of the cell occurs within the first hour of NGF stimulation. I did not present these 
results in the result section of this chapter because I only repeated these results twice. 
This experiment was only a test experiment. I wanted to deepen this experiment 
investigating what would happen when the cells were treated with U0126 after 5 min, 
10 min (that is the peak of the phosphorylation of ERK after NGF stimulation), 30 min 
and 1h after NGF stimulation. However I encountered some problems, such as cell 
contaminations, and I could not repeat the results. I think it was important to mention 
this experiment and it would be interesting to repeat the same experiment trying 
different MEK inhibitor such as PD98059. 
To conclude, these results demonstrate that deregulating the cAMP pathway by 
inhibiting its degradation deregulates the ERK pathway, increases the differentiation of 
the cells and more dramatically can modify the mitogen signal. Indeed, upon high levels 
of cAMP, EGF can promote differentiation, which is the wrong signal! Moreover, the 
use of specific PDE inhibitors enabled to determine that PDE3 controls a pool of cAMP 
surrounding the ERK pathway. PDEs are essential to control the appropriate level of 
cAMP across the cells and then to maintain the function of the ERK signalling pathway 
and therefore the fate of the cell. 
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4.1  INTRODUCTION 
The second messenger cAMP was discovered in the sixties and was widely studied for 
its role in the regulation of metabolic pathways in response to hormones in mammalian 
cells. Over the years growing evidence has shown the involvement of cAMP in the 
proliferation and differentiation of cell (Gottesman et al., 1986). It was particularly 
demonstrated that cAMP can activate or inhibit the ERK signalling pathway depending 
on the cell type (Houslay and Kolch, 2000; Qiu et al., 2000). In the previous chapter it 
was demonstrated that cAMP increases the phosphorylation of ERK and the 
differentiation of PC12 cells. Surprisingly, high levels of cAMP could even turn the 
proliferation effect of EGF into a differentiation effect. These results proved that the 
level of the cAMP is crucial to maintain the correct function of the ERK signalling 
pathway and the fate of the cell (Dumaz et al., 2002; Stork and Schmitt, 2002). 
Disturbing the level of cAMP leads to altering the mitogen signal. The mechanisms 
through which cAMP regulates the ERK pathway have in part been elucidated (Stork 
and Schmitt, 2002) but many details remain unclear. Protein kinase A (PKA) was 
thought to be the only direct effector of cAMP (Brostrom et al., 1970; Walsh et al., 
1968), with the exception of the cyclic nucleotide-gated ion channels found in 
specialised cells like olfactory neurons (Zufall et al., 1997). However, recently guanine 
nucleotide exchange factors directly activated by cAMP (Epacs) were discovered (Bos, 
1998; de Rooij et al., 1998). This discovery raised the possibility that part of the effects 
attributed to the activation of PKA is in fact mediated by the activation of Epac. 
4.1.1  Protein Kinase A: the most studied effector of cAMP mediates the 
activation of ERK by cAMP through Rap1 but inhibits Raf-1 
The major effector of cAMP discovered in the seventies is the cAMP-dependent protein 
kinase A (PKA), which is a serine/threonine specific protein kinase (see chapter 1-
general introduction for further details). PKA is a heterotetramer consisting of two 
regulatory subunits (RI or RII) and two catalytic subunits (C). When cAMP binds to the 
R subunits, the C subunits are released and can phosphorylate a wide range of cytosolic 
and nuclear proteins. Four regulatory subunits have been identified (RI, RI, RII and 
RII). The R subunits exhibit different affinities for cAMP and are localised in different 
subcellular compartments. While the RI holoenzyme is found predominantly in the Chapter 4                                                                                      Ras, Rap1, PKA & Epac 
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cytoplasm, the RII holoenzyme is associated with cell structures, membranes and 
organelles. This localisation is due to anchoring by a family of specialised scaffold 
proteins called the A-kinase anchoring proteins or AKAPs (Houslay and Kolch, 2000; 
Wong et al., 2004). Over the years, it has emerged that PKA is at the centre of the 
regulation of cell proliferation and differentiation by cAMP (Stork and Schmitt, 2002; 
Vossler et al., 1997; Yao et al., 1998). Interestingly, cAMP is involved in both 
inhibition and activation of cell proliferation. It was demonstrated that PKA can inhibit 
Raf-1 by phosphorylation on serines 43, 233, 259 and 621 (Dhillon et al., 2002b; 
Dumaz et al., 2002) and promote its binding to 14-3-3 blocking Raf-1 recruitment to the 
plasma membrane (Dumaz and Marais, 2003). On the other hand, cAMP is involved in 
cell differentiation, and PKA was demonstrated to be required for the sustained 
activation of ERK by NGF (Yao et al., 1998; York et al., 1998). It was demonstrated 
that PKA can directly activate Rap1 (Vossler et al., 1997) in vitro and in vivo. However, 
it is still controversial whether the activation of Rap1 by PKA is a direct activation or if 
it occurs through the intermediate of a guanine exchange factor such as Epac or C3G 
(Dumaz and Marais, 2005; Stork and Schmitt, 2002), or through the tyrosine kinase Src 
(Obara et al., 2004). 
4.1.2  Exchange Protein directly Activated by cAMP: new perspectives 
More recently a new effector for cAMP, the exchange protein directly activated by 
cAMP or Epac, was discovered. This discovery came out when Bos’ group noticed that 
the activation of Rap1 was insensitive to the inhibition of PKA (de Rooij et al., 1998). 
Epac is a cAMP-responsive guanine nucleotide exchange factor (GEF) for the small 
GTP-binding proteins Rap1 and Rap2 (de Rooij et al., 1998). Two isoforms have been 
identified, Epac1 and Epac2. Both isoforms have an N-terminal DEP (dishevelled, Egl-
10, pleckstrin) domain involved in membrane localisation (de Rooij et al., 1998), a 
cAMP binding domain (CBD), a Ras exchange motif (REM) and a guanine nucleotide 
exchange factor homology domain (GEF) (Christensen et al., 2003). Epac 2 has another 
CBD and a Ras-association domain (RA) that can interact with active Ras. It is likely 
that the CBD folds upon the GEF domain to prevent interaction with effectors. The 
conformation of Epac changes when binding to cAMP, exposing the GEF domain that 
activates downstream targets (Qiao et al., 2002). The main effectors of Epac1 and 2 are 
the Ras-like small G-proteins Rap1 and Rap2 (de Rooij et al., 1998; Enserink et al., Chapter 4                                                                                      Ras, Rap1, PKA & Epac 
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2002; Rehmann et al., 2003). The fact that Epac activates Rap1, and that Rap1 mediates 
sustained activation of ERK (York et al., 1998) makes it logical to assume that Epac 
might be involved in the regulation of ERK by cAMP. Moreover the PACAP-stimulated 
neuritogenesis was demonstrated to not be blocked by PKA inhibitor (Lazarovici et al., 
1998), suggesting that cAMP can activate the ERK pathway independently of PKA. 
This could be a model to explain the activation of ERK by cAMP in a PKA-independent 
manner. A recent study (Kiermayer et al., 2005) has shown that Epac activation 
increased the duration of PKA-dependent ERK activation and caused cell 
differentiation. However, the regulation of ERK by cAMP mediated by Epac in a PKA-
dependent or independent manner remains controversial, and Bos’ group is not 
convinced that cAMP-induced activation of Rap1 mediated by Epac can regulate ERK 
(Bos, 2003). 
4.1.3  Specific Agonists for the activation of PKA and Epac 
Different cAMP analogues were designed by Bos’ group to specifically activate either 
PKA or Epac (Christensen et al., 2003; Enserink et al., 2002). They compared the 
amino-acid sequences of the cAMP-binding domains of Epac and PKA. The major 
difference is that Epac does not have a glutamate residue that forms hydrogen bonds 
with the 2’-hydroxyl of the cAMP ribose group (Su et al., 1995). This hydroxyl group 
was replaced by a 2’-O-methyl group on the ribose ring of cAMP. The deletion of the 
2’-OH impaired the ability of the cAMP analogue to bind PKA but not Epac. Thus, 2’-
O-Me-cAMP analogues bind selectively to Epac. However, the affinity of a 2’-O-Me-
cAMP for Epac was 8-fold less than that of cAMP. The introduction of a 
parachlorophenylthio (pCPT) group at position 8 on the adenine moiety of 2’-O-Me-
cAMP improved the affinity of the cAMP analogue to Epac. In addition, the presence of 
a hydrophobic pCPT increased the membrane permeability of the cAMP analogue in 
vivo (Enserink et al., 2002). In vivo, it was also demonstrated that the 8-pCPT-2’-O-Me-
cAMP activated Rap1 without stimulating CREB (Christensen et al., 2003), which is a 
well-known PKA substrate, proving that this analogue can activate specifically Epac but 
not PKA in vivo. It was demonstrated that the cAMP analogues modified at the position 
6 of the adenine ring, particularly 6-Bnz-cAMP, stimulate strongly the phosphorylation 
of CREB without activation of Rap1 in vivo (Christensen et al., 2003) and therefore 6-
Bnz-cAMP activate specifically PKA but is not able to activate Epac. Chapter 4                                                                                      Ras, Rap1, PKA & Epac 
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In this chapter, the role of cAMP in the regulation of ERK was investigated by 
decomposing the effect of cAMP on ERK phosphorylation using cAMP analogues that 
specifically activate either PKA or Epac. As described above, 8-pCPT-2’-O-Me-cAMP 
activates specifically Epac without activating PKA, whereas 6-Bnz-cAMP activates 
specifically PKA. In addition the activity of Ras and Rap1, upon NGF and EGF with or 
without cilostamide, was assessed by affinity pull-down assay in order to find out which 
small G-protein is involved in the cross-talk between the ERK and the cAMP signalling 
pathways. 
 
 
 
 
Figure 4. 1: Structures of cAMP analogues that specifically activate either PKA or 
Epac. a) Structure of cAMP. b) The hydroxyl group on the ribose ring of cAMP was 
substituted by a 2’-O-methyl group to impair the ability of the cAMP analogue to bind 
to PKA. The parachlorophenylthio (pCPT) group at position 8 on the adenine improved 
the affinity of the cAMP analogue to Epac and improved cell permeability. This 
analogue is a specific activator for Epac without activating PKA. c) This analogue 
contains a benzoyl group on the position 6 on the adenine ring that improves its affinity 
for its binding to PKA. This analogue can activate PKA without activating Epac. Chapter 4                                                                                      Ras, Rap1, PKA & Epac 
  103 
4.2  RESULTS 
4.2.1  Ras and Rap1 activation upon NGF and EGF: cAMP sensitises Rap1 
In the previous chapter it was demonstrated that accumulation of cAMP induced by 
PDE inhibition, increased the phosphorylation of ERK upon NGF and EGF stimulation. 
The results obtained pertaining to EGF stimulation were surprising because it was 
expected that cAMP would activate PKA, which would inhibit Raf-1 and therefore 
would switch off the ERK pathway. From these results, it was hypothesised that cAMP 
in response to mitogen stimulation could activate a second pathway, Rap1/B-Raf, to 
activate ERK. It was then crucial to investigate through which small G-proteins, i.e. Ras 
and/or Rap1, the signal is mediated in response to NGF and EGF stimulation. 
The activity of Ras and Rap1 were measured by affinity pull-down assay. This assay is 
based on the differential affinity of Ras-GTP and Ras-GDP for the Ras Binding Domain 
(RBD) of Raf-1, and of Rap1-GTP and Rap1-GDP for the Rap Binding Domain (RBD) 
of RalGDS. It was demonstrated that Raf-1 RBD binds specifically to GTP loaded Ras 
(the active form of Ras) and that RalGDS RBD binds specifically to GTP loaded Rap1 
(the active form of Rap1) (Franke et al., 1997; Taylor and Shalloway, 1996). The GST-
tagged RalGDS-RBD beads were obtained from Upstate
®. The GST-tagged RBD of 
Raf-1 was expressed in E. coli and the fusion protein was purified on glutathione-
Sepharose beads. Figure 4.2 shows the purity of the Raf-1-RBD beads. The lanes 
“RBD” prove that there was no Ras detected in the beads. The lane “Control-RBD” 
corresponds to the cell lysate before the affinity pull-down, which shows the presence 
of Ras in the lysate. The lanes “Control+RBD, NGF and EGF” in the left panel 
correspond to the RBD beads after being incubated in the cell lysates of unstimulated 
and stimulated cells. It demonstrates that a small portion of Ras corresponding to GTP-
Ras was pulled-down. The lanes “Control+RBD, NGF and EGF” on the right panel, 
which correspond to the cell lysates after affinity pull-down, show that GDP-Ras 
remains in the lysate. 
To measure the activity of Ras and Rap1, PC12 cells were seeded onto poly-L-lysine 
pre-coated 10 cm dishes and let to set overnight. The cells were serum starved in serum 
free medium for 3 to 4 hours. The cells were treated with cilostamide for 10 min before 
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were prepared as described in the section 2.1.6, and the protein concentration was 
normalised for each sample. 30l of each lysate was set apart to be resolved by 
electrophoresis and probed for Ras, Rap1, pERK (to measure the activity of ERK) and 
for ERK. The rest of the lysates was assayed for Ras and Rap1 activity using in vitro 
affinity pull-down assays described in section 2.2.10. The Raf-1-RBD beads and the 
RalGDS-RBD beads were resolved by electrophoresis. After the transfer of the proteins 
onto nitrocellulose membranes, the membranes were probed for Ras-GTP or Rap1-
GTP, the active forms of Ras and Rap1, using anti-Ras and anti-Rap1 antibodies 
respectively. 
This experiment has only been repeated twice for each mitogen stimulation, therefore it 
is not possible to draw any conclusion from the results obtained.  
Upon EGF stimulation (Fig. 4.3), the time courses were shorten from 0 to 5 min in order 
to detect Ras-GTP (or active Ras). This indicated that the activation of Ras was rapid. 
Ras was the most active at 1.5 min, and the activation of Ras was back to basal already 
after 5 min of stimulation. The treatment with cilostamide seemed to slightly increase 
the activation of Ras at 1.5 min, but did not modify the kinetic of the Ras activation. In 
contrast, no Rap1-GTP was pulled down upon EGF stimulation. This might indicate 
that Rap1 was not activated in response to EGF, which would support the results from 
York’s group (York et al., 1998). Interestingly, when the cells were pre-treated with 
cilostamide, Rap1-GTP was detected at times 0 and 1.5 min. However, ERK was not 
phosphorylated at time 0. Thus, the pre-treatment with cilostamide seemed to sensitised 
Rap1 but was not sufficient to activate ERK. Taken together these results might 
demonstrate that EGF might activate Ras but not Rap1. Cilostamide possibly increased 
the activation of Ras. Moreover, cilostamide on its own seemed to activate Rap1, but it 
was not sufficient to activate ERK. Rap1 remained active after 1.5 min of stimulation 
with EGF, which seemed to correlate with the increase in the phosphorylation of ERK. 
From these results, it seems that the increase in the phosphorylation of ERK due to 
cilostamide and upon EGF stimulation, might be due to the activation of both Ras and 
Rap1.  
Upon NGF stimulation (Fig. 4.4), unfortunately the results obtained for Ras activation 
were not convincing enough in the two experiments made, and therefore no conclusion 
can be made regarding to the effect of cilostamide on the activation of Ras. Although, in Chapter 4                                                                                      Ras, Rap1, PKA & Epac 
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the literature it is generally accepted that Ras is activated in response to NGF 
stimulation (Kao et al., 2001; York et al., 1998).  
In contrast to the cells stimulated with EGF, Rap1 was activated in response to NGF . 
Its activation started around 5 min and remained activated after 20 min, which 
correlates with the sustained activation of ERK upon NGF stimulation. The pre-
treatment with Cilostamide again seemed to activate Rap1 independently of the mitogen 
stimulation but was not sufficient to activate ERK. The activation of Rap1 was stronger 
and started after 2 min of NGF stimulation, and remained activated up to 20 min of 
stimulation. Again, these results correlate with the increase of the activation of ERK 
upon cilostamide treatment, which might confirm the role of Rap1 in the sustained 
activation of ERK. 
These results confirm that EGF uses only Ras to mediate the signal toward the ERK 
pathway but was not able to activate Rap1, whereas NGF can mediate the signal 
through Rap1 (and certainly Ras according to the literature). The activation of Rap1 
correlates with the sustained activation of ERK upon NGF stimulation. Then, the results 
show that cilostamide increases the activation of Ras upon EGF stimulation. The most 
important findings are that cilostamide  seemed to sensitise Rap1 independently to 
mitogen stimulation; that Rap1 becomes active upon EGF stimulation; and finally that 
Rap1 is activated earlier and stronger upon NGF stimulation. Chapter 4                                                                                      Ras, Rap1, PKA & Epac 
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Figure 4. 2:  Control of the purity of the Raf-1-RBD beads. GST-tagged fusion 
protein corresponding to the human Ras Binding Domain (RBD) of Raf-1 was 
expressed in E. coli. Left panel: The lysates of unstimulated cells (control+RBD) or 
cells stimulated with NGF or EGF were incubated with 2L of Raf-1-RBD beads to 
pull-down GTP-Ras. The beads were resolved by electrophoresis along side with the 
cell lysate (control-RBD) to visualise Ras, and probed for Ras and GST. 
Right panel: After the pull-down of GTP-Ras, the remaining cell lysates were probed 
for Ras. M stands for protein marker. The blots presented are representative of 3 
repeated blots. 
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Figure 4. 3: Activity of Ras and Rap1 upon EGF stimulation in PC12 cells. Serum 
starved PC12 cells were treated for 10 min with Cilostamide (10 μM) before being 
stimulated with EGF (100 ng/ml) for the indicated periods of time. GTP-Ras and GTP-
Rap1 were pulled down with Raf-1 RBD and Ral-GDS beads respectively. The beads 
were probed with anti Ras and anti Rap1 antibodies and the lysates were probed for 
Ras, Rap1 and pERK. M stands for protein marker. This blot is representative of two 
independent experiments. 
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Figure 4. 4: Activity of Ras and Rap1 upon NGF stimulation in PC12 cells. Serum 
starved PC12 cells were treated for 10 min with Cilostamide (10 μM) before being 
stimulated with NGF (100 ng/ml) for the indicated periods of time. GTP-Ras and GTP-
Rap1 were pulled down with Raf-1 RBD and Ral-GDS beads respectively. The beads 
were probed with anti Ras and anti Rap1 antibodies and the lysates were probed for 
Ras, Rap1 and pERK. M stands for protein marker. This blot is representative of two 
independent experiments. Chapter 4                                                                                      Ras, Rap1, PKA & Epac 
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4.2.2  Effect of PKA and Epac agonists on ERK phosphorylation 
In the previous chapter it was demonstrated that the inhibition of PDE3 by cilostamide 
raised the level of cAMP, which increased the phosphorylation of ERK and enhanced 
the differentiation of PC12 cells. However, the exact molecular mechanisms through 
which the crosstalk between the ERK and the cAMP signalling pathway occurs are 
unknown. As described in the introduction, different research groups (Kiermayer et al., 
2005; Vossler et al., 1997; Yao et al., 1998) have identified Ras, Rap1, PKA and Epac 
as the molecules mediating the crosstalk between the ERK and the cAMP signalling 
pathways. To investigate this hypothesis, cAMP analogues were used to activate 
specifically either PKA or Epac. 
PC12 cells were plated onto poly-L-lysine pre-coated 6-well plates in normal medium 
and left overnight to set. Then, they were starved for 3 to 4 hours in a serum free 
medium. The cells were treated for 10 minutes with PKA agonist (6-Bnz-cAMP), a 
specific Epac agonist (8-pCPT-2’-O-Me-cAMP/8-CPT-2’-O-Me-cAMP) and 
cilostamide (PDE3 inhibitor). The cells were then stimulated with either NGF or EGF 
for the indicated periods of time. The cell lysates were analysed by Western Blotting 
using the ODSSEY imager. The nitrocellulose membranes were probed with antibodies 
against phosphorylated ERK to measure the activation of ERK, and against ERK to 
measure the total amount of protein loaded on the gel. These primary antibodies were 
detected with fluorescently labelled secondary antibodies as described in the section 
3.1.2 (Fig. 4.5). Then, the ratio between pERK and total ERK (integrated intensity 
values) were calculated and normalised as percentage of the highest ratio, which was 
the peak of activation upon NGF or EGF stimulations. The results obtained were plotted 
onto a graph (Fig. 4.6). 
First of all, phosphorylated ERK was not detected without mitogen stimulation, which 
meant that neither cilostamide nor any of the cAMP analogues at the concentrations 
used could activate the ERK pathway on their own (Fig. 4.5.a). 
Upon NGF stimulation (Fig. 4.6.a) the phosphorylation of ERK increased 2.5 fold when 
the cells were treated with cilostamide (PDE3 inhibitor). Treating the cells with a cAMP 
analogue that specifically activates Epac had a similar effect on the ERK activation. 
However, the treatment of the cells with a cAMP analogue that specifically activates 
PKA had no effect on ERK phosphorylation, and did not block the ERK pathway. Chapter 4                                                                                      Ras, Rap1, PKA & Epac 
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Surprisingly, the combination of both cAMP analogues did not mimic the effect of 
cilostamide and the phosphorylation was only increased by 1.5 fold at the peak of 
activation. This may suggest that the enhancement of ERK phosphorylation by the Epac 
agonist might be reduced by the effect of PKA agonist.  
Upon EGF stimulation (Fig. 4.6.b), again the treatment with cilostamide increased the 
phosphorylation of ERK 2 fold. The treatment with the Epac agonist also increased the 
phosphorylation of ERK. However the treatment with the PKA agonist had an inhibition 
effect and decreased the activation of ERK. However, ERK was still phosphorylated 
meaning that the ERK pathway was still switched on. Surprisingly the combination of 
both cAMP analogues had no effect on the phosphorylation of ERK and did not mimic 
the effect of cilostamide. 
In order to reduce possible manipulation errors that might occur during a time course, a 
similar but simpler experiment (same protocol as the previous experiment) was made. 
Instead of stimulating the cells over a time course (Fig. 4.5.b) and c) and Fig. 4.6), cells 
were stimulated for 10 minutes with NGF and for 5 minutes with EGF, which are the 
peaks of activation of ERK by NGF and EGF respectively (Fig. 4.7). The results 
obtained were similar to the results described above. The activation of Epac using a 
cAMP analogue had a similar effect on the phosphorylation of ERK than the treatment 
with cilostamide (or as increasing the level of cAMP by inhibiting PDE3 with 
cilostamide), which was significantly different from the control in both case. This 
remains to be confirmed by doing an experiment where Epac would be inhibited. 
Unfortunately, at this time there was no tool available to inhibit Epac (siRNA or an 
Epac inhibitor). The results also showed that the PKA agonist used did not have a 
significant effect on the phosphorylation of ERK upon NGF stimulation compare to the 
control. However, the activity of ERK was significantly decreased due to the treatment 
with the PKA agonist upon EGF stimulation compare to the control, which meant that 
the ERK pathway was altered likely because of the activation of PKA that might inhibit 
Raf-1.  
These results are consistent with the results described in the previous chapter and add 
more information. In the previous chapter it was demonstrated that high level of cAMP 
can activate or switch the mitogen signal from Ras/Raf-1/MEK/ERK to other pathways 
such as Rap1/B-Raf/MEK/ERK. The results presented here confirm the existence of at Chapter 4                                                                                      Ras, Rap1, PKA & Epac 
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least two independent pathways to mediate the mitogen signal to the nucleus. Based on 
the fact (Fig. 4.3) that upon EGF stimulation the signal is transiently mediated only 
through Ras/Raf-1 (Bos, 1998) and that activated PKA inhibits Raf-1 (Dumaz and 
Marais, 2003; Sidovar et al., 2000), therefore the signal should be switched off upon 
PKA agonist treatment. Here the results demonstrate that upon EGF stimulation and 
PKA agonist, the signal was still transduced although it was diminished, which 
confirms the contribution of another pathway. According to Kao et al (Kao et al., 2001), 
the signal upon EGF is transiently mediated through Ras/Raf-1 but might also be 
transduced through B-Raf via Ras or Rap1. According to the previous results, cAMP 
sensitises Rap1 so it is possible that the PKA agonist can activate Rap1 upon EGF 
stimulation, or Ras activates B-Raf. 
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Figure 4. 5: Effect of EPAC and PKA agonists on ERK phosphorylation. Serum 
starved PC12 cells were treated with Cilostamide (10 μM), Epac agonist (8-pCPT-2’-O-
Me-cAMP/8-CPT-2’-O-Me-cAMP at 10 μM) or with PKA agonist (6-Bnz-cAMP at 10 
μM) for 10 min before being stimulated with b) NGF (100 ng/ml) or with c) EGF (100 
ng/ml) and incubated at 37ºC for 0, 2, 5, 10, 20 and 40 min. The activation of ERK was 
evaluated by probing Western blots of cell lysates with anti-phospho-ERK1/2 antibody. 
The total amount of ERK was evaluated by probing Western blots with anti ERK1/2 
antibody. M stands for protein marker. 
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Figure 4. 6: Effect of EPAC and PKA agonists on ERK phosphorylation. Serum 
starved PC12 cells were treated with Cilostamide (10 μM), Epac agonist (8-pCPT-2’-O-
Me-cAMP/8-CPT-2’-O-Me-cAMP at 10 μM) or with PKA agonist (6-Bnz-cAMP at 10 
μM) for 10 min before being stimulated with a) NGF (100 ng/ml) or with b) EGF (100 
ng/ml) and incubated at 37ºC for 0, 2, 5, 10, 20 and 40 min. The activation of ERK was 
evaluated by probing Western blots of cell lysates with anti-phospho-ERK1/2 antibody. 
The total amount of ERK was evaluated by probing Western blots with anti ERK1/2 
antibody. The values represent the ratio between pERK and ERK and are expressed as 
the percentage of the highest value in the control. The values shown are the mean of 3 
independent experiments ± S.D. The error bars for the treatment with PKA+Epac 
agonists upon NGF stimulation were removed for the clarity of the graph. 
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Figure 4. 7: Effect of cAMP analogues on ERK phosphorylation at the peak of 
activation by mitogens. Serum-starved PC12 cells were treated with Cilostamide (10 
μM), Epac agonist (10 μM), PKA agonist (10 μM) or with both Epac and PKA agonists 
for 10 min before being stimulated with b) NGF (100 ng/ml) for 10 min or with c) EGF 
(100 ng/ml) for 5 min. The activation of ERK was evaluated by probing Western blots 
of cell lysates with anti-phospho-ERK1/2 antibody. The total amount of ERK was 
evaluated by probing Western blots with anti ERK1/2 antibody. The values represent 
the ratio between pERK and ERK and are expressed as the percentage of the highest 
value in the control. The values shown are the mean of 3 independent experiments ± 
S.D. The effects of the different treatments were compared to the respective control, * p 
< 0.05. 
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4.2.3  Effect of PKA and Epac agonists on PC12 cells differentiation 
Since it was demonstrated that both PKA and Epac agonists can modulate the 
phosphorylation of ERK, it was crucial to examine whether or not they can also affect 
the differentiation of PC12 cells. 
To assess the possible involvement of PKA and/or Epac in the differentiation of PC12 
cell, the cells were seeded onto 6-well plates pre-coated with poly-L-lysine, incubated 
in normal medium at 37ºC and let to set over-night. At day 0 the cells were examined 
under the microscope to ensure that no cells were differentiated. The cells were then 
treated with Cilostamide, Epac agonist (8-pCPT-2’-O-Me-cAMP/8-CPT-2’-O-Me-
cAMP) or PKA agonist (6-Bnz-cAMP) at the indicated concentrations for 10 minutes 
before being stimulated with either NGF or EGF. The cells were then incubated for 72 
hours at 37ºC. About 10 phase-contrast images of the cells were taken randomly for 
each treatment to have a significant number of cells. A cell was only considered fully 
differentiated if the neurite extension was at least twice the length of the cell body. The 
percentage of differentiated cells was expressed as the number of cells with neurites 
compared to the total number of cells for each treatment (Fig. 4.8). 
Without mitogen stimulation, PC12 cells did not differentiate, which meant that neither 
cilostamide nor both Epac and PKA agonists at the concentrations used here, could 
trigger cell differentiation. However, other research showed that these agonists were 
able to initiate neurite extension, but at least 10 times more agonist were used 
(Christensen et al., 2003; Kiermayer et al., 2005). Upon EGF, 15% more cells 
differentiated upon cilostamide treatment compare to the untreated cells. Unexpectedly, 
none of the cAMP analogues that specifically activate Epac or PKA significantly 
contributed to enhance the differentiation of the cells. Upon NGF, cilostamide increased 
the differentiation of PC12 cells by 36%. There was a slight (but not significantly 
different from the control) increase of the differentiation by 10% in the presence of 
Epac agonist in the medium. It seems also that PKA agonist slightly (but not 
significantly) blocked the differentiation of the cells and only 40% of the cells 
differentiated compare to 45% of differentiated cells upon NGF stimulation only. 
Unexpectedly, the Epac agonist did not increased considerably the differentiation of 
PC12 cells as expected. This will be discussed further in the discussion section of the 
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Figure 4. 8: Effect of EPAC and PKA agonists on PC12 cell differentiation. a) 
PC12 cells were treated with Cilostamide (10 μM), Epac agonist (10 μM) or with PKA 
agonist (10 μM) for 10 min before being stimulated with NGF (100 ng/ml) or with EGF 
(100 ng/ml) and incubated at 37ºC. After 72h of incubation, phase-contrast images of 
representative cells were taken. b) The percentage of differentiated cells was determined 
by comparing the number of neurons over the total number of cells for each treatment. 
The values shown are means ± S.E. of 4 independent experiments. * p < 0.05. 
Note: the pictures for “no treatment” and for “+Cilostamide” were shown on figure 3.9. Chapter 4                                                                                      Ras, Rap1, PKA & Epac 
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4.3  DISCUSSION 
The aim of this chapter was to investigate the route and the mechanisms through which 
cAMP regulates the activation of ERK and particularly to assess the role of PKA, Epac, 
Ras and Rap1 in these mechanisms. The chosen approach was to decompose the effect 
of cAMP by activating its two main effectors PKA and Epac using specific cAMP 
analogues.  
One of the main aims of this research was also to understand how the signal by NGF is 
sustained whereas it is transient upon EGF stimulation and if cAMP is involved in these 
mechanisms. It is generally accepted that both NGF and EGF can activate the small G-
protein Ras, which in turn activate the protein kinase Raf-1. However, this activation is 
transient and does not sustain the activation of ERK. According to recent studies NGF 
can also activate B-Raf through Rap1 and that the activation of B-Raf is required to 
sustain the phosphorylation of ERK (York et al., 1998). Therefore it was hypothesised 
at the start of this research that NGF and EGF would use different pathways to modulate 
the longevity of the activation of ERK. Thus, upon EGF the signal would be transiently 
mediated through the activation of Ras/Raf-1, whereas upon NGF the signal would also 
be transiently mediated through Ras/Raf-1 and sustained by the activation of Rap1/B-
Raf. According to several lines of research (Dhillon et al., 2002b; Dumaz and Marais, 
2003) PKA can directly inhibit Raf-1 by phosphorylating Raf-1 on ser259 (Dhillon and 
Kolch, 2002). Thus, it was expected that an elevation of cAMP that activates PKA 
would switch off the ERK pathway. However, in the previous chapter, it was 
demonstrated that upon EGF and high level of cAMP, the phosphorylation of ERK 
increased. This result proved that cAMP could activate ERK through a different 
pathway than Ras/Raf-1, which might be the Rap1/B-Raf pathway. Here, the results 
show that the signal triggered by NGF was mediated through Rap1 and according to the 
literature through Ras, whereas the signal was only mediated through Ras upon EGF 
stimulation. However, when the level of cAMP was high (cilostamide treatment) Rap1 
was sensitised, and Rap1 became transiently active upon EGF stimulation correlating 
with the increase of the phosphorylation of ERK. 
It was then important to investigate whether NGF and EGF can activate Raf-1 and/or B-
Raf. To do so I tried to measure the activation of both kinases upon NGF and EGF Chapter 4                                                                                      Ras, Rap1, PKA & Epac 
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stimulation, with or without cilostamide treatment, by an in vitro non radioactive kinase 
assay (results not shown). This assay consisted of immunoprecipitation of the kinase of 
interest using a specific antibody immobilised on sepharose beads. Then the kinase is 
incubated with inactive recombinant MEK and ERK as substrates. The reaction is 
initiated by adding ATP and incubated at 30ºC. The reaction is stopped by adding 
sample buffer. The samples are resolved by electrophoresis following by Western 
Blotting. The membrane is then blotted for phospho-ERK using a phospho-specific 
antibody giving the readout of the kinase activity. Unfortunately, I did not manage to 
get significant results. It is probably because this assay was not sensitive enough on 
endogenous proteins. However, Kao et al showed that Raf-1 is transiently activated in 
response to NGF and EGF, and that B-Raf is transiently activated in response to EGF 
and its activation is sustained in response to NGF (Kao et al., 2001). Moreover it was 
demonstrated that elevation of cAMP in rat fibroblasts and vascular smooth muscle 
cells inhibits the ERK pathway (Cook and McCormick, 1993; Wu et al., 1993), which is 
the result of the inhibition of Raf-1 by PKA (Dhillon et al., 2002b; Hafner et al., 1994). 
However, our results suggest that NGF mediates the signal through both Ras and Rap1 
to sustain the activation of ERK, and that EGF mediates the signal only through Ras but 
elevated cAMP concentration sensitised the activation of Rap1. Then, the route for 
cAMP in the regulation of ERK was investigated by decomposing the effect of cAMP 
using different cAMP analogues to activate specifically either PKA or Epac. The results 
obtained showed that upon NGF stimulation, the effect of Epac agonist mimicked the 
effect of cilostamide that increased the phosphorylation of ERK. In contrast, PKA 
activation did not modify the phosphorylation of ERK, suggesting that the possible 
inhibition of Raf-1 by PKA does not affect the activation of ERK through Rap1/B-Raf. 
The effect of Epac agonist was reduced in presence of the PKA agonist. This was 
surprising because it was expected that the activation of PKA would not interfere with 
the activation of Epac. Christensen et al showed the same phenomenon using the same 
agonists (Christensen et al., 2003). They suggested that “the activation of Epac had a 
strongly enhancing effect on PKA” and they showed that the activation of Epac 
enhanced the activation of PKA activator. Upon EGF stimulation, again the Epac 
agonist mimicked the effect of cilostamide on the activation of ERK. In contrast to NGF 
stimulation, the PKA agonist had an inhibitory effect on the phosphorylation of ERK. 
This makes sense because contrary to the NGF stimulation, the signal is only mediated 
through Ras/Raf-1 upon EGF stimulation. Therefore, if PKA does inhibit Raf-1, then Chapter 4                                                                                      Ras, Rap1, PKA & Epac 
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the pathway should be switched off. However ERK was still slightly phosphorylated. 
This is probably because Ras can activate B-Raf. The effect of Epac agonist on ERK 
activation was totally abolished in the presence of the PKA agonist. 
The results obtained on the differentiation of PC12 cells were disappointing. Neither 
Epac nor PKA agonists did improve the differentiation of the cells upon EGF 
stimulation similar to cilostamide. Upon NGF stimulation, only the Epac agonist 
slightly increased cell differentiation. It would have been interesting to investigate if the 
combination of both agonists would mimic the effect of cilostamide and improve cell 
differentiation upon both NGF and EGF stimulation. Christensen et al demonstrated 
that the Epac agonist on its own could induce neurite extension (Christensen et al., 
2003) but they used 60 times more Epac agonist than I did. From their results they 
concluded that Epac has an important role in the cAMP-induced neurite extension in 
PC12 cells. Kiermayer et al did similar experiments using the same PKA agonist, but 
they used 2-Me-cAMP as Epac agonist (Kiermayer et al., 2005). They showed that on 
their own none of the agonists could initiate neurite outgrowth. However, when they 
combined the two agonists together and stimulated PC12 cells with EGF, cells elicited 
neurite outgrowth. They concluded that cAMP-induced neurite outgrowth requires the 
activation of both Epac and PKA. 
To summarise, these results taken together confirm that EGF utilises the Ras/Raf-1 
pathway to transduce the extracellular signal and that NGF transduces the signal 
through Ras/Raf-1 and Rap1/B-Raf. Elevation of cAMP can switch on the Rap1/B-Raf 
pathway likely though Epac that strengthens the activation of ERK upon both NGF and 
EGF stimulations. Furthermore, these results show that the differentiation of PC12 cells 
induced by cAMP is mainly mediated through Epac rather than PKA as it was 
suggested in previous research (Vossler et al., 1997; Yao et al., 1998; York et al., 1998). 
However, the activation of PKA and Epac together seems essential to initiate the 
differentiation of the cells. It seems that in response to cAMP level PKA and Epac 
synergise together to mediate the correct signal (Christensen et al., 2003; Kiermayer et 
al., 2005). 
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5.1  INTRODUCTION 
In the previous chapter it was demonstrated that NGF mediates its signal through the 
small G-proteins Ras and Rap1 whereas EGF mediates its signal through Ras only. In 
addition, it was demonstrated that an increase in cAMP by cilostamide sensitised Rap1 
that became active upon mitogen stimulation. In these conditions the signal initiated by 
EGF was also mediated through Rap1. The activation of Rap1 upon both NGF and EGF 
stimulations correlated with the increase in the phosphorylation of ERK suggesting that 
Rap1 is involved in the regulation of ERK by cAMP. In contrast, when decomposing 
the effect of cAMP using cAMP analogues, it was demonstrated that specific PKA 
agonist slightly inhibited the phosphorylation of ERK upon EGF stimulation. Ras and 
Rap1 are the small G-proteins that link the mitogen receptors to the ERK kinase cascade 
by activating Raf-1 and B-Raf (Marshall, 1998; Stork and Schmitt, 2002; Zwartkruis 
and Bos, 1999). While Ras activates both Raf-1 and B-Raf (Kao et al., 2001; Marais et 
al., 1997), Rap1 was reported to be a selective activator of B-Raf in PC12 cells (Marais 
et al., 1997; Vossler et al., 1997; York et al., 1998). It is still unclear how signalling is 
coordinated between Ras/Rap1 and Raf-1/B-Raf and how cAMP is involved in these 
mechanisms. This chapter is dedicated to determine through which Raf kinases the 
signal is mediated in response to NGF or EGF, what the involvement of Rap1 is, and 
also to investigate a potential molecular mechanism for the inhibition of Raf-1 by PKA. 
5.1.1  Activation of Raf-1 and B-Raf kinases 
The Raf kinases are activated by small G-proteins of the Ras family in response to 
extracellular stimuli. The Ras proteins are targeted to the plasma membrane and their 
activation involves the recruitment of guanine nucleotide exchange factors (GEFs) to 
activated growth factor receptors or activated G-protein coupled receptors. The Ras 
GEFs stimulate the release of GDP from Ras to allow GTP to bind, causing a 
conformational change of Ras that enables it to interact with Raf kinases and other 
effectors with high affinity (Avruch et al., 2001). Activated Ras recruits Raf from the 
cytosol to the plasma membrane where Raf activation takes place. Ras binds to the Ras 
binding domain (RBD) and to the cysteine-rich domain (CRD) of Raf (Brtva et al., 
1995; Hu et al., 1995). Although both Raf-1 and B-Raf are activated by binding to Ras, 
their respective activation mechanisms are different (Fig. 5.1). Raf-1 requires secondary Chapter 5                                                                                     Raf-1, B-Raf and AKAPs 
  122 
signals to be fully activated, whereas B-Raf can be activated by Ras alone. Raf-1 
requires the phosphorylation of four sites located in the kinase domain (CR3) to be fully 
activated: S338 and Y341 within the negative-charge regulatory region (Fabian et al., 
1993; King et al., 1998), and T491 and S494 within the activation loop (Chong et al., 
2001). Raf-1 requires a Src family tyrosine kinase to phosphorylate Y341 (Marais et al., 
1997) and S338 is probably phosphorylated by different kinases including PAK3 (King 
et al., 1998; Sun et al., 2000). The activation loop sites T599 and S602, equivalent to 
T491 and S494 respectively, are conserved in B-Raf. S446 corresponding to S338 is 
also conserved in B-Raf; however this serine is constitutively phosphorylated. 
Furthermore, Y341 is replaced by an aspartic acid (D449) in B-Raf (Mason et al., 1999) 
conferring a negative charge to the protein. Therefore, B-Raf does not require 
phosphorylation by a tyrosine kinase and other kinases, and hence requires fewer events 
to be fully activated (Marais et al., 1997). 
 
Figure 5. 1: Phosphorylation sites for the activation and inhibition of Raf-1 and B-
Raf kinases. Both Raf isoforms share a common architecture with three conserved 
regions (CR1, CR2 and CR3). The kinase domain resides in the CR3 at the C-terminus. 
Raf activation occurs at the plasma membrane. Active Ras recruits Raf to the plasma 
membrane by direct binding to the Ras binding domain of Raf (RBD) and the cysteine-
rich domain of Raf (CRD). The activation of B-Raf requires fewer events than Raf-1 
mainly because S446 is constitutively phosphorylated, and because the amino acid 
corresponding to Y341 in Raf-1 is replaced by aspartic acid in B-Raf. Raf-1 requires 
secondary signals to be fully activated such as Src family tyrosine kinases, whereas Ras 
alone can fully activate B-Raf. Deactivation of Raf-1 involves feedback 
phosphorylation by ERK on serines 29, S43, S289, 296, 301 and 642 (Dougherty et al., 
2005). The activating phosphorylation sites are highlighted in red. The phosphorylation 
sites involved in the regulation of Raf are highlighted in blue. The asterix indicates the 
PKA phosphorylation sites. The inhibitory ERK feedback phosphorylation sites are 
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Another major difference in the activation of Raf-1 and B-Raf is that B-Raf can be 
activated by Rap1, which is a Ras-related small G-protein (Kao et al., 2001). Rap1 can 
be activated via a large range of receptors such as the NGF receptor in response to 
different stimuli. Like Ras, Rap1 requires GEFs to exchange GDP to GTP to be 
activated. Crk SH3 domain-binding exchange guanine nucleotide factor (C3G) was the 
first Rap1 GEF to be cloned (Gotoh et al., 1995) and Crk can bind to various tyrosine 
kinase receptors targeting Rap1 to the plasma membrane. Rap1 is specific for B-Raf and 
does not activate Raf-1. 
5.1.2  PKA inhibits Raf-1 by direct phosphorylation 
It is generally accepted that cAMP inhibits Raf-1 through direct phosphorylation by 
PKA, but there are still debates about the exact mechanisms. It was demonstrated that 
PKA can phosphorylate Raf-1 on serines 43, 233, 259 and 621 both in vitro and in vivo 
(Dhillon et al., 2002b; Dumaz et al., 2002; Hafner et al., 1994; Sidovar et al., 2000). 
These sites appear to be phosphorylated in resting cells but are hyperinduced by PKA 
(Dhillon et al., 2002a). Moreover, these sites work independently to inhibit Raf-1 and 
they have to be all mutated to render Raf-1 completely resistant to PKA inhibition 
(Dumaz et al., 2002; Sidovar et al., 2000). Wu et al demonstrated that the 
phosphorylation on S43, which is located just upstream to the RBD, lowers the affinity 
of Raf-1 to Ras.GTP that is the active form of Ras (Wu et al., 1993). Therefore the 
phosphorylation of S43 by PKA prevents Raf-1 binding and activation by Ras. 
However, the phosphorylation of S43 is not exclusive for the inhibition of Raf-1 by 
PKA as it was demonstrated that mutation of S43 to alanine does not overcome the 
effect of cAMP and that Raf-1 is still susceptible to inhibition by PKA (Dhillon et al., 
2002b; Dumaz et al., 2002). S43 is also one of the six feedback phosphorylation sites 
that are phosphorylated by activated ERK and contribute to the deactivation of Raf-1 
(Dougherty et al., 2005). Phosphorylated serines 233, 259 and 621 are docking sites for 
14-3-3 proteins, which are adapter proteins that bind to short phosphorylated peptide 
motifs (Yaffe, 2002). It was demonstrated that S259 is the major phosphorylation site 
for the inhibition by PKA (Dhillon and Kolch, 2002). When 14-3-3 binds to these sites, 
it antagonises Ras binding. The mechanisms through which this occurs remained 
unclear but it is thought that 14-3-3 binding to Raf-1 might directly compete with Ras 
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and Marais from their research have suggested a model for the regulation of Raf-1 by 
cAMP (Dumaz and Marais, 2005). They proposed (Fig. 5.2) that in resting cells, S259 
and S621 are phosphorylated allowing 14-3-3 to bind and trap Raf-1 in an inactive 
form. In normal conditions, Ras activation recruits Raf-1 to the plasma membrane 
removing 14-3-3 from the phosphorylated S259, which can be dephosphorylated by 
PP2A. Once S259 is dephosphorylated then Raf-1 can be activated through a series of 
further phosphorylations (see section 5.1.1). Activated PKA can also phosphorylate 
Raf-1 on S43 and S233. The phosphorylation on S233 creates a new binding site for 14-
3-3. It seems that 14-3-3 has a higher affinity for phosphorylated S233 than S621, and 
therefore 14-3-3 would bind to phosphorylated S233 rather than to phosphorylated 
S621. Their hypothesis is that in this particular conformation, Ras cannot displace 14-3-
3 from phosphorylated S259 and Raf-1 cannot be activated. 
 
Figure 5. 2: Model for the regulation of Raf-1 by PKA. 1) In resting cells, Raf-1 is 
trapped in a closed but activatable conformation stabilised by 14-3-3 binding to S259 
and S621. 2) Active Ras can displace 14-3-3 from S259, allowing PP2A to 
dephosphorylate S259 at the plasma membrane. Raf-1 can now be phosphorylated for 
activation. 3) Active Raf-1 stimulates MEK, which activates ERK. ERK terminates the 
signaling by phosphorylating Raf-1 locking it into an open but inactive conformation. 
Rephosphorylation of S259 allows 14-3-3 to bind and stabilises the inactive 
conformation. 4) When cAMP is elevated, PKA phosphorylates Raf-1 on S43 and S259 
blocking the interaction with Ras and the recruitment of Raf-1 to the plasma membrane. 
PKA phosphorylates S233 creating a new binding site for 14-3-3, causing a 
rearrangement that switches 14-3-3 from S621 to S233 but maintaining contact with 
S259. Raf-1 is locked in a conformation that cannot be activated by Ras. Figure 
reproduced from (Dumaz and Marais, 2005). Chapter 5                                                                                     Raf-1, B-Raf and AKAPs 
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5.1.3  AKAPs: A Kinase Anchoring Proteins 
The AKAP family comprises about 50 anchoring proteins that have diverse structures. 
But they have in common that they bind to PKA and co-precipitate with PKA catalytic 
activity (Tasken and Aandahl, 2004; Wong et al., 2004). All AKAPs contain a PKA-
binding domain located at the C-terminus and a unique targeting domain in the N-
terminus that participates in the association of AKAPs to membranes confining the 
PKA-AKAP complex to specific subcellular structures. All AKAPs bind to the RII 
subunits of PKA with high affinity. The PKA-binding domain consists of 14-18 
hydrophobic amino acids forming an amphipathic -helix that binds to the N-terminal 
dimerisation domain of the R subunits of PKA (Dell'Acqua and Scott, 1997; Newlon et 
al., 1997; Wong et al., 2004). More recently it was reported that some AKAPs bind 
specifically to the RI subunits of PKA (McConnachie et al., 2006; Wang et al., 2006a) 
and others have dual affinity for both RI and RII PKA subunits (Huang et al., 1999). 
AKAP79, AKAP82 and AKAP220 were characterised as dual specific AKAPs and can 
bind to both RI and RII PKA subunits (JarnÃss and TaskÃ©n, 2007). In addition to 
PKA regulatory subunits, AKAPs are also able to bind to phosphatases as well as 
kinases and other proteins involved in signal transduction, forming multivalent signal 
transduction complexes (Baillie et al., 2005; Dodge-Kafka and Kapiloff, 2006; Tasken 
and Aandahl, 2004; Wong et al., 2004).  Chapter 5                                                                                     Raf-1, B-Raf and AKAPs 
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5.2  RESULTS 
5.2.1  Depletion of Raf-1 in PC12 cells 
In the previous chapter it was demonstrated that the signal initiated by NGF is mediated 
through Ras and Rap1, whereas the signal initiated by EGF is mediated only through 
Ras. It was also demonstrated that cilostamide sensitises Rap1 to become active upon 
mitogen stimulation correlating with the increase and the duration of the 
phosphorylation of ERK. A siRNA approach was used to investigate which Raf kinases 
are activated by small G-proteins to transduce the signal. 
PC12 cells were plated onto poly-L-lysine pre-coated 6-well plates and let to set 
overnight. The cells were transfected with a Raf-1 siRNA from Qiagen for 6 hours in a 
reduced serum medium, following which the cells were incubated for 72 hours in 
normal medium. The transfected cells were serum starved for 3 to 4 hours and then they 
were treated for 10 min with cilostamide before being stimulated for 10 minutes with 
NGF or for 5 minutes with EGF at the indicated concentrations. The cell lysates were 
resolved by electrophoresis and Western Blotting. The nitrocellulose membranes were 
probed for C3G, phosphorylated ERK and ERK as loading control (Fig. 5.3). Each band 
was quantified by the ODYSSEY software, and the amount of phosphorylated ERK was 
normalised to the total amount of ERK. The percentage of the activation of ERK was 
calculated from the value “NGF” or “EGF” corresponding to the maximal activation of 
ERK upon mitogen stimulation (Fig. 5.3.c). 
The results show that the Raf-1 siRNA used for this experiment knocked down about 
80% of Raf-1 (Fig. 5.3.b). Upon NGF stimulation, the depletion of Raf-1 did not modify 
the activation of ERK in cells either treated or not with cilostamide (Fig. 5.3 panels a 
and c). These results might show that Raf-1 is not essential in the activation of ERK 
upon NGF stimulation, suggesting that B-Raf might be responsible for the majority of 
the activation of ERK by NGF. This is consistent with the works from Kao et al (Kao et 
al., 2001) who demonstrated that B-Raf is responsible for 90% of the activation of ERK 
in response to NGF stimulation. However, Raf-1 was not completely knockdown and it 
might be possible that the remaining Raf-1 was enough to activate ERK in response to 
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In the previous chapter it was demonstrated that EGF in normal conditions, activates 
Ras and was unable to activate Rap1. From these results it was hypothesised that EGF 
would mediate the signal preferably through Ras/Raf-1. Therefore, knocking down Raf-
1 would result in the loss of ERK activation upon EGF stimulation. Unexpectedly, the 
depletion of Raf-1 did not reduce the activation of ERK upon EGF stimulation. Once 
again, the activation of ERK in response to EGF in the Raf-1-depleted cells might be 
due to the fact that the knockdown of Raf-1 was not complete. Another hypothesis is 
that the signal might have been mediated through a different route. As described in the 
introduction, Ras can activate B-Raf (Kao et al., 2001; Kuroda et al., 1996; Marais et 
al., 1997). It might be possible that upon EGF stimulation the signal is not only 
mediated through Raf-1 but also through B-Raf and that B-Raf compensates the 
depletion of Raf-1. Furthermore, in the Raf-1 knockdown, the activation of ERK was 
slightly increased upon EGF stimulation and cilostamide treatment compared to the 
cells expressing Raf-1. According to the results obtained in the previous chapter, it was 
demonstrated that cAMP sensitised Rap1 that became active upon EGF stimulation and 
high level of cAMP. This suggests that activated Rap1 is likely to activate B-Raf that 
strengthens the signal. However, this can only be confirmed by measuring the activity 
of B-Raf.  Chapter 5                                                                                     Raf-1, B-Raf and AKAPs 
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Figure 5. 3: Depletion of Raf-1 in PC12 cells. a) PC12 cells were transfected with or 
without siRNA against Raf-1 using Lipofectamine
TM 2000 for 6 hours in Opti-MEM
® I 
Reduced Serum Medium. The cells were incubated for 72 hours in normal medium, and 
serum starved for at least 3 hours. Then they were treated with Cilostamide (10 μM) for 
10 min before being stimulated with NGF (100 ng/ml) for 10 min or with EGF (100 
ng/ml) for 5 min, as indicated. The lysates were analysed by Western Blotting and the 
membranes were probed for Raf-1, phospho-ERK and ERK as loading control. b) The 
graph represents the percentage of the depletion of Raf-1. c) The graph represents the 
percentage of ratio between pERK/ERK. The values shown are the mean of 3 different 
experiments ± S.D. The effect of each treatment was compared to their respective 
control, ** p < 0.01. M stands for protein marker and U stands for unstimulated. Chapter 5                                                                                     Raf-1, B-Raf and AKAPs 
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5.2.2  Effect of C3G depletion on the activation of ERK 
Four different siRNAs against B-Raf from different companies were tested to deplete 
PC12 cells from B-Raf without success (results not shown). Therefore a protein 
upstream of B-Raf was targeted to be knocked down. This protein was the Rap1-GEF 
C3G (Crk SH3 domain guanine nucleotide exchanger). The association of C3G with the 
Crk adaptor molecule allows C3G to be recruited to the plasma membrane via the SH2 
domain of Crk (Feller, 2001; Wang et al., 2006b). The membrane-translocated Crk-C3G 
complex is active and enables receptor tyrosine kinases to activate Rap1 (Kao et al., 
2001; York et al., 2000; Zwartkruis and Bos, 1999). 
PC12 cells were plated onto poly-L-lysine pre-coated 6-well plates and let to set 
overnight. The cells were transfected with C3G pool of four siRNAs from Qiagen for 6 
hours in a reduced serum medium, following of which the cells were incubated for 72 
hours in normal medium. The transfected cells were serum starved for 3 to 4 hours and 
then they were treated for 10 min with cilostamide before being stimulated for 10 
minutes with NGF or for 5 minutes with EGF at the indicated concentrations. The cell 
lysates were resolved by electrophoresis and analysed by Western Blotting. The 
nitrocellulose membranes were probed for C3G, phospho-ERK and ERK as loading 
control (Fig. 5.4). Each band was quantified by the ODYSSEY software, and the 
amount of phosphorylated ERK was normalised to the total amount of ERK. The 
percentage of the activation of ERK was calculated from the value “NGF” or “EGF” 
corresponding to the maximal activation of ERK upon mitogen stimulation (Fig. 5.4.c). 
The results show that the C3G pool of siRNAs knocked down significantly about 60 to 
80% of C3G (Fig. 5.4.b). Upon NGF stimulation (Fig. 5.4 panels a and c), the depletion 
of C3G did not impair the activation of ERK. However, when the cells were treated 
with cilostamide to increase the level of cAMP, the phosphorylation of ERK tended to 
be reduce when C3G was knocked down compared to the cells expressing C3G and 
treated with cilostamide. Upon EGF stimulation, the depletion of C3G had no effect on 
the phosphorylation of ERK and did not impair the activation of ERK by cAMP 
(cilostamide treatment). 
It was expected that the depletion of C3G would reduce the activation of ERK upon 
NGF stimulation, abrogate the enhancing effects of cilostamide, and even cause further 
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al the activation of ERK in response to NGF is mainly due to the action of B-Raf (Kao 
et al., 2001). They estimated that Raf-1 contributes to only 10% of the activation of 
ERK. However, this remaining Raf-1 activity conceivably could take over when B-Raf 
activation is blocked, and may explain why upon NGF stimulation and depletion of 
C3G ERK can still be phosphorylated. However, it was expected that when the level of 
cAMP is high as under cilostamide treatment, then Raf-1 would be inhibited by cAMP-
dependent PKA resulting in the total switch off of the ERK pathway. However, the C3G 
knock-down was not complete and there is the possibility that the remaining C3G is 
sufficient for maintaining ERK activation. Another explanation would be that Ras might 
activate B-Raf and compensate the loss of C3G. Alternatively, it is possible that C3G is 
not the only route of Rap1 activation. C3G, which links Rap1 to the mitogen receptors, 
resides upstream B-Raf and Rap1. Therefore depleting C3G does not exclude the 
possibility that Rap1 can be activated independently from C3G, suggesting that cAMP 
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Figure 5. 4: C3G knockdown in PC12 cells. a) PC12 cells were transfected with or 
without C3G pool of four SiRNAs using Lipofectamine
TM 2000 for 6 hours in Opti-
MEM
® I Reduced Serum Medium. They were incubated for 72 hours in normal 
medium. The cells were serum starved for at least 3 hours and then they were treated or 
not with Cilostamide (10 μM) for 10 min before being stimulated for 10 min with NGF 
(100 ng/ml) or for 5 min with EGF (100 ng/ml). The lysates were analysed by Western 
Blotting and the membranes were probed for C3G, phospho-ERK and ERK as loading 
control. M stands for protein marker and U for untreated cells. b) The graph represents 
the percentage of the depletion of C3G (the bands corresponding to C3G are indicated 
with an x symbol). c) The graph represents the percentage of the ratio between 
pERK/ERK. The values shown are the mean of 3 different experiments ± S.D. Each 
effect of the different treatment was compared to their respective control, * p < 0.05 and 
** p < 0.01. Chapter 5                                                                                     Raf-1, B-Raf and AKAPs 
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5.2.3  Raf-1 binds to AKAPs 
It is now commonly accepted that PKA inhibits Raf-1 in vitro (Hafner et al., 1994) and 
in vivo (Wu et al., 1993) by phosphorylating directly Raf-1 on serines 43, 233, 259 and 
621 (Dhillon et al., 2002b; Dumaz et al., 2002; Sidovar et al., 2000). As serines 233, 
259 and 621 are 14-3-3 binding sites, and 14-3-3 needs to be dissociated from Raf-1 for 
efficient activation by Ras (Dhillon, 2002) PKA phosphorylation of Raf-1 will promote 
its binding to 14-3-3 and blocking of Raf-1 recruitment to the plasma membrane 
(Dumaz and Marais, 2003). The subcellular localisation of PKA is due to anchoring to 
AKAPs through the RII regulatory subunits of PKA. Therefore AKAPs target PKA to 
distinct subcellular localisations to confine PKA phosphorylation activity to specific 
sets of potential substrates (Carnegie and Scott, 2003; Jarnæss and Taskén, 2007; Wong 
et al., 2004). Every AKAP contains a PKA-anchoring domain and typically is also able 
to bind to phosphatases as well as kinases and other proteins involved in signal 
transduction, forming multivalent signal transduction complexes (Baillie et al., 2005; 
Dodge-Kafka and Kapiloff, 2006; Tasken and Aandahl, 2004; Wong et al., 2004). From 
these observations has emerged the idea that AKAPs might scaffold a complex between 
PKA and Raf-1 and possibly B-Raf, which would allow PKA to regulate these Raf 
kinases directly. This hypothesis was investigated by co-immunoprecipitation assays as 
described below. 
Growing PC12 cells were lysed as described in section 2.1.6 of chapter 2. Different 
endogenous AKAPs (AKAP79, 82 and 220) were immunoprecipitated from the PC12 
cell lysates. These AKAP immunoprecipitates were probed for co-precipitating Raf-1 
and B-Raf (Fig. 5.5.a). Reciprocally, Raf-1 and B-Raf were immunoprecipitated from 
the cell lysates and probed for associated AKAP79 (Fig. 5.5.b). In order to confirm the 
presence of these AKAPs, the immunoprecipitates were loaded alongside the cell 
lysates and probed with their respective antibodies (Fig. 5.6). Due to the poor affinity of 
AKAP220 antibody, no AKAP220 could be detected in the cell lysate or 
immunoprecipitate (result not shown). 
The results show that Raf-1 co-precipitated with all three AKAPs, whereas B-Raf did 
not co-precipitate with any AKAPs. However, AKAP79 did co-precipitate with B-Raf, 
suggesting that there might be some selectivity in the interaction of AKAPs and Raf 
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immunoprecipitation. Because AKAPs bind to the regulatory subunits of PKA (Dodge 
et al., 2001; Houslay and Adams, 2003; McConnachie et al., 2006; Michel and Scott, 
2002) these results are really interesting suggesting the existence of a complex between 
PKA, AKAP and Raf-1 and a possible mechanism for PKA to regulate Raf-1 and 
possibly B-Raf. 
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Figure 5. 5: Raf-1 co-precipitates with AKAPs. a) Endogenous proteins AKAP79, 
AKAP82 and AKAP220 were immunoprecipitated as indicated from PC12 cells lysates. 
The lysates before immunoprecipitation (as control to prove the presence of Raf-1 and 
B-Raf in the lysates), the immunoprecipitated proteins and empty protein G sepharose 
beads (as control to make sure that the beads did not pulldown Raf-1 or B-Raf) were 
probed for associated Raf-1 and B-Raf. b) Raf-1 and B-Raf were immunoprecipitated 
and probed for associated AKAP79. M stands for the protein marker. These blots are 
representative of 3 independent experiments. 
 
 
Figure 5. 6: Control of the presence of AKAP79 and AKAP82 in the PC12 cell 
lysates and immunoprecipitates. Endogenous AKAP79 and AKAP82 were 
immunoprecipitated from PC12 cells lysates. The lysates before immunoprecipitation 
(as control to prove the presence of AKAP 79), the AKAP immunoprecipitates and the 
protein G sepharose beads (as control to make sure that the beads do not pulldown 
AKAP 79) were probed for AKAP79 and for AKAP82. 
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5.2.4  Activation status of Raf-1 bound to AKAP79 
Since it was demonstrated that AKAP79 co-precipitated with Raf-1, it was logical to 
investigate the activity of Raf-1 bound to AKAP79 in order to propose a possible 
molecular mechanism for PKA to inhibit Raf-1. 
PC12 cells were plated on 10 cm dishes pre-coated with Poly-L-lysine and incubated at 
37ºC until they reached 80% of confluence. Then the cells were treated for 10 min with 
either cilostamide or forskolin at the indicated concentrations before being lysed in 3T3-
lysis buffer. To measure the activation status of Raf-1 bound to AKAP79, AKAP79 was 
first immunoprecipitated from the cell lysates. Then, the remaining Raf-1 unbound to 
AKAP79 was immunoprecipitated from the supernatant of the first 
immunoprecipitation. A 1:2 serial dilution of the Raf-1 immunoprecipitate (IP) was 
loaded alongside in order to obtain a calibration curve to quantify the percentage of total 
Raf-1 and the percentage of phosphorylated Raf-1 pulled down in the AKAP79 IPs. The 
IPs were resolved by electrophoresis and the proteins were transferred onto 
nitrocellulose membranes by Western Blot. The membranes were probed first for 
phosphorylated S259 indicating the inactive form of Raf-1, then stripped to be probed 
for phosphorylated S338 indicating the active form of Raf-1. The membranes were 
again stripped and probed for Raf-1 to evaluate the total amount of Raf-1 on each 
membrane (Fig. 5.7). The membranes were analysed using the ECL detection (i.e. 
section 2.2.3.4). The AKAP IPs and the dilution of Raf-1 IPs were also loaded along to 
the lysates before immunoprecipitation and probed for AKAP79. There was no 
AKAP79 detected in the Raf-1 IP, which proved that the totality of AKAP79 was 
immunoprecipitated before immunoprecipitating Raf-1 (Fig. 5.8). 
On the blots two bands around the molecular weight of Raf-1 (74 kD) were detected, 
both of which correspond to Raf-1. The gels shown were run longer than normal in 
order to achieve a good separation between the Raf-1 band and the IgG heavy chain 
bands. As the heavy chains are in vast access they tend to saturate the image and make 
quantification difficult if they are not far enough away from the bands of interest. When 
the gels were run normally, then only one Raf-1 band was detected at 74 kDa. This 
suggested that the two bands detected corresponded to Raf-1. 
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Each band was quantified using ImageJ software from the National Institutes of Health, 
which calculates the integrated intensity of band on Western Blots. The values obtained 
for the 1:2 serial dilution of Raf-1 IPs were analyzed using a linear regression method to 
obtain a calibration curve. The percentage of unknown Raf-1 pulled down in the 
AKAP79 IPs was calculated from that curve. In order to compare the amount of 
phosphorylated Raf on the 3 different blots (that correspond to the different treatments), 
the percentage of phosphorylated S259 and phosphorylated S338 were normalized to 
the total amount of Raf-1 in the AKAP79 IPs present on each blot as a ratio phospho-
Raf/Raf-1. 
According to Dhillon et al the phosphorylation of Raf-1 on S259 and on S338 is 
mutually exclusive and S259 has to be dephosphorylated to allow phosphorylation on 
S338 and then activation of Raf-1 (Dhillon et al., 2007). The results (Fig. 5.7) show that 
the two phosphorylated forms of Raf-1 pS259 and pS338 co-exist in resting cells and 
co-precipitated with AKAP79. This suggests the existence of two different pools of 
phosphorylated Raf-1 on AKAP79. 
When the cells were treated with forskolin (Fig. 5.7.c), the ratio between p259 and Raf-
1 was increased by 2.7 fold, suggesting that upon forskolin treatment, the pool of Raf-1 
phosphorylated on S259 is enriched. The ratio p338/Raf-1 was also increased but only 
by 1.4 fold. This suggests that forskolin increased the pool of inactive Raf-1 by 
stimulating S259 phosphorylation, and also slightly increased the pool of active Raf-1 
on AKAP79. 
When the cells were treated with cilostamide (Fig. 5.7.b), the p259/Raf-1 ratio was 
increased by 3 fold compare to the control. However, the p338/Raf-1 ratio was reduced 
by 4 fold. 
This experiement was made only once therefore it has to be repeated before to draw any 
conclusion. However, the presented results suggest that forskolin and cilostamide have 
differential effects on the phosphorylation status of Raf-1. Both drugs seem to increase 
the fraction of inactive Raf-1 (p259) tethered to AKAP79, but only cilostamide seems to 
reduce the fraction of active Raf-1. This will be discussed further in the discussion part 
of this chapter. Chapter 5                                                                                     Raf-1, B-Raf and AKAPs 
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Figure 5. 7: Activation status of Raf-1 bound to AKAP79. a) Growing PC12 cells 
were treated for 10 min b) with cilostamide (10 M) or c) with forskolin (100 M) as 
indicated. AKAP79 was first immunoprecipitated from the PC12 cell lysates. Then 
unbound Raf-1 was immunoprecipitated from the lysates. The nitrocellulose membranes 
were probed for phospho-S259 corresponding to the inactive form of Raf-1, then for 
phospho-S338 corresponding to the active form of Raf-1 and finally for Raf-1 to 
evaluate the total amount of Raf-1 pulled down by AKAP79. Each band was quantified 
using ImageJ software. The Raf-1 IPs were diluted in a 1:2 serial dilution to obtain a 
calibration curve to determine the percentage of active and inactive Raf-1 bound to 
AKAP79 displayed under the corresponding band. The relative amount of phospho-Raf 
was normalised as the ratio between phospho-Raf/Raf-1 (in bold). This experiment was 
made only once. M stands for protein marker. Chapter 5                                                                                     Raf-1, B-Raf and AKAPs 
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Figure 5. 8: Control that the totality of AKAP79 was immunoprecipitated from the 
lysates before immunoprecipitating Raf-1. a) Growing PC12 cells were treated for 10 
min b) with cilostamide (10 M) or c) with forskolin (100 M) as indicated. The 
AKAP79 IPs and the Raf-1 IP dilutions were loaded along to the lysates before 
immunoprecipitations (input lysate). The nitrocellulose membranes were probed for 
Raf-1 and AKAP79. AKAP79 was not detected in the Raf-1 IP dilution, which 
indicated that AKAP79 was totaly immunoprecipitated from the lysate before the Raf-1 
immunoprecipitations.  Chapter 5                                                                                     Raf-1, B-Raf and AKAPs 
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5.2.5  Over-expressed B-Raf binds to AKAP 79 in HEK293 cells 
As shown in the section 5.2.3, although B-Raf did not co-precipitate with AKAP79, 
AKAP79 co-precipitated with B-Raf in PC12 cells suggesting a weak or indirect 
interaction between these two proteins. In order to confirm this interaction, B-Raf was 
co-transfected with AKAP79. Because PC12 cells are difficult to transfect, B-Raf and 
AKAP79 were transfected in HEK293 cells. Two mutants of B-Raf showing high 
kinase activity were also transfected in HEK293 cells. Mutations of BRAF (the gene 
encoding for B-Raf) were identified in about 7% of all cancers. In 90% of these cancers 
the mutation of BRAF results in the substitution of a valine at the position 600 to a 
glutamic acid, B-RafV600E (Davies et al., 2002). B-RafV600E has a high kinase 
activity and induces constitutive ERK signalling through hyperactivation of the MAPK 
pathway (Dhomen and Marais, 2007). BRAF mutation resulting in the substitution of 
lysine at the 499 position to a glutamic acid B-RafK499E within the kinase domain, was 
identified in cardio-facio-cutaneous (CFC) syndrome (Niihori et al., 2006). This B-Raf 
mutant shows as well high kinase activity, although surprisingly CFC patients do not 
have a cancer predisposition. 
HEK 293 cells were plated onto 10 cm dishes and grown at 37ºC until they reached 50 
to 80% confluence. Then, they were co-transfected with AKAP79 and with FLAG-
tagged B-Raf or with two FLAG-tagged B-Raf mutants K499E and V600E using 
PolyFect
® transfection reagent from Qiagen. The cells were incubated at 37ºC for 24 to 
48 hours. Cells were lysed as described in section 2.1.6 of chapter 2. To investigate 
possible interactions between AKAP79 and B-Raf, AKAP79 was immunoprecipitated 
from the cell lysates and probed for co-precipitated B-Raf using anti-FLAG antibody 
(Fig. 5.9.a). Reciprocally, to confirm the interaction between B-Raf and AKAP79, B-
Raf was immunoprecipitated using the anti-FLAG antibody and probed for co-
precipitated AKAP79 (Fig. 5.9.b). 
The results obtained show that AKAP79 co-precipitated with B-Raf and the B-Raf 
mutants in HEK293 cells. It seems that the B-Raf mutants had a better affinity for 
AKAP79 than the wild type B-Raf. This suggests a possible formation of a complex 
between AKAP79, B-Raf mutants and PKA, and the perspective of a mechanism for the 
regulation of B-Raf mutants by PKA. Chapter 5                                                                                     Raf-1, B-Raf and AKAPs 
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Figure 5. 9: Over-expressed B-Raf mutants bind to AKAP79 in HEK293 cells. 
HEK 293 cells were co-transfected with AKAP79 and with FLAG-tagged B-Raf, 
FLAG-tagged B-RafK499E or FLAG-tagged B-RafV600E. a) AKAP79 was 
immunoprecipitated and immunoblotted for the presence of transfected B-Raf mutants 
using an anti-FLAG antibody. b) Inversely, the different B-Rafs were 
immunoprecipitated using an anti-FLAG antibody and immunoblotted for the presence 
of transfected AKAP79. IP stands for immunoprecipitate, L for lysate and B for beads. 
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5.3  DISCUSSION 
This chapter aimed to investigate deeper the mechanisms through which the extra 
cellular signal is transduced through the ERK cascade particularly at the level of the Raf 
kinases. A key experiment would have been to measure the respective activities of Raf-
1 and B-Raf in response to mitogen stimulations and to cAMP by performing kinase 
assays. Unfortunately, as described in the previous chapter (i.e. section 3.4), this kinase 
assay was not sensitive enough on endogenous proteins. Therefore a siRNA approach 
was used to knock down Raf-1 and B-Raf respectively in order to determine which 
kinase is involved in the transduction of the signal. As described in the section 5.2.2, the 
siRNA targeted against B-Raf failed to deplete B-Raf. Therefore C3G, which is an 
upstream GEF for Rap1, was targeted instead. 
The Raf-1 knockdown experiment revealed that in PC12 Raf-1 might not be essential 
for the transduction of the signal in response to NGF, and suggests that Ras might 
mediate the signal through B-Raf upon EGF stimulation. This is supported by the work 
of Kao et al., who measured the activity of Raf-1 and B-Raf upon NGF and EGF (Kao 
et al., 2001). Both growth factors activated Raf-1 and B-Raf simultaneously. Upon 
stimulation by either growth factor, the activation of Raf-1 was transient. Upon EGF, 
the activation of B-Raf was also transient whereas it was sustained upon NGF 
stimulation. They also demonstrated that most of the activation of ERK is due to B-Raf 
and that the contribution of Raf-1 to activate ERK is only 10%. Furthermore, in the 
previous chapter, it was demonstrated that EGF only activates Ras and was unable to 
activate Rap1. Therefore upon EGF stimulation, the pathway should be switched off. 
The data show that the signal is still transduced, suggesting that it is mediated through 
another route. Taken together, these results confirm that Ras might activate B-Raf to 
compensate the loss of Raf-1. When cilostamide was applied, cAMP has still an 
enhancing effect on the phosphorylation of ERK upon both NGF and EGF stimulation. 
This suggests that cAMP might strengthen the mitogen signal by stimulating the 
hypothesised Rap1/B-Raf pathway, which is consistent with the affinity pulldown 
assays demonstrating that Rap1 is sensitised and activated in response to high levels of 
cAMP. However, as demonstrated in figure 5.3, Raf-1 was not totally depleted. 
Therefore it might be possible that the remaining Raf-1was enough to fully activate 
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The C3G knockdown experiment has to be interpreted cautiously. C3G is upstream of 
Rap1 and links Rap1 to the growth factor receptors (Zwartkruis and Bos, 1999). As just 
described above, Ras is able to activate B-Raf, thus when C3G is depleted this should 
not interfere with the activation of B-Raf by Ras. Furthermore, C3G is not the only GEF 
for Rap1, for example Epac is also a specific GEF for Rap1 (de Rooij et al., 1998). 
Therefore, Rap1 is still subject to be activated by Epac or other activators particularly 
when the levels of cAMP are elevated. Then this experiment cannot be compared to a 
direct B-Raf knockdown experiment. This experiment reveals that the depletion of C3G 
did not affect the activation of ERK upon NGF stimulation. However C3G seems to be 
important for the activation of ERK by cAMP as the activation of ERK was slightly 
reduced when C3G was knocked down and cilostamide was applied. Therefore, C3G 
might be involved in the activation of ERK by cAMP. However, the results also show 
that the C3G knockdown has absolutely no effect on the activation of ERK upon EGF 
stimulation with or without the treatment with cilostamide. In order to confirm that the 
enhancing effect of cAMP on the phosphorylation of ERK is mediated through Rap1/B-
Raf via Epac, it will be interesting to inhibit Epac. So far there is no compound 
available to inhibit Epac. An siRNA approach could be considered instead. 
In chapter 4, it was demonstrated that PKA agonist had an inhibiting effect on the 
activation of ERK upon EGF stimulation (section 4.2.2). It was suggested that the 
alteration of the activation of ERK was due to the inhibition of Raf-1 by PKA. As 
described in section 5.1.3 of this chapter, PKA is anchored to AKAPs to be directed to 
specific subcellular localisations and subset of cAMP pools, coordinating the 
phosphorylation of specific substrates by PKA. Here, it is the first time that an 
interaction between AKAPs and Raf-1 has been demonstrated. Although the interaction 
between AKAP and PKA had not been demonstrated here, it is likely that PKA is 
tethered to AKAP79. Therefore, the fact that Raf-1 can bind to AKAP79 (section 5.2.3) 
suggests that AKAP79 scaffolds a complex including PKA and Raf-1 and participates 
to the regulation of Raf-1 by PKA. This is consistent and supported by data from 
Dumaz  et al (Dumaz and Marais, 2003). Indeed their data show that Raf-1 co-
precipitates with the PKA RII subunits and that PKA participates to the phosphorylation 
of Raf-1 on S43, S233 and S259. 
In rat cell extracts, Dodge et al (Dodge et al., 2001) demonstrated that both RII subunit 
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anchoring protein). They also demonstrated that the activity of PKA is enhanced by the 
inhibition of mAKAP-associated PDE4 activity, suggesting that active PDE4 can down 
regulate PKA (Fig. 5.10). Moreover, the phosphorylation of PDE4D3 by PKA enhances 
the affinity of PDE4D3 to mAKAP, suggesting the activation of mAKAP-associated 
PKA enhances the recruitment of PDE4, allowing quicker signal termination by PDE4 
(Carlisle Michel et al., 2004). In previous research it was observed that PKA can 
phosphorylate PDE4 (Houslay and Adams, 2003; Sette and Conti, 1996) and also PDE3 
(Murthy et al., 2002) in order to enhance their PDE activity. These findings suggest that 
AKAPs play a role in the regulation of cAMP, so that PKA activity is attenuated by 
PDE activity in a negative-feedback loop. It was hypothesised that under basal 
conditions, mAKAP-anchored PDE4D maintains local cAMP level at a low level 
insufficient to activate PKA. Upon hormonal stimulation, increased levels of cAMP 
overcome the PDE activity and cAMP can activate PKA that releases its active C 
subunit from the AKAP complex. The C subunits can in turn phosphorylate PDE4D, 
which becomes more active and lowers the level of cAMP back to basal levels, 
favouring the reformation of the inactive PKA holoenzyme. 
 
Figure 5. 10: Dodge et al‘s proposal for the feedback inhibition of PKA by PDE4D3 
anchored to mAKAP. A) In resting conditions the basal PDE activity prevent PKA to 
be activated by cAMP. B) Increasing level of cAMP activates PKA that phosphorylates 
and activates PDE4D3. C) The increasing PDE activity lowers the level of cAMP and 
PKA holoenzyme is reformed and inactivated (Dodge et al., 2001). 
In this context and taking these observations together, we propose a molecular 
mechanism for the inhibition of Raf-1 by PKA (Fig. 5.11). Under basal conditions, Raf-
1 bound to AKAP79 can be in an active form phosphorylated on S338 and in an 
inactive form phosphorylated on S259. As the phosphorylation of S259 and S338 is 
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two separate pools. When forskolin was applied increasing the level of cAMP, Raf-1 
showed an increase in both S259 and S338 phosphorylation. This suggests that forskolin 
might increase the pool of inactive Raf-1 by stimulating S259 phosphorylation, and also 
the pool of active Raf-1. This might be a mechanism to trap active Raf-1 away from its 
substrate. Cilostamide had a similar effect although it seems to deplete the pool of 
active Raf-1 tethered to AKAP79 probably by promoting its dissociation from 
AKAP79. This suggests that cilostamide might be less efficient in promoting Raf-1 
inhibition by PKA than forskolin. This is consistent with cilostamide being most 
efficient to hyperstimulate ERK pathway activation in response to both EGF and NGF. 
Furthermore, these results may indicate that the event which causes Raf-1 to dissociate 
from AKAP79 is not due to S259 phosphorylation, but may be attributable to one of the 
other PKA phosphorylation sites in Raf-1, such as S43, S233 or S621. It will be 
interesting to test such point mutants for AKAP79 binding and dissociation.  
The apparent lack of cilostamide having inhibitory effects on Raf-1 may be explained if 
PKA would phosphorylate PDE3 preferentially over Raf-1, which would increase PDE3 
activity and lower the level of cAMP. While cAMP returns to basal, then PKA 
holoenzyme would reform preventing the inhibition of Raf-1. 
More work needs to be undertaken in order to confirm this hypothesis. First, it will be 
crucial to investigate a possible interaction between AKAP79 and PDE3 (or another 
PDE) or at least if they co-localise as both AKAP79 and PDE3B are membrane 
targeted. Then, it will be also interesting to investigate the phosphorylation status and 
kinase activities of Raf-1 anchored to AKAP79 under different conditions of mitogen 
stimulations and high levels of cAMP. 
The data suggest that cilostamide might reduce the fraction of Raf-1 phosphorylated on 
S338 and increase the fraction of Raf-1 phosphorylated on S259. It was hypothesized 
above that PKA phosphorylating Raf-1 might dissociate Raf-1 from AKAP79. Another 
hypothesis would be that a phosphatase might be recruited to AKAP79 and would 
dephosphorylate S338, allowing PKA to phosphorylate Raf-1 on S259. However this 
possible phosphatase remains to be determined.  
Another hypothesis that will be consistent with Dumaz’s model described in the 
introduction in section 5.1.2 (Dumaz and Marais, 2003), will be that the constitutively 
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cAMP, where PKA would phosphorylate S233 displacing 14-3-3 from S621 to S233 
changing the conformation of Raf-1 into a closed and non-activatable conformation. To 
confirm this hypothesis, it will be interesting to investigate the phosphorylation of S233. 
 
 
 
Figure 5. 11: Proposed mechanisms for the inhibition of Raf-1 by PKA anchored to 
AKAP79. 1: In resting conditions, the basal PDE activity regulating cAMP to basal 
level prevents PKA from being active. Active and inactive Raf-1 co-exist on AKAP79 
2: Upon forskolin treatment, the level of cAMP increases activating PKA, which might 
phosphorylate Raf-1 stimulating the recruitment of inactive Raf-1 and stimulating the 
dissociation of active Raf-1 from AKAP79. PKA also might phosphorylate and activate 
PDE3. 3: Increased PDE activity reduces the level of cAMP, PKA holoenzyme reforms 
and PKA becomes inactive. 
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Biological processes are controlled by complex cellular signalling pathways that relay 
extracellular stimuli into the nucleus where specific genes are activated. The cellular 
signal is tightly regulated and is the result of crosstalk between different signalling 
pathways in order to deliver the correct response. In PC12 cells the ERK and the cAMP 
signalling pathways are both involved in the determination of the fate of the cell. While 
the ERK pathway controls cell proliferation and differentiation, the cAMP pathway 
promotes the differentiation of PC12 cells. It is becoming apparent that cAMP induces 
cell differentiation by activating the ERK pathway. 
So far to study the crosstalk between these two pathways, the common strategy has been 
to activate adenylyl cyclase using hormones or an activating agent. Here a novel 
approach was undertaken by targeting the degradation of cAMP. Indeed, 
phosphodiesterases are key regulators of the intracellular concentration of cAMP. PDE 
isoforms are organised in different subsets to delimitate compartments of cAMP within 
subcellular microdomains to control distinct downstream effects. The phosphodiesterase 
inhibitors assayed for this research showed a great ability to elevate the level of cAMP 
within the cells, thus they were suitable to study the crosstalk between the ERK and the 
cAMP signalling pathways. The advantage was that instead of elevating the general 
content of cAMP, here the inhibition of selective PDEs allowed the accumulation of 
cAMP within specific subcellular compartments as the different PDE isoforms control 
distinct pools of cAMP. Therefore, using the appropriate PDE inhibitors might reduce 
crosstalk between the cAMP pathway with other pathways than the ERK signalling 
pathway. In PC12 cells, the accumulation of cAMP induced by cilostamide was 
responsible for the increase in the activation of ERK upon both NGF and EGF 
stimulation, and therefore identifying PDE3 to be controlling the pool of cAMP 
surrounding the ERK pathway. Moreover, cilostamide had an enhancing effect on the 
differentiation of PC12 cells and induced more robust and longer neurite outgrowth 
upon NGF stimulation. The most surprising result was that the combination of 
cilostamide with rolipram dramatically caused cell differentiation upon EGF 
stimulation. The data presented proved that modifying the intracellular concentration of 
cAMP can totally disturb and deregulate the mitogen signal and even turn the 
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The level and duration of ERK signalling are tightly regulated at several levels 
throughout the pathway to ensure the appropriate biological response. The main 
regulation mechanisms occur at the receptor level where specific complex formation of 
adaptor proteins and GEFs are recruited to stimulate specific small G-proteins that link 
the receptors to the ERK pathway. Scaffolding proteins regulate the duration of the 
signalling by stabilising the formation of these complexes. The termination of the signal 
is as well controlled by negative feedback loops. The data presented here show that 
NGF can stimulate Rap1 contrary to EGF. This is consistent with previous research that 
demonstrated that the sustained activation of ERK upon NGF stimulation correlated 
with the activation of Rap1 through the long-life Crk/C3G complex that is stabilised by 
FRS2 only at the NGF receptor. It was also demonstrated that accumulated cAMP can 
sensitise Rap1, which become active upon EGF stimulation, which correlated with the 
activation of ERK. It is highly probable that the sensitisation of Rap1 is independent 
from the activation by Crk/C3G, which was confirmed by the result obtained when C3G 
was depleted and upon EGF stimulation. Therefore, cAMP might be able to activate the 
Rap1/B-Raf pathway independently from the activation of the receptor tyrosine kinases 
that would strengthen the activation of ERK. Upon NGF stimulation, it seems that C3G 
remains important for the activation of ERK by cAMP as it mediates the sustained 
activation of ERK. 
The specificity of the signal is also ensured by the expression level of the different Raf 
kinase isoforms. In cells that do not express B-Raf, cAMP induces profound inhibition 
of the ERK pathway and inhibition of cell growth. It is generally accepted that PKA is 
responsible for the inhibition of Raf-1 by cAMP. In cells expressing B-Raf such as 
PC12 cells, cAMP promotes cell growth and proliferation. B-Raf can be activated by 
different small G-proteins. It is transiently activated by Ras, while its activation is 
sustained when it is activated by Rap1 in response to NGF stimulation. Recent studies 
have demonstrated that the GEFs Epac1 and Epac2 can also specifically activate Rap1. 
The major difficulty in the study of this crosstalk is that the effects of cAMP on the 
ERK pathway counteract with each other: while cAMP inhibits Raf-1, it activates B-
Raf. In previous research it was demonstrated that B-Raf contributes to 90% of the 
activation of ERK, therefore the whole effect of cAMP on the activation of ERK is due 
to B-Raf. Here cAMP analogues were used to specifically activate either PKA or Epac 
in order to investigate the routes of the regulation of ERK by cAMP. The data clearly Chapter 6                                                                                             General Discussion 
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showed that the Epac agonist reproduced the effects of cilostamide upon both NGF and 
EGF stimulations confirming that the activation of ERK by cAMP is mediated mainly 
through Epac. However the PKA agonist reduced the activation of ERK upon EGF 
stimulation, which confirmed that PKA could inhibit Raf-1. Upon NGF stimulation the 
PKA agonist had not effects on the phosphorylation of ERK, which can be conceivable 
since the majority of the signal is transduced through B-Raf. But the effect of the PKA 
agonist abrogated the enhancing effect of the Epac agonist on the activation of ERK 
upon NGF stimulation. It seems that PKA by inhibiting Raf-1 protects the ERK 
pathway from high levels of cAMP.  
Finally an interaction between Raf-1 and AKAP79 has been demonstrated for the first 
time. This finding might provide a molecular mechanism by which AKAP would 
participate to the regulation of ERK by cAMP. AKAP would target PKA near the ERK 
pathway to inhibit Raf-1 and trap Raf-1 in an inactive conformation upon high levels of 
cAMP. It would be interesting to investigate further the role of AKAP and PKA in the 
regulation of ERK by cAMP by using for example the targeting peptide Ht31 that 
competes with the PKA RII subunit for the binding with AKAP. It would be also 
interesting to find out the interaction sites of Raf-1 and AKAP79 using peptide array 
and mutagenesis techniques. 
The work presented in this thesis is a contribution to elucidate the mechanisms of the 
crosstalk between the ERK and the cAMP signalling pathways. This work provides new 
insights into this particular field with the finding that the activation of ERK by growth 
factors is deregulated by the inhibition of specific PDEs. The ERK pathway is 
hyperstimulated in 30% of all human cancers. Studying the crosstalk between the ERK 
and the cAMP signalling pathways allow a better understanding on how the ERK 
pathway is regulated. The fact that cAMP is involved in the regulation of the ERK 
pathway opens the possibility to find new drug targets in order to improve cancer 
therapy. For example, potent PDE inhibitors could be used in the treatment of certain 
types of cancers to elevate the intracellular concentration of cAMP and therefore to 
suppress constitutive oncogenic Ras activity. Chapter 6                                                                                             General Discussion 
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Figure 6. 1: Proposed mechanism for the effect of cAMP on the ERK signalling 
pathway upon EGF stimulation. a) Upon EGF stimulation, the signal is transiently 
mediated through Ras/Raf-1. b) The accumulation of cAMP due to PDE inhibitor 
(cilostamide) induced stronger and delayed phosphorylation of ERK. This might be due 
to the activation of Rap1/B-Raf through the activation of Rap1 by Epac. The effect of 
cilostamide and rolipram were additive and lead to the differentiation of PC12 cells. 
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Figure 6. 2: Proposed mechanism for the effect of cAMP on the ERK signalling 
pathway upon NGF stimulation. a) Upon NGF stimulation, the signal is transiently 
mediated through Ras/Raf-1 pathway and the signal is sustained through the Rap1/B-
Raf pathway due to the FRS2/Crk/C3G complexe at the receptor level. b) Accumulation 
of cAMP due to PDE inhibitor causes stronger phosphorylation of ERK. The effect of 
cAMP seems to be mediated through Epac. Appendix 
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Abstract: The epidermal growth factor receptor (EGFR) activated extracellular-signal regulated kinase (ERK)
pathway is a central cell signalling pathway that mediates many biological responses including cell proliferation,
transformation, survival and motility. Deregulation of the pathway either through mutation of components or
overexpression of EGFRs is associated with several forms of cancer. Under normal conditions, EGF stimulates a
rapid but transient activation of ERK as the signal is rapidly shutdown, whereas under cancerous conditions,
the ERK signal cannot be shutdown and is sustained. Computational modelling techniques have been used to
investigate the signalling dynamics of the EGFR/ERK pathway, focusing on identifying the key processes
involved in signal termination and what role the ERK to son of sevenless (SOS) negative feedback loop plays in
generating a transient response. This model predicts that this negative feedback loop is not needed to achieve
a transient activation of ERK as the process of receptor degradation alone is enough to terminate the signal.
Importantly, the behaviour and predictions of this model are veriﬁed with laboratory data, as is essential for
modern systems biology approaches. Further analysis showed that the feedback loop and receptor degradation
were both redundant processes, as each could compensate for the absence of the other. This led to the
prediction that in the case of a receptor which is not degraded, such as the insulin receptor, the negative
feedback loop to SOS will actually be essential for a transient response to be achieved. Overall, the results shed
new light on the role of negative feedback in EGF receptor signalling and suggest that different receptors are
dependent on different features within the ERK pathway when relaying their signals.
1 Introduction
The extracellular-signal regulated kinase (ERK) pathway is
one of the principal intracellular signalling pathways linking
the activation of cell surface receptors to cytoplasmic and
nuclear effectors. The core ERK pathway consists of the
three kinases Raf, MAPK/ERK kinase (MEK) and ERK,
which are activated by a diverse range of receptors such as
the epidermal, nerve, ﬁbroblast and platelet-derived growth
factor receptors as well as the insulin receptor [1, 2]. Upon
ligand binding, cell surface receptors such as the epidermal
growth factor receptor (EGFR) change into their active
dimeric form thereby juxtaposing the intracellular kinase
domains for mutual trans-phosphorylation on several
tyrosine residues [3]. These phospho-tyrosine residues act
as docking sites that enable receptors to recruit a large
number of cytoplasmic signalling proteins [4] including
adaptor proteins such as Shc and Grb2, which can
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factor SOS (Fig. 1). This recruitment brings SOS into
close proximity to its membrane bound target, the small G-
protein Ras, where it can activate Ras through the loading
of guanosine triphosphatase (GTP). Ras-GTP is then able
to bind Raf-1 with high afﬁnity, translocating it from the
cytoplasm to the cell membrane where Raf-1 activation
ensues. Active Raf-1 can then dual-phosphorylate and
activate MEK, which in turn dual-phosphorylates and
activates ERK [1, 2]. Activated ERK can phosphorylate
over 160 substrates in the cytoplasm and nucleus [5] and
can regulate gene expression by directly phosphorylating
transcription factors such as Ets, Elk and Myc [6].I n
addition, activated ERK is able to phosphorylate SOS both
directly and indirectly, via p90 RSK-2, resulting in the
dissociation of SOS from Grb2 and thus forming a
negative feedback loop [7–11].
How distinct receptors can utilise the same pathways to
relay different signals and generate distinct cellular
outcomes has long fascinated many researchers. However,
recent work with the rat pheochromocytoma PC12 cell line
has greatly increased our understanding of this biological
phenomenon. In PC12 cells, EGF stimulates a transient
activation of ERK leading to cellular proliferation, whereas
nerve growth factor (NGF) stimulates a sustained activation
of ERK leading to neuronal differentiation. There is now
compelling evidence that the duration of the ERK signal
governs whether PC12 cells proliferate or withdraw from
the cell cycle and differentiate into a neuronal phenotype
[12–14]. Differences in ERK signal duration can affect
cellular outcome via gene expression, as the sustained
activation of ERK by NGF results in its translocation to
the nucleus [15] where it can activate nuclear targets such
as nuclear transcription factors. In contrast, far less
translocation of ERK is observed during its transient
activation by EGF [15]. Furthermore, more recent work
has suggested that the duration of ERK signalling is
regulated by a dynamic restructuring of feedback loops in
response to EGF and NGF [16], and that the differing
kinetics are interpreted in the nucleus not so much through
the differential expression of immediate-early genes, but
rather due to differential stabilisation of the early gene
products [17]. Although the PC12 system has been well
studied, it is still not completely clear how different ERK
dynamics can be robustly controlled by different upstream
receptors. In the case of EGF and NGF, it is not exactly
known how the two receptors utilise the same pathway to
generate different ERK responses and what the critical
differences between the two receptor systems are. However,
there are currently a number of theories to explain this,
such as differences in the strength of feedback loops
between receptors [16, 18] and differences in the adaptor
proteins that can bind to the receptor [14].
Over recent years, the computational modelling of
biological systems has become increasingly valuable. As the
EGFR-activated ERK (EGFR/ERK) pathway is such an
important signalling pathway, which is implicated in
various forms of cancer [19], it has become a popular topic
for computational modelling strategies. Currently, there are
a wide variety of models of the EGFR/ERK pathway
available which have led to some novel insights and
interesting predictions as to how this system functions [6].
Three of the most recent and popular models of the
EGFR/ERK pathway are the Brightman [18], Schoeberl
[20] and Brown [21] models. We recreated and analysed
these three models to investigate in more detail how the
EGFR/ERK pathway behaved and noticed that these
models contradict one another in some salient aspects.
Speciﬁcally, the Brightman and Brown models predict that
the negative feedback loop from ERK to SOS is essential
for a transient activation of ERK to be achieved; deleting
the feedback loop in these models results in a sustained
activation of ERK (Fig. 2). In contrast, the Schoeberl
model implies that the negative feedback loop is not
Figure 1 Basic diagram of the EGFR/ERK signalling pathway
This is a basic diagram of the EGFR/ERK signalling pathway which depicts the major proteins and interactions involved in the transduction
of the signal from the plasma membrane to cell nucleus; see the above text for a detailed overview of the pathway
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even considered in the original model. However, we also
noticed a number of biological inaccuracies and
oversimpliﬁcations within the Schoeberl model which,
when amended, could possibly resolve this apparent
contradiction.
Therefore we used computational modelling techniques to
investigate whether or not the negative feedback loop from
ERK to SOS was actually needed for the transient
activation of ERK induced by EGF. If the feedback loop
was found to be redundant, we aimed to identify the
critical biological processes involved in signal termination,
and validate any predictions made from the modelling with
experimental data. Thus, we aimed for a better, more
general and system level understanding of the EGFR/ERK
pathway by identifying the key processes involved in
generating a transient rather than sustained response.
Furthermore, as the cause of the transient response is a
fundamental feature, it was hoped that this investigation
could also shed some light on how different upstream
receptors can generate different ERK activation dynamics.
2 Methods
2.1 Computational modelling
As the Schoeberl model contradicted both the Brightman
and Brown models, we decided to investigate the
Schoeberl model further and use it as a base to develop
from and investigate the role of the ERK to SOS negative
feedback loop. The Schoeberl model is an ordinary
differential equation-based model of the EGFR-activated
ERK pathway that consists of 125 reactions involving 94
species [20]. The model was originally used to investigate
the effects of receptor internalisation on the ERK
pathway, and also the signal–response relationship
between the binding of EGF to its receptor at the cell
surface and the activation of downstream proteins in the
signalling pathway. Interestingly, the original Schoeberl
model did not even consider the ERK to SOS negative
feedback loop suggesting that it was not needed for
the transient response and efﬁcient signal shutdown.
An updated version of the Schoeberl model was later
made available by the authors online (http://www.mpi-
magdeburg.mpg.de/en/research/projects/1010/1022/1017)
which did include the ERK to SOS feedback loop, as well as
a number of additional degradation reactions. However, the
addition of these reactions had little effect on the behaviour
of the model (Supplementary Fig. 1).
Examination of the Schoeberl model reveals a number of
biological inaccuracies and oversimpliﬁcations. First, GAP
must bind to the receptor before any other adaptor protein
can bind. This is incorrect as all adaptor proteins, such as
Shc and Grb2, can bind directly to various receptor
phospho-tyrosine residues through SH2 and PTB domains
and there is no requirement for GAP to be present [4, 22–
24]. In actual fact, GAP directly competes with some
adaptor proteins for binding and indirectly competes with
others due to the close proximity of the phospho-tyrosine
residues [4, 23, 24]. Furthermore, this assumption creates a
stoichiometric bottleneck in the model as the pre-binding
of GAP limits the number of activated receptors that can
actually activate the downstream ERK pathway, as there are
50 000 receptors but only 12 000 molecules of GAP.
Secondly, there is a form of Ras called Ras-GTP
 , which is
formed after the activation of Raf-1 and dissociation of the
Ras-GTP/Raf-1 complex. In the model, Ras-GTP
  is
activated but cannot bind to its effector Raf-1, thus
limiting the number of Raf molecules that Ras-GTP can
activate to one. However, there is no evidence that the
number of Raf molecules that Ras-GTP can activate is
limited as Raf binding to Ras-GTP is not a static process
but subjected to dynamic turnover [6, 25]. Therefore the
introduction of Ras-GTP
  is artiﬁcial as there is no
Figure 2 Simulations of the Brightman and Brown models with and without the SOS negative feedback loop present
This ﬁgure contains simulations from the Brightman model (left chart) and Brown model (right chart). In both cases, the x-axis represents
time in minutes, the y-axis represents the concentration of activated ERK (ERK-PP) in molecules/cell, and the black (þFB, diamonds) and
grey (–FB, squares) lines represent the simulated levels of ERK-PP with and without the SOS negative feedback loop present, respectively.
As can be seen in both models, knocking out the negative feedback loop has a dramatic effect with the ERK-PP signal switching from a
transient to a sustained response, suggesting that the feedback loop is essential for the transient response and efﬁcient signal termination
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interact with effectors. Thirdly, Ras-GTP
  can only be
deactivated and recycled back to Ras-GDP by binding to
receptor complexes containing SOS. However, Ras is
deactivated by GAP and there is no evidence that Ras
deactivation can only occur in an EGFR complex that
contains both GAP and SOS. Overall, simulations of the
original Schoeberl model show that the vast majority of Ras
(97%) rapidly builds up and remains in the Ras-GTP
 
form (Supplementary Fig. 2) which is an intermediate with
no function. Essentially, this means that the activation
(GTP loading) of Ras is in fact sustained in the original
Schoeberl model. However, the GTP loading of Ras in
response to EGF stimulation is well known to be transient
without the sustained accumulation of Ras-GTP [14],
especially in PC12 cells. Indeed, we have our own
laboratory data that shows the EGF stimulated GTP
loading of Ras is rapidly transient in nature (Supplementary
Fig. 3). Therefore we constructed a new model of the
EGFR/ERK pathway to investigate the role of feedback,
by using the original Schoeberl model as a template. We
amended the three biological inaccuracies described above
by detaching GAP binding, deleting the Ras-GTP
 
species, and enabling Ras-GTP to be deactivated by all
GAP complexes, respectively, and also added the ERK to
SOS feedback loop. In addition, there were also a number
of minor errors in the original Schoeberl model, such as
receptor degradation reactions also degrading any bound
adaptor proteins, which is incorrect and was also corrected.
As we had fundamentally changed some aspects of the
model, we used parameter estimation techniques to re-
estimate the parameters relating to GAP binding and the
deactivation of Ras-GTP which had been previously
estimated in the original Schoeberl model.
Technically, the biochemical simulation tool Gepasi [26]
was used for model construction, simulation and parameter
estimation. A sensitivity analysis of the model was also
performed by writing a custom script and simulating the
model in MATLAB (Mathworks Inc.; http://www.
mathworks.com/); sensitivity analysis is a general technique
for establishing the contribution of individual parameter
values to the overall performance of a complex system [27].
To accomplish this, we simulated the model under normal
parameter conditions for 3600 s (1 h), monitoring the
concentration of activated ERK at each second giving 3600
data points. We then calculated the area underneath the
activated ERK curve by simply summing up all the data
points. We then took each reaction rate parameter in turn
and increased it by 10%, re-simulated the model and re-
calculated the area underneath the activated ERK curve. The
sensitivity (S) of the system to the change in the parameter
(P) with respect to our selected system output, activated ERK
(E), could then be calculated as S ¼ (DE/E)/(DP/P)w h e r e
DE is the change in E caused by the change in P(DP). A
similar process was used to calculate the sensitivity of the
system to changes in initial species concentrations in order to
identifythecriticalspeciesinvolvedinthesignal’stransduction.
2.2 Cell culture
PC12 cells were maintained in Dulbecco’s modiﬁed Eagle’s
minimal (DMEM) medium (Sigma) supplemented with
10% (v/v) horse serum, 5% (v/v) newborn calf serum
(Sigma), 1% (v/v) glutamax, 100 U/mL penicillin and
100 mg/mL streptomycin (Gibco BRL, Paisley, UK) at 5%
CO2. For treatment with EGF, PC12 cells were plated on
poly-lysine coated six-well plates at 50–60% conﬂuency
and deprived of serum for 8 h in DMEM medium
supplemented with 1% (v/v) glutamax, 100 U/mL
penicillin and 100 mg/mL streptomycin. Then, EGF
(Promega) was added to a ﬁnal concentration of 50 ng/mL
and the cells were incubated at 37ºC, 5% CO2 for the
desired time interval. The treatment was stopped by
washing the cells with ice-cold PBS and immediate ﬂash-
freezing in dry ice. To inhibit MEK1/2, U0126 (Cell
Signalling Technologies) was added to a ﬁnal concentration
of 25 mM 1 h prior to EGF treatment.
2.3 Western blotting
Cells were lysed at 4ºC in 3T3-cell lysis buffer (25 mM
HEPES pH 7.4, 50 mM NaCl, 5 mM EDTA, 1% Triton
X-100) supplemented with protease inhibitors (Protease
Figure 3 Block diagram of our EGFR/ERK pathway model
This is a block diagram of our model of the EGFR/ERK pathway
which depicts the basic structure of the model and the basic
relationships between the main species involved; positive
activating relationships end with arrows, whereas negative
deactivating relationships end with diamonds
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NaF, 0.2 mM NaP2O5, 0.5 mM sodium orthovanadate,
10 mM b-glycerophosphate). Lysates were cleared by
centrifugation at 16 000   g at 4ºC for 15 min. Protein
concentrations were quantiﬁed by a modiﬁed Lowry assay
(Bio-Rad Dc protein assay; Bio-Rad Laboratories). The
samples were separated by sodium dodecylsulfate–
polyacrylamide gel electrophoresis using NOVEX 4–12%
BisTris gradient gels (Invitrogen) and transferred to
nitrocellulose membranes (Schleicher and Schuell). After
blocking with TBS-Tween buffer (150 mM NaCl, 50 mM
TrisHCl pH 7.4, 0.1% Tween-20) containing 5% non-fat
dry milk for 1 h at room temperature, the membranes
were probed with primary phosho-ERK1/2 (1:1000),
ERK1/2 (1:1000), phospho-MEK1/2 (1:1000) and
MEK1/2 antibodies (Cell Signalling Technologies) diluted
in TBS-Tween plus 5% non-fat dry milk, as indicated. The
phospho-speciﬁc antibodies speciﬁcally detect the activating
phosphorylations and therefore can be used to assess
activation of MEK and ERK. The blots were then
incubated with the appropriate secondary antibodies
conjugated with LI-COR IRDye# 680 nm and the band
intensities were quantiﬁed by immunoﬂuorescence using an
Odyssey scanner (LICOR). Total amounts of MEK or
ERK remained constant under these experimental
conditions.
3 Results
We now present a new model of the EGFR/ERK pathway
consisting of 123 reactions involving 16 distinct protein
species, which form 83 different complexes (Fig. 3). Our
model is essentially an amended version of the original
Schoeberl model and therefore utilises a receptor-complex
strategy, which comprehensively includes the processes of
receptor internalisation and degradation, and also includes
the Shc-dependent and independent pathways leading to
the activation of Ras. We have validated the behaviour of
this new model and its predictions with experimental data
showing that our model better reﬂects the true biology and
dynamics of the EGFR/ERK pathway. We have made a
Systems Biology Markup Language (SBML; [28]) version
of our model available at http://www.dcs.gla.ac.uk/~rorton/
egf, as well as the original Schoeberl, Brightman and
Brown models.
Initially, we validated the behaviour of our model by
comparing the simulation traces of activated ERK (ERK-
PP) from the model to our own laboratory data of activated
ERK after EGF stimulation in PC12 cells. The phospho-
ERK antibody detects the activating phosphorylation sites,
and therefore ERK-PP levels directly correspond to the
levels of activated ERK. As can be seen in Fig. 4a, there is a
reasonable ﬁt between the simulation and laboratory data as
both sets show a rapid transient activation with ERK-PP
levels peaking at around 5 min and returning to basal levels
around 20 min. This also conforms well with previously
published data of ERK activation in PC12 cells [14, 29].I n
addition, the activation (GTP loading) of Ras in our model
is very much transient, unlike the original Schoeberl model
where Ras built up in RasGTP
  form (Supplementary Fig. 2).
We were speciﬁcally interested in investigating whether or
not the negative feedback loop from ERK to SOS was
actually needed for the transient ERK response and efﬁcient
signal shutdown. Therefore our ﬁrst experiment was to knock
out the feedback loop by deleting all the corresponding
reactions from the model. As can be seen in Fig. 5, knocking
out the feedback loop has only a small effect on the behaviour
of the model. ERK activation proceeds with the same
kinetics and reaches the same peak amplitude and is only
slightly prolonged. MEK phosphorylation also occurs with
the same velocity, but reaches a higher and slightly later peak
with the overall activation only slightly extended. Therefore
our model clearly predicts that the feedback loop is not
needed for the transient ERK phosphorylation and efﬁcient
signal shutdown. To test this prediction experimentally, we
stimulated PC12 cells with EGF with or without U0126
present and monitored both phospho-MEK and phospho-
ERK levels. U0126 is a small molecule inhibitor that binds to
MEK with high afﬁnity resulting in a conformational change
that does not interfere with the activating phosphorylation of
MEK, but prevents MEK from binding to and activating its
substrate ERK [30–32]. As U0126 blocks the activation of
ERK, it blocks the ERK to SOS negative feedback loop.
One can therefore investigate the role of the negative
Figure 4 Comparison of simulation and laboratory data for
ERK activation
At the top is a chart of the simulated levels of total activated ERK
(ERK-PP) from the model where the x-axis represents time in
minutes and the y-axis represents the total concentration of
ERK-PP in molecules/cell. At the bottom are the corresponding
laboratory data where cell lysates from PC12 cells stimulated
with EGF for the indicated periods were Western blotted and
probed for activated ERK using anti-phospho-ERK antibodies.
There is a reasonable agreement between the simulated and
laboratory data with activated ERK levels being transient,
peaking at 5 min, remaining high at 10 min, and returning to
basal levels at around 20 min. Total ERK levels remained
constant (data not shown)
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and without feedback to examine if the signal switches from
transient to sustained after the feedback loop is abolished;
obviously, ERK activation is experimentally not measurable
under these conditions as it is prevented by U0126. As can
be seen in Fig. 5, knocking out the feedback loop through
U0126 treatment results in a slightly prolonged but still very
much transient phosphorylation of MEK; therefore validating
our model prediction that feedback is not needed for a
transient response. However, an apparent delay in the
activation of MEK after U0126 treatment is observed in the
experimental results, which is much more exaggerated than in
the model. We believe that this is a result of U0126
interference, as U0126 stops MEK-PP from binding to ERK
and the formation of MEK-PP/ERK complexes is therefore
slowed down. As MEK-PP/ERK complexes actually protect
MEK-PP from being deactivated by phosphatases, the
activation of MEK is slower due to the increased vulnerability
to phosphatase activity. It is important to note that no delay
is observed in the computational model because the feedback
loop was simply deleted without explicitly taking the
intricacies of U0126 into account. The purpose of the
experiment rather was to test the model’s prediction that
the feedback loop was not needed for signal termination.
This is clearly the case, and in this respect the results of this
experiment validate the prediction from the model showing
that the ERK to SOS feedback loop is dispensable for the
transient response and efﬁcient signal shutdown.
Figure 5 Comparison of simulation and laboratory data for feedback loop knockout
At the top are the model simulations for ERK-PP (left) and MEK-PP (right). In both cases, the x-axis represents time in minutes, the y-axis
represents the corresponding total species concentration in molecules/cell, the black line represents the simulations from the normal
feedback intact model (þFB, diamonds), whereas the grey line represents simulations from the feedback knockout model (–FB,
squares). Knocking out the feedback loop has only a small effect on activated MEK or ERK levels which, although slightly prolonged,
still remain transient. At the bottom are the corresponding laboratory data for ERK-PP (left) and MEK-PP (right); control represents
normal EGF stimulation conditions where the feedback loop is intact (compare to þFB) whereas þU0126 represents treatment with
U0126 prior to EGF stimulation in order to knock the feedback loop out (compare to –FB). When the feedback loop is knocked out by
U0126 treatment of cells, the activation of ERK by MEK is blocked and therefore no active ERK is observable. However, the signal can
still be monitored at the level of MEK phosphorylation which is not prevented by U0126. The experiment shown was repeated four
times and the data shown is a representation of four independent experiments. A quantiﬁcation of the MEK-PP blots is also shown, as
can be seen the MEK-PP signal, although slightly prolonged, is still very much transient showing that feedback is not needed for signal
termination
178 IET Syst. Biol., 2008, Vol. 2, No. 4, pp. 173–183
& The Institution of Engineering and Technology 2008 doi:10.1049/iet-syb:20070066
www.ietdl.orgWe next investigated why the negative feedback loop
from ERK to SOS appears to be redundant, and what the
key processes involved in generating the transient response
actually were. Analyses of the model showed that there are
two key processes involved in signal termination and
generating the transient response, namely the process of
receptor degradation and the negative feedback loop from
ERK to SOS itself. The model predicts that these two
processes are individually redundant as each can
compensate for the absence of the other. This is
effectively demonstrated in the model, as individually
deleting the feedback loop or the process of receptor
degradation has little effect on the transient nature of
ERK activation (Fig. 6). However, deleting both the
feedback loop and receptor degradation has a dramatic
effect with the ERK signal switching from a transient to a
sustained response (Fig. 6). Therefore the model predicts
that in the case of the EGF receptor, the negative
feedback loop from ERK to SOS is redundant because
the process of receptor degradation alone is sufﬁcient for
the transient response and efﬁcient signal shutdown.
Consistent with our model, Hendriks et al. [33] observed
that EGFR mutations that delay receptor internalisation
had no effect on the kinetics of ERK activation, but
extended Akt signalling.
The above analysis of our model also led to another
interesting prediction, namely that in the case of a receptor
which is not degraded, the negative feedback loop from
ERK to SOS will in fact become essential for a transient
response. A case of such a receptor is the insulin receptor,
which is more efﬁciently recycled back to the plasma
membrane rather than being degraded, but still only gives a
transient rather than sustained ERK signal [8, 34].T o
investigate this, we removed the process of receptor
degradation from the model and ran simulations with or
without the feedback loop present. As can be seen in
Fig. 6, in the absence of receptor degradation, knocking
out the negative feedback loop from ERK to SOS now
causes the ERK signal to switch from a transient to a
sustained response. Therefore our model predicts that the
ERK to SOS negative feedback loop is essential for the
transient response in the case of receptors which are not
degraded, such as the insulin receptor. Interestingly, this
prediction has already been validated by a previous
experimental study where, as in our experiment, the
feedback loop was knocked out using an MEK inhibitor
and its effect on the signal ﬂowing through the pathway
after insulin stimulation was monitored upstream [8].I n
this case, it was found that knocking out the feedback loop
resulted in the signal switching from a transient to a
sustained response of Ras activity (see Fig. 3 in [8]), thus
showing that the feedback loop was essential for the
insulin-induced transient response and further validating
our model and its predictions.
We next performed a classical sensitivity analysis of the
model as an additional way to identify the key reactions
involved in generating the transient ERK response.
Sensitivity analysis can be used to identify the model
parameters, and therefore reactions, which have the greatest
inﬂuence on the ERK signal. A small change to a critical
parameter will have a big effect on the ERK signal and
therefore parameters with the highest sensitivity have the
largest inﬂuence on the system output being considered.
The parameter sensitivity analysis showed that the ERK
signal was clearly most sensitive to the parameters
concerned with the activation of Ras by SOS and the
deactivation of Ras by GAP (Fig. 7). Furthermore, the
species sensitivity analysis showed that the ERK signal was
most sensitive to changes in the initial concentrations of
GAP, closely followed by Ras and then EGFR
(Supplementary Fig. 4). Taken together, this highlights the
critical role of the Ras protein, which represents the bridge
between the activated receptors at the membrane and the
cytoplasmic ERK cascade. Furthermore, it also highlights
the importance of the GAP protein which was found to be
the most sensitive protein, whereas the deactivation of Ras
by GAP was found to be the most sensitive reaction
parameter. The process of Ras deactivation by GAP is
obviously a critical step in ERK signal termination, as Ras
essentially dictates what happens to the cytoplasmic ERK
cascade. If Ras remains active, it will continue to stimulate
the ERK cascade resulting in pathologies such as cancer,
whereas if it is deactivated the stimulation of the ERK
cascade stops and the kinases Raf, MEK and ERK are
simply deactivated by their respective phosphatases. It is
therefore no surprise that one of the most common
Figure 6 Model simulations with feedback and degradation
knockouts
This is a chart of simulated ERK-PP levels under normal EGF
stimulation conditions (EGF, black line, diamonds), after the
feedback loop has been knocked out (–FB, grey line, squares),
after receptor degradation has been knocked out (–Deg, grey
line, triangles), and after both the feedback loop and receptor
d e g r a d a t i o nh a v eb e e nk n o c k e do u t( – F B&D e g ,b l a c kl i n e ,
circles); the x-axis represents time in minutes and the y-axis
represents the concentration of total ERK-PP in molecules/cell.
In addition, this chart also contains the simulated ERK-PP levels
under normal insulin stimulation conditions (insulin, grey line,
triangles), and after the feedback loop has been knocked out
(–FB, black line, circles); this isb e c a u s et h eo n l yd i f f e r e n c e
between the EGF and insulin systems is the lack of receptor
degradation in the case of insulin
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(glycine to valine) which renders Ras insensitive to
inactivation by GAP and thus locked in the ‘on’ state [35].
4 Discussion
In this study, we have used computational modelling
techniques to investigate the signalling dynamics of the
EGFR/ERK pathway, focusing on identifying the key
processes involved in signal termination and determining
what role the ERK to SOS negative feedback loop plays in
generating a transient response. Our model predicted that the
negative feedback loop is in fact redundant and not required
to achieve a transient activation of ERK as the process of
receptor degradation alone was enough to terminate the
signal. Further analysis showed that the feedback loop and
receptor degradation were both individually redundant
processes, as each could compensate for the absence of the
other. This led to the prediction that in the case of a receptor
which is not degraded, such as the insulin receptor, the
feedback loop will actually be essential for a transient
response to be achieved. In actual fact, if one examines Fig. 6
in more detail, one could argue that receptor degradation is
more redundant than the feedback loop, as knocking out
receptor degradation has less of an effect on the ERK-PP
signal. Indeed, both our computational models and previous
experimental work by Waters et al. [8] show that the receptor
system is able to function perfectly well without receptor
degradation and still achieve a transient response, as in the
case of the insulin receptor.
It is important to note that receptor degradation and the
ERK to SOS negative feedback loop are not the only
important processes concerned with signal termination and
the transient response. The activities of GAP as well as all
the phosphatases are essential for the signal to be fully
terminated. If any one of them were absent, or severely
impaired, their respective target would remain active
leading to an uncontrolled sustained response. Indeed, the
results from the sensitivity analysis showed that the
deactivation of Ras by GAP was perhaps the most critical
step in ERK signalling. The deactivation of Ras is not a
trivial process, as GAP must ﬁrst bind to an activated
receptor (in order to get into close proximity to its
membrane bound target), but as receptors are rapidly
degraded, GAP has only a short time window in which to
bind to receptors and deactivate Ras to terminate the
signal. Furthermore, in the initial stages of signalling, GAP
must not interfere with the other adaptor proteins binding
to the receptor, such as Shc and Grb2 which subsequently
recruit SOS to activate Ras and initiate the signal. Overall,
this therefore suggests that the regulation of GAP binding
and activity is a critical and perhaps highly regulated
process. Indeed, recent studies have highlighted a potential
role in the regulation of GAP for SHP-2, which has been
shown to dephosphorylate the GAP binding sites on
activated EGF receptors as well as on the docking protein
Gab1 [36, 37]. Furthermore, studies on the related Torso
receptor in Drosophila melanogaster showed that the SHP-2
homologue Corkscrew was able to bind directly to the
receptor, dephosphorylate the binding site for Ras-GAP,
while also acting as an adaptor protein for binding the
Grb2 homologue DRK [38].
The ERK pathway is a core cell signalling module that is
utilised by numerous cell surface receptors to relay different
signals. Although ligand speciﬁc, these receptors are all
similar and can recruit the same family of adaptor proteins,
such as Shc and Grb2, to activate the downstream ERK
pathway. Our results suggest that the ERK pathway has
Figure 7 Sensitivity coefﬁcients of reaction rate parameters
This chart displays the sensitivity coefﬁcients of the 82 reaction rate parameters with respect to the overall ERK-PP signal. All parameters
with a sensitivity coefﬁcient higher than 0.5 are labelled with a brief description of their corresponding reaction
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that can be robustly utilised by different receptors with
different properties to generate the same ERK response.
Although certain features of the pathway are essential for
signalling from one receptor, the same feature may be
redundant for signalling from a different receptor. For
instance, the negative feedback loop from ERK to SOS
appears essential for the transient signalling stimulated by
insulin, but not for the transient signalling stimulated by
EGF. This could therefore suggest that other features
within the ERK pathway are redundant under speciﬁc
signalling conditions. Perhaps, different receptors rely on
different features of the ERK pathway to relay their signal
properly. However, it is also important to note that
although EGF and insulin both stimulate a similar
transient activation of ERK, they lead to very different
cellular responses: EGF primarily stimulates cells to
proliferate, whereas insulin primarily has metabolic effects.
Therefore this suggests that is not just the ERK signal that
governs the cellular response. Additional pathways are also
likely to be important, as receptors are able to bind other
adaptor proteins which can initiate other pathways.
For example, the insulin receptor also binds and activates
IRS-1 (insulin receptor substrate one) which initiates the
IRS-1/PI3K/Akt pathway which can activate the
transcription factor NFkB thus affecting gene expression
[39–42]. The fact that our model does not consider such
additional pathways could also explain a potential
contradiction between our results and previous studies on
mutated EGFR receptors that report when EGFR
internalisation (the ﬁrst step towards degradation) is
impaired, ERK signalling is sustained [43]; the sustained
signal from these mutated receptors could well be passing
down one of these additional pathways not considered in
our model such as the Rap1 pathway. Furthermore,
although we suspect the observed experimental delay in
MEK activation (Fig. 5) is caused by the interference of
U0126, an alternative explanation could be the presence of
a positive feedback loop involving ERK, or a downstream
target, which leads to increased activation of Raf-1 or
MEK; an example of such a positive feedback loop is the
Raf kinase inhibitor protein (RKIP) feedback loop [44, 45].
Our initial investigation into the role of the negative
feedback loop was initially inspired by comparisons of three
existing models of the EGFR/ERK pathway. Our results
suggest that both the Brightman and Brown models are in
fact good representations of the insulin, rather than EGF,
activated ERK pathway. This is because they both lack the
process of receptor degradation which therefore makes the
presence of the ERK to SOS negative feedback loop
essential for a transient response to be achieved. However,
it is important to emphasise that a model is not a real or
exact representation of a biological system. Rather, it is a
simpliﬁed description to assist in analysis and to help us to
better understand the real by making computational
predictions about the system that are testable in the
laboratory. Our biochemical understanding of the EGFR/
ERK pathway is by no means complete and is constantly
improving and evolving over time. Therefore computational
models can be used to suggest interesting new hypotheses
and explanations for the observed data that challenge our
current understanding. However, it is important to note
that any predictions from a model must be veriﬁed
experimentally in the laboratory. Like our knowledge of the
pathway, models too can evolve over time. This is
demonstrated in our study, as we have used the original
Schoeberl model as a basis for the development of a new
model of the pathway which we believe better reﬂects the
pathway and the true dynamics of its behaviour. Although
we have validated the behaviour of our model and its
predictions with experimental data, it is important to
remember that it is still very much a simpliﬁcation. For
example, our model does not consider true spatial aspects
such as the translocation of ERK to the nucleus, ERK’s
effect on gene expression, scaffold proteins, additional
adaptor proteins that can bind to the receptor such as
SHP-2 or the Rap1/b-Raf pathway. Therefore in the years
to come, our model may be proven to be incomplete or
even incorrect in certain aspects and may need to be
expanded or evolved in the future to explain additional
laboratory data. In conclusion, it would seem ﬁtting to end
with a quote from the statistician George E. P. Box, who
once wrote ‘essentially, all models are wrong, but some are
useful’ [46].
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